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Split enzymes have been used in Protein Complementation Assays (PCA) for 
several years to study protein-protein interactions. Recently Affimers, non-
antibody binding proteins, have been created as new tools for studying 
molecular interactions.  Combining these technologies offers substantial 
benefits for development of highly sensitive and specific diagnostic 
devices.  For proof-of-principle, two fragments of β-lactamase have been 
generated with two His tags.  The binding of the His tag on each fragment to 
nickel ions facilitates the association of β-lactamase fragments to generate a 
functional enzyme capable of substrate turnover.  Substrates, such as the 
cephalosporin nitrocefin giving rise to a colour change (yellow to red) 
detectable at 492 nm.   
Following this proof of principle, the project focuses upon a novel split alkaline 
phosphatase to underpin an amperometric detection system developed with 
colleagues in the School of Electronic Engineering, University of 
Leeds.  Alkaline phosphatase is a homodimer and the monomeric form of this 
protein does not turnover substrate.  Current work in this study is focused on 
engineering the dimer interface to generate novel monomers that do not 
spontaneously associate.  This is followed by exploring whether the mutated 
monomers can become associated and brought together, and catalyse 
substrate turnover. 
This study also focuses on preparing Affimers that can bind a target molecule, 
mGFP, at two separate epitopes. Followed by generating a cross linked protein 
between the Affimers and alkaline phosphatase. The binding of Affimer to 
target will be amplified by enzyme activity allowing detection. The system 
should allow single step detection of a target present at very low 
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Chapter 1  






1.1 Diagnostics in healthcare 
Healthcare and improved health are two of the long term social and economic 
factors affecting the stability of many countries, including the UK (Regidor 
2006).  There are hundreds of diagnostic tests and medical procedures used 
in healthcare to help physicians treat patients (Siontis et al. 2014).  It follows 
then that if the diagnosis can be improved and made more informative and 
cost effective then so can healthcare in general.  Early diagnosis can reduce 
the morbidity and mortality of disease outcomes.  Human Immunodeficiency 
Virus (HIV) diagnosis is a good example of how diagnostic assays have 
improved over time (Cornett and Kirn 2013).  The HIV virus is undetectable in 
blood plasma until 10 days after infection, and there are different types of 
infection by HIV-1 and HIV-2.  The first generation of enzyme immunoassay 
(EIA) that detected HIV-1 antibodies was introduced in 1985 but was unable 
to detect infection until 6-8 weeks after infection.  A similar second-generation 
assay was introduced which allowed diagnosis up to one week earlier.  The 
antigen used in this assay was produced using recombinant technology.  A 
major improvement came in 2007 with the third-generation diagnostic.  This 
assay was able to detect antibodies against both types of virus just three 
weeks after infection. A fourth-generation assay can detect infection just two 
weeks after infection, and detects both the antibody response and a protein 
called p24 antigen which is produced by the virus.  If a blood sample is sent to 
a laboratory for an EIA it typically takes a few days but can be available on the 
same day and requires a 4 ml blood sample.  HIV rapid tests give a result in 
just 30 minutes based on a lateral flow device which detects the same 
antibodies as EIA (Cornett and Kirn 2013). 
1.1.1 Biomarkers 
A medical biomarker is a molecule that indicates the presence, or absence, of 
a disease state (Strimbu and Tavel 2010). There are pre-disposition 
biomarkers that distinguish patients at a high risk of developing a particular 
disease.  Screening biomarkers help with early detection of a specific disease.  
Diagnostic biomarkers identify a patient with an actual disease, and 




Hayes 2012).  Cancer biomarkers, for example, can be a germline mutation 
such as the BRCA1 mutation that indicates a higher estimated risk for 
development of breast and ovarian cancer (Easton, et al. 1995).  An example 
of a screening biomarker would be prostate specific antigen, which is used for 
screening for prostate cancers.  It is usually elevated above 4 ng/ml of blood 
in men with prostate cancer (Lin, et al. 2008).  An example of a diagnostic 
biomarker is the antibodies the human body produces in response to an 
infection, such as the antibody against HIV (Cornett and Kirn 2013).  Mutations 
in the KRAS protein can help predict a patient’s response to therapy in 
colorectal cancers (Allegra, et al. 2009).  To investigate recurrence of germ 
cell tumors α-fetoprotein can be monitored in serum (Gilligan, et al. 2010).  The 
use of these types of biomarkers can help improve healthcare, through 
monitoring people with predisposition to certain illness or disease.  This will 
lead to earlier diagnosis, as would the use of diagnostic biomarkers, which can 
lead to earlier treatment.  Prognostic biomarkers improve healthcare by 
helping the practitioner decide on a course of treatment. 
1.1.2 Environmental Analytes 
Analytes in environmental samples can indicate contaminants, or toxins, which 
could be identified then removed and disposed of in an appropriate safe 
manner.  Bisphenol A is known to migrate from packaging to food and could 
be used as a food safety marker (Baluka and Rumbeiha 2016).  Oil companies 
have an obligation to avoid harmful effects to the environment, including 
marine life (Sanni, et al. 2017).  To monitor the contaminants in the aquatic 
environment, the level of alkylated phenols, polycyclic aromatic hydrocarbons, 
and carbazoles, which are found in crude oil, need to be tested.  These all 
have a detrimental effect on the environment and levels should be kept as low 
as possible (Harman, et al. 2008).  A biosensor can detect these biomarkers 
allowing safe and effective removal. 
1.2 Biosensors 
A biosensor comprises a recognition element, a transducer, and an output 




have the potential to offer a portable, inexpensive and rapid substitute to 
traditional lab-based analytical processes, by determining the presence of a 
biomarker or analyte.  Some biosensors can give further information, such as 
the concentration of the analyte.  Multiplex devices simultaneously provide 
information on a range of different biomarkers or analytes thus streamlining 




Figure 1.1 Illustration of the process by which biosensors function. 
The input from a sample analyte interacts with the recognition 
element.  The transducer converts the recognition event into a 
measurable signal.  The output signal can then be measured by 
electronic instrumentation and an output can be read on a 
computer or other electronic device.   
 
1.2.1 Elements of a biosensor 
Figure 1.1 illustrates the elements of a biosensor.  The input from a sample is 
taken up by the recognition element, usually a binding event for example when 
a biomarker binds an antibody.  A transducer converts that binding event into 





1.2.1.1 Recognition element 
The recognition element of a biosensor is the part of the sensor that interacts 
with the biomarker or analyte.  The typical molecular receptors include; 
antigens, enzymes, nucleic acids, receptors, and antibodies.  The different 
types of molecule have different advantages and disadvantages in areas such 
as selectivity, ease of production, expense and stability, as discussed below.  
1.2.1.1.1 Antigens. 
Antigens are molecules that elicit an immune response and produce antibodies 
in the host immune system.  If an antigen is used to detect a particular antibody 
then it would need to be the same structure as the disease causing agent or a 
section of it.  An example of using an antigen in a biosensor is the HIV-1 
peptide gp41 and gp120. These correspond to envelope regions of HIV-1 
(Delaney, et al. 2011). The peptide(s) interacts with antibodies in whole blood 
in the sample that contains HIV-1.  These systems are usually very specific, 
but the antigens can be difficult to produce in sufficient quantities. 
1.2.1.1.2 Enzymes 
An enzyme can be used as a recognition element where the active site 
recognises the biomarker or analyte, and can, therefore, interact with it.  The 
glucose biosensor uses glucose oxidase and is the most widely studied 
enzyme for uses as a recognition element. The medical importance of 
diabetes, particularly type I, drove the need for a glucose biosensor as there 
is a need for glucose monitoring (Heller and Feldman 2008, Lan, et al. 2016). 
Glucose oxidase binds to glucose in the blood, and turns it over to give a 
signal.  A detailed description can be found in Section 1.2.4. 
Lysozyme is an enzyme which binds to a peptidoglycan molecule that is 
present in the cell wall of bacteria.  It has been utilised as a recognition element 
in an experiment where lysozyme was labeled with fluorescein.  The lysozyme 
was able to bind different bacteria including Staphylococcus aureus, Bacillus 
cereus, Micrococcus luteus, Edwardsiella tarda, Vibrio alginolyticus, and 
Escherichia coli.  Detection by fluorescence was seen in all cases, but there 




are Gram-positive bacteria.  There are more peptidoglycan molecules in Gram-
positive bacteria, thus the lysozyme can bind more readily (Zheng, et al. 2016). 
Urease is an enzyme that binds urea, which is indicator of renal function. High 
levels of urea are a sign of kidney failure.  A study by Barhoumi et al (2006) 
used urease in a biosensor which could monitor the level of urea from 100 μM 
to 100 mM.  Table 1-1 lists these and more examples of enzymes that have 




Table 1-1 Enzymes used as recognition elements in biosensors. 
Enzyme Brief Description 
Glucose 
oxidase 
Binds directly to glucose in blood samples 
(Heller and Feldman 2008, Lan, et al. 
2016).(Saglam, et al. 2016) 
Lysozyme Lysozyme binds to peptidoglycan molecules 
that are present in the cell wall of bacteria.  
Lysozyme was labeled with fluorescein 
(Zheng, et al. 2016). 
Urease Urease binds urea for monitoring for both 
medical and environmental applications 
(Barhoumi, et al. 2006). 
Alcohol 
dehydrogenase 
A study by (Gomez-Anquela,  et al. 2015) 
uses alcohol dehydrogenase on gold 
nanoparticles to monitor ethanol oxidation  
Glucose 
dehydrogenase 
PQQ glucose dehydrogenase was used to 
measure calcium ion concentrations in 
biological fluid (Guo, et al. 2016)  
Lactate 
dehydrogenase 
A study by (Azzouzi, et al. 2015) uses lactate 
dehydrogenase on gold nanoparticles to 
monitor lactate which is a tumour biomarker. 
Alcohol oxidase An electrochemical sensor for detecting the 
alcohol level using sweat, utilised alcohol 
oxidase as the recognition element 
(Gamella, et al. 2014). 
Ascorbate 
oxidase 
Vitamin C sensors have been established 
using ascorbate oxidase as recognition 





The amount of cholesterol in blood has been 
measured using cholesterol esterase, 





1.2.1.1.3 Nucleic acids 
Libraries of nucleic acids; either DNA or RNA, called aptamers, can be 
produced using the systematic evolution of ligand exponential enrichment 
(SELEX) (Tuerk and Gold 1990).  These oligonucleotides can bind a wide 
range of targets including small molecules, proteins and whole cells 
(Chambers, et al. 2008).  A DNA aptamer for α-synuclein, which is a biomarker 
for the diagnosis of Parkinson’s disease, has been used recently.  When the 
aptamer was adsorbed onto gold nanoparticles in high salt concentration they 
remained monomeic in solution with a red colour.  When the aptamer was 
bound to the α-synuclein, the nanoparticles were able to aggregate, triggered 
by the high salt concentration, and turned from red to blue (Sun, et al. 2017). 
1.2.1.1.4 Receptors 
Similar to an enzyme, a receptor protein or domain can be used as a 
recognition element.  For example, the oestrogen receptor protein can be used 
as a recognition element to detect a number of pollutants. The oestrogen 
receptor naturally binds a wide range of endocrine disrupting chemicals, which 
are toxic but are increasingly found in water products.  The ligand binding 
domain of the oestrogen receptor is sufficiently small and stable to be 
produced in E. coli, and can be used in an Enzyme-Linked Immunosorbent 
Assay (ELISA) type assay instead of an antibody, which is normally specific to 
just one endocrine disrupting chemical (Pedotti, et al. 2015). 
1.2.1.1.5 Antibodies 
Antibodies are typically ‘Y’ shaped molecules and consist of constant and 
variable regions, and are secreted by B-cells as part of a humoral immune 
response.  Antibodies generally consist of two heavy chains made up of at 
least four domains, and two light chains that generally have two domains 
(Figure 1.2).  Each of the domains comprises approximately 110 amino acids 
and have similar secondary and tertiary structures, known as the 
immunoglobulin fold and which is a very stable, β-strand structure.  The 
variable region is at the N-terminal end of each of the peptide chains (Janeway, 




hypervariable loops, three each from the variable regions of the heavy chain 
and the light chains (Skerra 2003).    
 
 
Figure 1.2 Structure of an antibody molecule.   
This schematic shows the heavy chain in blue and the light chain 
in red.  The constant and variable regions are also shown.  The 
variable regions of both the light and heavy chain make up the 
antigen binding site.  
 
Given that antibodies in nature are required to bind to foreign antigens entering 
the immune system, they are an ideal molecule for a recognition element.  Anti 
C-reactive protein (CRP) antibodies were used to detect CRP in blood and 
saliva samples (Justino, et al. 2013, Justino, et al. 2014, Justino, et al. 2016).  
Anti HER3 antibodies have been used to detect HER3, which is a biomarker 
for cancer.  An impedimetric biosensor was functionalised with anti-HER3 and 





In a recent study by Vasques et al. (2017) two antibodies that bind to two 
different epitopes of Streptococcus agalactiae were used to fashion a 
biosensor.  S. agalactiae is a Gram-positive bacterium which can be 
responsible for sepsis and meningitis.  The antibodies were able to bind to the 
bacteria; one antibody was biotinylated, and the other was conjugated to 
horseradish peroxidase (HRP). After incubation with the S. agalactiae cells, 
the biotinylated antibody was fixed to a neutravidin coated electrode and the 
second antibody was incubated with the antibody S. agalactiae mixture.  The 
activity of the HRP was measured to identify whether or not the S. agalactiae 
was present (Vasquez, et al. 2017). 
1.2.2 Scaffold Proteins. 
A scaffold is a robust protein that has a region which is permissible to 
mutations, insertions, and deletions.  Scaffolds are generally much smaller 
than antibodies, (Hey, et al. 2005) with some being based on antibody 
molecules or fragments of antibody molecules, others are engineered from 
non-immunological domains (Wurch, et al. 2008, Wurch, et al. 2012).   
Antibody-derived domains are based on the immunoglobulin fold.  However, it 
is just the isolated variable chain, without any constant domains.  Antibody 
fragments that have been evolved to be monomeric and soluble have been 
used as binding molecules.  Some antibodies, for example antigen receptors 
in sharks (IgNAR) or camelids, are only made up of the heavy chain and no 
light chain (Skerra 2007).   Non-antibody binding proteins are not based on 
antibodies and include proteins, such as the anticalins, whose scaffold is 
based on lipocalins, the AdNectin scaffold, which is based on fibronectin 
DARPin, which in turn are based on ankyrin repeats, Avimers, which are based 
on a domain of the LDL receptor (Wurch, et al. 2012) and Affimers developed 
in Leeds.  
1.2.2.1 Affimer™  
An Affimer (Tiede, et al. 2014), shown in Figure 1.3, is a scaffold protein and 
was developed by the BioScreening Technology Group (BSTG) at the 
University of Leeds using a scaffold constructed from phytocystatins.  These 




seven coding sequences of phytocystatins were used to generate a consensus 
sequence.  In theory, this should produce a very stable protein as the most 
conserved residues are included in the sequence and the non-conserved 
areas tolerate changes, such as inserts and mutations.  The two loops shown 
in Figure 1.3 are VVAG and PWE and are consensus sequences that interact 
with proteins that are degraded by cysteine proteases. Since the scaffold was 
developed from cysteine proteases inhibitor the end result turned out to be, as 
expected, a very good cysteine protease inhibitor. These highly conserved 
loop regions, which already represent protein interactions loops, were replaced 
to remove the inherent protease inhibitory activity and to provide the sites for 
generation of library of proteins containing the variable regions.  The Affimer 
library was constructed by splice overlap extension of two PCR products.  The 
two nine amino acid variable regions were introduced by the second PCR 
product, which has degenerate regions corresponding to the loop regions.  
Trimers representing a single codon for each of the 19 amino acids (excluding 
cysteine) were introduced by degenerate (NNN) primers. The library of 
Affimers expressed from phagemid vectors are displayed as N-terminal 
fusions to a truncated D2-D3 pIII protein of M13 phage, in a process known as 








Figure 1.3 Structure of an Affimer.   
The binding loops on the top of this picture are the original loop 
from the consensus sequence.  There are four β-strands making 
up a β-sheet and a α-helix.  From PBD ID 4N6U, adapted from Tiede 
et al (2017) 
 
A screening process, wherein the library is panned against an immobilised 
target of interest, is used to narrow the search for a suitable binding protein.  
The unbound phage are then washed away leaving an enriched library of 
Affimers.  These are eluted and amplified to use in a second round of panning.  
A phage ELISA against the target is performed after panning and ‘hits’, Affimer-
expressing phage that bind the target, are confirmed as described in Figure 
1.4.  The ‘hits’ are then recovered as phagemid DNA containing the coding 






Figure 1.4 Phage display of Affimers.   
A library of phage each displaying a different Affimer are exposed 
to a target, the unbound phage are washed off, enriching the 
bound phage.  These are eluted and amplified for the next round.  
To verify ‘hits’ Affimer that have bound the target a phage ELISA 
is done after panning. 
Affimers have a wide range of uses (Bedford, et al. 2017, Tiede, et al. 2017, 
Xie, Tiede et al. 2017), the first published use of an Affimer was as a 
recognition element for the myc protein (Raina, et al. 2015).  This was on an 
impedance based biosensor and could detect concentrations between 6.7 pM 
and 6.7 nM (Raina, Sharma et al. 2015).  An IL8 Affimer was used as a 
recognition element to create an impedance biosensor for interleukin 8 (IL8) 
(Sharma, et al. 2016).  IL8 is an inflammation biomarker and is involved in the 
recruitment of neutrophils during injury or infection.  The Affimer, described in 
the paper as a small non-antibody binding protein, has a KD of 35 ± 10 nM.  
Using an impedance based biosensor, concentrations as low as 90 fg/ml were 
detected.  Given that clinically relevant levels are 5-10 pg/ml the biosensor 
could therefore easily pick up the target molecule at clinically relevant levels 























A transducer converts the interactions of the recognition element into a signal 
that can be measured.  These can be made up of a simple physical component 
such as an electrode, but more often have a chemical component linking the 
recognition element to the working electrode.  Electrodes have three parts: the 
working electrode, where you place a sample, the counter electrode and a 
reference electrode. The reference electrode has a stable, established 
electrode potential.  A schematic of a screen-printed electrode is shown in 
Figure 1.5 (Hernández, et al. 2016). 
 
 
Figure 1.5 A schematic of a screen printed electrode. 
The working, counter and a reference electrode are shown, as well 
as the connections for each of the electrodes.   
 
1.2.3.1 Electrochemical Biosensors 
Electrochemical sensors offer the advantage of being small and easy to use.  
The glucose meter, described in section 1.2.4 is an example of an 
electrochemical biosensor.  Electrochemical biosensors include 









1.2.3.1.1 Amperometric  
An amperometric biosensor measures electrical current and is often based on 
oxidase enzymes that generate hydrogen peroxide and consume oxygen (Wu, 
et al. 2017).  The movement of electrons is detected when a potential is applied 
between two electrodes.  Superoxide dismutase (SOD) was used to create an 
amperometric biosensor to measure the total antioxidant capacity of several 
berry samples.  The SOD biosensor was compared with established laboratory 
methods: a spectrophotometric method and a spectrofluorimetric method.  The 
SOD was immobilised in Kappa carrageenan gel and sandwiched in between 
two membranes and fixed to an electrode.  The total antioxidant capacity was 
measured as a concentration of superoxide radicals.  SOD converts 
superoxide radicals and hydrogen ions to hydrogen peroxide and molecular 
oxygen.  The release of hydrogen peroxide was oxidised at the anode giving 
an amperometric signal proportional to the concentration of superoxide 
radicals present.  The magnitude of the measurement was different for the 
three methods, but the trend of total antioxidant capacity of the different 
samples was the same (Tomassetti, et al. 2015). 
1.2.3.1.2 Conductometric 
An impedance biosensor measures the electrical impedance of an interface.  
The impedance of an electrode solution interface changes when a target is 
captured (Daniels and Pourmand 2007).  As an example, a gold electrode was 
functionalised with a monothiol-alkane-PEG acid self-assembled monolayer 
(SAM).   The carboxylic acid group was activated with 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide hydrochloride (EDC) and N-
hydroxysulfosuccinimide (NHS) and an IL8 binding protein was then 
immobilised via a covalent bond on to the SAM.  This electrode was then used 
to detect IL8 by the electrochemical impedance (Sharma, et al. 2016).    
1.2.3.1.3 Potentiometric 
A potentiometric biosensor measures a change in the distribution of charge 
using ion-selective electrodes, for example, a pH meter.  A potentiometric 
biosensor was developed to detect the presence of urea in milk.  The biosensor 




electrode.  The biosensor had a detection limit of 25 μM, with a response time 
of 20 to 30 seconds (Trivedi, et al. 2009). 
1.2.3.2 Biosensor Output 
The output of a biosensor is made up of three parts: amplifier, processor, and 
display.  The electrodes translate the bio recognition event into an electrical 
signal in an electrochemical biosensor.  This signal can then be measured by 
electronic instrumentation and an output can be read on a computer or other 
electronic device (Li, et al. 2016).  Photometric biosensors can detect either 
fluorescent or luminescent photons with photomultiplier tubes or a photo diode 
system. Piezoelectric devices detect the specific angle at which electron 
waves are emitted. Colourimetric biosensor devices have an output that can 
be seen, for example the pregnancy test when a coloured line is displayed.  In 
other systems the colour might not be able to be seen by eye, but a UV-VIS 
spectrometer can detect absorbance within the visual spectrum.   
1.2.4 Glucose Biosensor 
One of the most widely used biosensors on the market is a glucose sensor.  
People with diabetes require a glucose meter to measure the level of glucose 
in their blood. The biosensor recognises glucose, which is a biomarker in 
blood, and gives an electrochemical signal as an output, that is then converted 
into a concentration.  The resulting number assists the diabetic person to 
calculate the amount of insulin needed, or how to modify their diet to change 
that level (Lan, et al. 2016).  The development of this particular biosensor has 
changed dramatically since the 1970’s when a semi-quantitative device was 
used that required multiple steps and took over 2 minutes and required about 
25 μl of blood. The latest device is an electrochemical quantitative device that 
takes approximately 5 seconds and requires as little of 0.3 μl of blood (Heller 
and Feldman 2008, Lan, et al. 2016). 
Modern glucose meters use a disposable test strip, which contains a capillary 
that draws up a specific amount of blood.  The glucose in the blood reacts with 
the recognition element, an enzyme electrode.  A mediator reagent oxidizes 
the enzyme, and an electric current is generated by the mediator once 




enzymes that are used in blood glucose meters; glucose oxidases (GOx) and 
glucose dehydrogenases (GDH).  These enzymes have been engineered to 
improve their production, improve the purification process and specific activity, 
and enhance the stability and the selectivity for glucose (Heller and Feldman 
2008).  
Glucose oxidase requires a cofactor; the mediator, flavin adenine dinucleotide 
(FAD). Together the enzyme and the cofactor turn the glucose and oxygen 
substrates into hydrogen peroxide and gluconolactone.  FAD is an electron 
acceptor from glucose, which is oxidised to gluconolactone, and FAD is 
reduced to FADH, which is normally oxidised by oxygen, and oxygen is 
reduced to hydrogen peroxide (Wohlfahrt, et al. 1999, Newman and Turner 
2005).  Glucose oxidase based biosensors use an electrode instead of oxygen 
to take up the electrons.  In many cases the electron acceptor, FAD or 
ubiquitin, is replaced by ferrocene or its derivatives as a mediator reagent 
(Newman and Turner 2005). 
Glucose dehydrogenase (GDH) enzymes use a mechanism that is 
independent of oxygen.  Glucose is oxidised to gluconolactone like glucose 
oxidase, but a cofactor such as NAD+ is used and NADH is produced.  The 
NAD+ cofactor is unstable, but other GDHs use pyrroloquinoline quinone 
(PQQ) as a cofactor, PQQ-GDH is an efficient enzyme as the electron transfer 
rate is high, but it is expensive compared with the other GDHs (Newman and 
Turner 2005). 
1.3 Optimisation of Enzymes for Biosensors 
Enzymes in nature are evolved for their biological function in the environment 
in which they are required to operate.  In a biosensor, this function is being 
exploited for a different purpose for which it is not optimised.  Mutagenesis is 
often used as a means to optimise an enzyme, by changing the genetic code 
in order to create variant forms of the enzyme.  Furthermore, orientation and 
proximity of the enzyme to, its cofactor, or substrates, or products, and in some 




product.  In the case of biosensors, the orientation and proximity of the enzyme 
to the electrode is fundamental to optimal function. 
PQQ GDH is one such enzyme that has been modified for use in biosensor 
technology.  PQQ-GDH was engineered to enable direct electron transfer to 
the electrode instead of using an electron mediator (Okuda and Sode 2004). 
The cytochrome c domain of quinohemoprotein ethanol dehydrogenase was 
fused to the C-terminal of PQQ-GDH. The fusion protein showed intra-
molecular electron transfer, between PQQ and heme, and electron transfer 
from heme to the electrode (Okuda and Sode 2004). Initially, Guo et al. (2016) 
engineered PQQ-GDH, for use as a Ca2+ biosensor.  This was done by 
inserting calmodulin into a loop within PQQ-GDH (Guo, et al. 2016).  This was 
then adapted to be used as a universal biosensor platform, by splitting the 
protein into two fragments at the previous insertion site, but held together using 
two interacting proteins.  The two interacting proteins were replaced with 
receptors or protein domains for immunosuppressant drugs, α-amylase protein 
and proteases.  The newly engineered PGG-GDH was used for the detection 
of immunosuppressant drugs, α-amylase protein, and for detecting protease 
activity of thrombin and Factor Xa (Guo, et al. 2016, Guo, et al. 2016).  
1.3.1 Optimisation of Electron Transfer pathways 
The proximity and orientation of an enzyme and an electrode have a 
fundamental effect on electron transfer.  Historically, most amperometric 
biosensors use a mediator between the electron active centre of the enzyme 
and an electrode (Degani and Heller 1987).  Direct electron transfer from the 
enzyme to the electrode is better because it reduces interference from side 
reactions and it better mimics the redox potential of the enzyme. Furthermore, 
it is a simpler process as there is only one step in the reaction (Gorton, et al. 
1999). In either case; with or without a mediator, the distance between the 
electrode and the electron centre is of paramount importance for a functioning 
biosensor.  Figure 1.6 demonstrates how the orientation of an attached 
enzyme can affect the distance an electron has to travel.  Electrons from the 
active site in (A) would probably not transfer to the electrode, whereas when 
the enzyme is orientated as in (B), the distance is much shorter and electrons 





Figure 1.6 Enzyme orientation and proximity of the active site to an 
electrode.   
Electrons in the active site of the enzyme (A) would likely not reach 
the electrode whereas those from (B) would reach the electrode 
and create an electrical signal. Figure adapted from (Freire, et al. 
2003) 
 
1.3.1.1 Immobilisation  
There are different ways to immobilise an enzyme to an electrode surface.  
Physical adsorption, as depicted in Figure 1.7A, is where the enzyme interacts 
with the electrode with a combination of different interactions including 
electrostatic attraction, hydrophobic/hydrophilic interaction, hydrogen bonding, 
and Van der Waals interactions (Moulton, et al. 2003, Walcarius, et al. 2013).  
Crosslinking or inclusion in a conducting polymer is depicted in Figure 1.7B.  
The enzyme is either mixed with or crosslinked with the polymer at some point 
in the polymerisation process (Walcarius, et al. 2013).  Finally, oriented 
attachment to self-assembled monolayers is depicted in Figure 1.7C.  This 











Figure 1.7 Immobilisation of enzyme to an electrode.  
A) physical adsorption.  B) crosslinking or inclusion in conducting 
polymer C) orientated attachment to self-assembly monolayers.  
Figure adapted from (Freire, et al. 2003) 
 
To aid correct orientation, a variant enzyme can be generated by inserting or 
changing a residue in a specific position to a chemically active residue.  
Examples of chemically active residues include a cysteine, which has a thiol 
group, a lysine, which has an amino group, or a glutamate or aspartate, which 
have a carboxyl group. The most commonly used for directed orientation is the 





1.4 Split proteins   
The use of split proteins for diagnostics in biosensors is a relatively new 
concept, but they have been used in protein complementation assays (PCA) 
for some time (Kerppola 2006, Remy, et al. 2007).  Protein complementation 
or split enzyme assays have been used to map protein-protein interactions 
(PPI) for several years.  The assays have used small proteins such as ubiquitin 
(Johnsson and Varshavsky 1994); enzymes, for example β-lactamase 
(Galarneau, et al. 2002), luciferase (Villalobos, et al. 2008) and dihydrofolate 
reductase (DHFR) (Pelletier, et al. 1998); and fluorescent proteins such as 
green fluorescent protein (GFP) and derivatives (Figure 1.9) (Kerppola 2006).  
These proteins have been split into N- and C-terminal fragments, Figure 1.8 
depicts different fragments; highlighted in different colours (blue and red); of 
GFP, firefly luciferase and β-lactamase. Each of the fragments are fused to 
one of a pair of potential interacting target proteins.  If the target proteins 
interact with each other, this interaction brings the two protein fragments 
together and a signal is produced (Michnick 2003, Barnard 2007).  The 
individual protein fragments should not exhibit any activity on their own.  When 
the two fragments are mixed in solution they should have a very low affinity for 
each other, but when brought together by the PPI, the restored activity of the 
two fragments should create a sustained measurable signal (Shekhawat and 
Ghosh 2011).  When splitting a protein, it is not always obvious at which site 
to generate the fragments and they are often insoluble or do not re-associate 







Figure 1.8 Examples of protein fragments that can be used to study 
protein interactions.   
The fragments are shown in red and blue using models based on 
the X-ray crystal structures of the intact proteins.  Figure adapted 
from (Kerppola 2006) 
1.4.1 Fluorescent Proteins 
Bimolecular fluorescent complementation (BiFC) is a sub-type of protein 
complementation assay. In BiFC a fluorescent protein is split and the signal 
change observed on the association of fragments is the fluorescence created 
by the fluorophore (Kerppola 2006).  GFP has 238 amino acids, three of which 
(Ser-65, Tyr-66 and Gly-76) are used to form the fluorophore (Tsien 1998). 
These residues initially cyclise followed by a dehydration reaction and an 
oxidation reaction to form the p-hydroxybenzylideneimidazolinone fluorophore 
(Tsien 1998).  Fluorescent proteins do not require a substrate or a small 
molecule, and are non-toxic to most cells, which make them a convenient 
reporter molecule in complementation assays.   GFP and its derivatives have 
been split into two fragments, each fragment being fused to a specific protein; 
when an interaction is observed, a green fluorescence is detected (Michnick 
2003, Remy and Michnick 2003, Kerppola 2006, Morell, et al. 2009, 





An advantage of BiFC compared with other protein fragment assays is the 
intrinsic fluorescence of the complex. Once the fusion proteins are produced, 
no other reagents are required; just the association of the component parts.  
Furthermore, several interactions can be seen at the same time in the same 
cell by using different fluorescent proteins.  Figure 1.9 shows the principle of 
the approach for two proteins, A and B, which can both interact with protein Z.  
If A interacts with Z then a yellow fluorescence is detected, but if B interacts 
with Z then a cyan fluorescence is detected.  Cell images show, by coloured 
fluorescence, where proteins A and B are localised (Kerppola 2008).  
 
Figure 1.9 Multicolour Fluorescence complementation.   
Protein Z interacts with both protein A and protein B.  When 
protein Z and A interact, the fluorescent protein recombines to 
make yellow fluorescent protein.  When protein Z and B interact, 
the fluorescent protein recombines to make cyan fluorescent 
protein.  The cell images show where the different protein localise 
within a cell.  Adapted from (Kerppola 2008).  
  




If the position of the interacting proteins is unknown, then 8 pairs of different 
interacting fusion proteins may need to be tested.  This is made up of 8 fusion 
proteins in total.  Each interacting partner needs to be fused to the N and C 
terminus of each of the protein fragments as demonstrated in Figure 1.10  In 
this theoretical example, only a subset will create a fluorescent signal. 
 
 
Figure 1.10  Multiple combinations of Fluorescent protein fragments and 
interacting partners.   
Where the interactions are not known and a rational design cannot 
be implemented, then 8 different combinations of fusion protein 
should be tested.  Both interacting proteins: A & B, on the C and 
N terminal of both fragments. Only the combinations that bring the 
fragments of fluorescent protein together will give a signal. Image 










There are advantages and disadvantages of different combinations of 
fluorescent protein fragments in BiFC analysis.  Yellow fluorescent protein 
(YFP) has a low spontaneous association, and would, therefore, give a low 
background, but the fluorescence intensity is weak. YFP can be combined with 
CFP so multi-colour analysis is possible.  Venus, a derivative of YFP, has a 
higher fluorescence intensity, but also a higher occurrence of spontaneous 
association, it too can be combined with CFP fragments.  The addition of the 
mutation M153T to Venus lowers the spontaneous association (Kerppola 
2008). 
The rates of the multiple steps in fluorophore formation vary for different 
fluorescent proteins (Robida and Kerppola 2009). Thus, in selecting the BiFC 
method, consideration must be given to the time taken for the fluorophore of 
the fluorescent protein to form.  Furthermore, once the fluorescent protein has 
been formed it cannot dissociate, therefore dynamic reactions cannot be 
observed.  However, this method is excellent for determining if protein ‘X’ 
interacts with protein ‘Y’ (Morell, et al. 2009).  In several recent studies by 
Robida and Kerppola (Kerppola 2006 A, Kerppola 2006 B, Kerppola 2006 C, 
Robida and Kerppola 2009), BiFC was used to visualize PPI in living cells, and 
showed that conditional BiFC complex formation depends upon the folding 
environment in the cell and the folding efficiencies of each of the fluorescent 
proteins.  In these studies, the interaction between the FK506-binding protein 
(FKBP) and FKBP rapamycin binding domain (FRB) was used as a model 
interaction.  Figure 1.11 shows this model interaction, which has been well 
documented and is inducible by rapamycin. FKBP and FRB fused to 
complementary fragments of YFP were expressed.  Inhibition of the interaction 
between FKBP and FRB stopped the further formation of the fluorescent 
protein but did not disrupt existing fluorescence.  More than one split 
fluorescent protein can be used at the same time.  If more than one colour of 
fluorescence is used, this gives the chance to see multiple PPIs 
simultaneously.  Care must be given to which fluorescent proteins are chosen, 
as their emission spectra must be distinguishable, and the time taken for 





Figure 1.11 Rapamycin inducible interaction between FKBP (the FK506-
binding protein) and FRB.   
This interaction is inducible by rapamycin, and is often used as a 
model interaction that can be turned on and off. 
 
1.4.2 Luciferases 
Several different luciferases have been split into two fragments, and these 
have been used to show many different PPIs in different cell types.  The 
luciferases are enzymes that produce bioluminescence through oxidation.  
Firefly (Paulmurugan and Gambhir 2003, Luker, et al. 2004, Paulmurugan, et 
al. 2006), Renilla (Paulmurugan and Gambhir 2003) and Guassia (Remy and 
Michnick 2006) luciferases have been split for use in PCAs.  More recently, 
click beetle luciferase has been split for use in dual colour PCAs (Villalobos, et 
al. 2010).  Intramolecular systems have also been designed where the target 
of interest is expressed in the middle of the two split luciferase fragments, and 
correct folding of the luciferase is induced on a ligand binding to the target 
protein (Binkowski, et al. 2009, Ataei, et al. 2013).  An advantage of the use of 
luciferases compared to fluorescent proteins is that the interaction is reversible 










Firefly luciferase was originally fragmented between amino acid 437 and 438.  
Paulmurugan et al (2005) fused fragments of firefly luciferase to MyoD and Id, 
which are two proteins that are known to interact.  Firefly luciferase oxidised 
D-luciferin when both fusion fragments were present, and bioluminescence 
was observed.  Studies showed similar results in both live mice and HEK 293T 
cells (Paulmurugan, et al. 2005, Paulmurugan, et al. 2006, Paulmurugan and 
Gambhir 2005).  There was, however, a high background due to residual 
activity in the N-terminal fragment.  Analysing many different fragments 
improved the signal to noise ratio.  The optimal protein fragments have an 18 
amino acid overlap, which would not have been predicted by rational design 
(Paulmurugan and Gambhir 2005). 
Firefly luciferase can be used in conjunction with Renilla luciferase.  Renilla 
luciferase oxidises a different substrate, coelenterazine.  The resulting 
emission spectrum of Renilla is different to that of Firefly luciferase, and 
therefore both systems can be used simultaneously to observe more than one 
interaction (Michnick, et al. 2010).  Split Renilla luciferase has also been used 
individually, for example to detect viral PPIs in influenza.  Influenza B 
polymerase acidic protein and basic protein were known to interact, which is 
consistent with literature (Deng, et al. 2011).   
Guassia luciferase is much smaller than Firefly and Renilla luciferase and its 
luminescence is 100-fold more intense (Tannous, et al. 2005).  Remy and 
Micknick developed an assay by fusing the split Guassia luciferase to each 
part of a leucine zipper (Remy and Michnick 2006).  They demonstrated that 
the system could work with a reversible PPI using the rapamycin inducible 
FKBP/FRB interaction (Figure 1.11).  Levels of bioluminescence observed 
correlated well with rapamycin concentrations (Remy and Michnick 2006).   
Despite only 48% sequence identity, the two click beetle luciferases have very 
similar predicted secondary structures to Firefly luciferase.  The click beetle 
luciferases were dissected into fragments based on those that had been 
engineered for firefly luciferase.  The fragments comprised amino acids 2-413, 
and amino acids 395-542.  The emission spectra of click beetle red (CBR) and 




While CBR and CBG both turn over the same substrate, their emission maxima 
are far enough apart to be resolved.  These fragment pairs were successfully 
tested with the rapamycin inducing interaction between FKBP and FRB (Figure 
1.11).  Both pairs of click beetle luciferase were used to show signalling in the 
ubiquitin - proteasome pathway.  The N-terminal fragment of CBR (red) was 
fused to IκBα and the N-terminal fragment of CBG (green) was fused to β-
catenin (β-cat), while the C-terminal fragment of CBG was fused to β-TrCP, 
which is a common partner of both β-cat and IκBα (Figure 1.12).  All three 
constructs were co-transfected into cells and luminescence was monitored and 
successfully showed the different interactions of the target proteins at different 
times (Villalobos, Naik et al. 2010).  
 
Figure 1.12 Fusion proteins for click beetle green (CBG) and click beetle 
red (CBR) luciferase.   
A) The N-terminal of CBR was fused to IκΒα, and the N-terminal of 
CBG was fused to β-cat.  B) The C-terminal of CBG was fused to 
βTrCP.  Image adapted from Villalobos, et al. (2010). 
 
Recently, purified firefly luciferase fragments have been used in a completely 
in vitro system, in the first demonstration that this type of assay with a 
luciferase is ideal for diagnostics.  The split firefly luciferase was fused to FKBP 
and FRB and the interaction was induced with rapamycin (Figure 1.11).  There 
was a high signal to background ratio and the detection of luminescence was 
very quick.  The stability was investigated by incubating the interacting proteins 
for 1 h at 37oC and then, on completing the assay, the luminescence reduced 






diagnostics, but these results show potential (Ohmuro-Matsuyama, et al. 
2013). 
 
1.4.3 Split TEM-1 β-lactamase 
The ampicillin resistance gene (amp) encodes the 29 kDa, monomeric TEM-1 
β-lactamase that inactivates β-lactam antibiotics.  Wehrman, et al (2002) and 
Galarneau, et al (2002) split β-lactamase for use in PCAs. In both cases, the 
enzyme was split at almost the same position (Galarneau, et al. 2002, 
Wehrman, et al. 2002), residues 26-196 (BLF[1]) & 198-290 (BLF[2]) and 
residues 25-197 (α-fragment) & 198-288 (ω-fragment) respectively. Flexible 
Gly4Ser linkers of different lengths were introduced between the target protein 
and the β-lactamase fragments in both studies (Galarneau, et al. 2002, 
Wehrman, et al. 2002).  The β-lactamase signal was optimised in the 
Galarneau et al (2002) study by introducing the M182T mutation that stabilises 
wt β-lactamase (Sideraki, et al. 2001) within the BLF[1] fragment (Galarneau, 
et al. 2002). The mutant version of BLF[1] displayed superior results compared 
with the original BLF[1] fragment (Galarneau, et al. 2002). 
In the Wehrman et al (2002) study, the fragments of β -lactamase were fused 
to the Jun and Fos helices of the transcription factor AP1, that are known to 
interact (Wehrman, et al. 2002). The interaction between the helices mimics 
the interaction of two target proteins in a PCA.  Using the interaction between 
Jun and Fos a library was made to screen for improvement in the split β-
lactamase system. The library comprised tri-peptide inserts that were 
introduced between the C-terminus of the α-fragment and the linker, and the 
N-terminus of the ω-fragment and the linker.  The peptides were produced 
from a reduced alphabet that enriched charged peptides by using the 
degenerate codon VRK, where ‘V’ is any base except thymine, ‘R’ is either of 
the 2 purines, and ‘K” is a Ketone.  Therefore, this degenerate codon set only 
produces the amino acids His, Gln, Arg, Asn, Lys, Ser, Asp, Glu, and Gly.  The 
purpose of enriching charged peptides relied on the premise that a charge-
charge interaction would have the greatest effect on stabilising the two 




selecting for clones using increasing ampicillin concentrations, 12 clones 
exhibiting enhanced activity were chosen and analysed.  The tripeptide inserts 
always occurred in the α-fragment, so the ω-fragment remained unchanged.  
The α-fragment with the insert Asn-Gly-Arg (NGR) exhibited the greatest effect 
and was further analysed.  The NGR mutant reduced the signal to noise ratio 
1000-fold for interaction with just the Jun and Fos helix.  A further interaction 
between the extracellular domain of the human immune cell antigen CD40, 
and a 12-mer peptide (BW10-1), which had previously been shown to interact, 
was also tested.  Here, the NRG mutant showed a 12-fold increase over the 
original α-fragment.   In the same study the rapamycin induced interaction 
between FKBP and FRB (Figure 1.11) was also used as a model interaction 
to successfully test this split protein assay in mammalian cells (Wehrman and 






Figure 1.13 In vitro nitrocefin assay with fragments of β-lactamase  
This schematic displays the interaction of the two β-lactamase fragments.  (A) Demonstrates the interaction being 
brought together with a small molecule, the divalent metal nickel, in this case.  (B) Demonstrates the two fragments 





Split proteins generally perform much better in vivo than in vitro.  The act of 
splitting a protein will compromise the integrity and stability of the protein.  The 
reason split proteins are better in cells is most likely due to the presence of 
chaperone proteins (Wehr and Rossner 2016).  There have, however, been 
some in vitro studies involving β-lactamase fragments (de las Heras, et al. 
2008, Fry, et al. 2008, Schnee, et al. 2012). 
In vitro studies have been conducted utilising purified fragments of split β-
lactamase. These were expressed with a His6 tag separated from the fragment 
by a linker.  As demonstrated in Figure 1.13 association of the fragments was 
initially mediated by using nickel ions and then using an anti-His-tag antibody.  
The interaction of the two β-lactamase fragments was detected using 
nitrocefin, showing functional complementation (de las Heras, et al. 2008).  
The same purified split β-lactamase system was used to detect anti-herpes 
simplex virus (HSV) type 1 and type 2 immunoglobulin G (IgG) (Fry, et al. 
2008).  One of the enzyme fragments was linked to a peptide, which is specific 
for HSV IgG, and the second enzyme fragment was linked to protein G, which 
binds all IgGs.  Upon peptide and protein G binding to HSV IgG the enzyme 
fragments were brought together. 
Split β-lactamase was used in another cell free assay to investigate the 
interactions of the human cytomegalovirus (HCMV) nuclear egress complex 
(Schnee, et al. 2012).  The two non-functioning fragments of β-lactamase 
(Galarneau, et al. 2002) were fused to the two proteins of interest from HCMV 
nuclear egress complex and then purified.  When brought together in a cell-
free PCA, a nitrocefin assay confirmed that the HCMV proteins interacted 
(Schnee, et al. 2012). 
1.4.4 Other split enzymes of interest 
In one particular study, the redox enzyme horseradish peroxidase HRP has 
been split and used in a PCA assay (Martell, et al. 2016).  This is of particular 
interest, in the context of this thesis, because HRP is a redox enzyme and 
could be used in conjunction with an electrode to create an amperometric 
biosensor.  Martell et al determined by rational design, 17 different split sites 




the 17 fragment pairs that were created, regained some activity (Martell, 
Yamagata et al. 2016).   
 
Figure 1.14 HRP gene with arrows indicating the 17 cut sites.   
Fluorescent images show that cut sites at 58, 195, 213, 224, 257, 
269, and 288 have some fluorescence.  Disulphide bonds are 
shown. Figure adapted from (Martell, Yamagata et al. 2016) 
 
The most active fragment pair, sHRPa’ and sHRPb’, still gave a lower 
fluorescence intensity than full-length HRP when tested with Amplex UltraRed 
in live cells.  The brightness was improved by directed evolution of the sHRPa’ 
and sHRPb’ fragments in turn, using yeast display.  The clones of interest were 
then tested in mammalian cells and two were shown to yield a signal as intense 
as full-length HRP (Martell, et al. 2016).  This has only been shown in vivo and 
there are serious challenges to expression of full length HRP in bacterial 
systems and so it is unlikely that this will be a useful system for in vitro PCAs. 
However, alternative simpler redox enzymes that can be produced and purified 
from bacteria may be developed, such as ascorbate peroxidase. 
1.4.5 Split enzymes in biosensor technology 
A split-protein protease sensor has been designed where intramolecular coiled 
coils were connected via a linker to the C-terminal domain of firefly luciferase. 
As depicted in Figure 1.15, upon cleavage of the intramolecular coiled-coil, a 
second coil attached to the N-terminal fragment of firefly luciferase interacted 
with the first coil, thus bringing the two fragments of luciferase back together.  
Figure 1.15 demonstrates how the cleavage leading to an ‘on’ state and light 





Figure 1.15 Split firefly luciferase used in a protease sensor.   
Auto inhibited coiled coils attached to fragments of firefly 
luciferase.  Upon cleavage of the coiled coils the fragments can 
come together and light is produced. Figure adapted from 
Shekhawat, et al. (2009).  
 
Shekhawat et al (2009) went on to use the same auto-inhibited coiled coil 
system with split β-lactamase with success.  These experiments were 
performed in rabbit reticulocyte lysates like many other PCA assays 














1.5 Alkaline phosphatase 
In nature there are many alkaline phosphatases (APs; EC 3.1.3.1) that occur 
in numerous organisms from all three domains of life: archaea (Wende, et al. 
2010, Sharma, et al. 2014) bacteria (Kim and Wyckoff 1991) and eukarya 
(Sharma et al., 2014). Generally, alkaline phosphatases are homodimeric 
enzymes and each catalytic site contains two zinc ions and one magnesium 
ion.  Mammalian alkaline phosphatases are less thermostable, have a higher 
pH optimum, and have higher Km values compared with bacterial APs.  These 
properties, however, differ noticeably between the different mammalian AP 
isozymes (Millan 2006).  E. coli has three isozymes of alkaline phosphatase, 
identified by different migration patterns on a starch gel and from different 
patterns after tryptic digest.  (Schlesinger and Andersen 1968).  The three 
isoforms are a product of 2 slightly different monomers, which differ only in an 
N-terminal arginine.  Isozyme 1 contains identical monomers with the arginine.  
Isozyme 3 contains identical monomers without the arginine, and isozyme 2 is 
a mixture of the two different monomers (Piggot, et al. 1972). 
The structure and mechanism of E. coli alkaline phosphatase (ECAP) is well 
studied and many wild type and mutant crystal structures are available.  It is a 
homodimer with 449 residues in each monomer without the N-terminal arginine 
(Garen and Levinthal 1960). There are 43 structures in the Protein Data Bank 
(PDB) to date, for ECAP.  These entries include wild type alkaline phosphatase 
(Kim and Wyckoff 1991, Stec, et al. 2000, Bobyr, et al. 2012), and ECAP in 
complex with tungsten, vanadate, cobalt phosphonic acid, mercaptomethyl 
phosphate and aluminium fluoride, (Holtz, et al. 1999, Holtz, et al. 2000, Wang, 
et al. 2005, Peck, et al. 2016) to help study intermediate catalytic states.  Other 
structures include mutations in the active site (Stec, et al. 1998, Wang and 
Kantrowitz 2006, Andrews, et al. 2013), mutation of residues that coordinate 
with metal ions (Tibbitts, et al. 1994, Ma, et al. 1995, Murphy, et al. 1995, Ma 
and Kantrowitz 1996, Tibbitts, et al. 1996, Murphy, et al. 1997, Zalatan, et al. 
2008) and mutations that change the kinetic parameters (Dealwis, et al. 1995, 
Dealwis, et al. 1995, Le Du, et al. 2002, Sunden, et al. 2015).  The residues 
responsible for catalysis have been investigated and are well understood 




deduced.   
 
1.5.1 Alkaline phosphatase mechanism 
Alkaline phosphatase catalyses the hydrolysis of phosphate monoesters, but 
a transphosphorylation reaction occurs when there is a large concentration of 
a phosphate acceptor, as depicted in the kinetic scheme for alkaline 
phosphatase, Figure 1.16 (Coleman 1992). 
 
Figure 1.16 Kinetic scheme for alkaline phosphatase.   
This description takes into account both hydrolysis and 
transphosphorylation. E is the enzyme, E-Pi is the 
phosphoenzyme complex, S is the substrate, R1OH is the alcohol 
product, ROH is the phosphate acceptor, and Pi is the inorganic 
phosphate  
The crystal structures of wild type ECAP, with and without phosphate in the 
active site, along with the crystal structure of the Cd (II) substituted enzyme, 
give enough information to suggest a mechanism.  Alkaline phosphatase 
without phosphate is clearly the native state, whereas when phosphate is 
bound, it is predominantly in the E.Pi form.  The Cd (II) substituted enzyme is 
mainly in the E-Pi form (Kim and Wyckoff 1991).  As shown in Figure 1.16 
alkaline phosphatase has two different types of activity; hydrolysis and 
transphosphorylation.  It is understood that the serine at position 102 creates 
the phospho-serine intermediate and both reactions go through a phospho-
serine intermediate (E-Pi). The structures of many mutant enzymes, with 
mutations all around the active site, are available (Murphy, et al. 1995, Tibbitts, 




O'Brien, et al. 2008, Zalatan, et al. 2008). Other amino acids around the active 
site and the metal ion hold the substrate in place ready for catalysis, as shown 
in Figure 1.17.  The rate limiting step is the release of phosphate (Murphy, et 
al. 1995, Tibbitts, et al. 1996, Holtz, et al. 2000, Wang, et al. 2005, Wang and 
Kantrowitz 2006, O'Brien, et al. 2008, Zalatan, et al. 2008). 
 
Figure 1.17 Chemical mechanism for alkaline phosphatase.    
Serine 103 is activated by the M2 zinc, which initiates a 
nucleophilic attack on the phosphate group of the phosphate.  The 
M1 zinc activate a water molecule which attacks the intermediate 
and releases the product.  Adapted from (Stec, et al. 2000) 
 
As shown in Figure 1.17 the zinc atom (M2) activates Ser 102, which in turn 
does a nucleophilic attack on the phosphate group of the substrate, creating 
the phospho-serine intermediate. The M1 zinc is positioned to activate a water 
molecule which attacks the phospho-serine intermediate, releasing the 








1.5.2 Mutational studies on the active site of alkaline phosphatase  
Before the amino acid composition was known it was identified that there was 
a catalytically important arginine residue (Daemen and Riordan 1974).  This 
was discovered by chemical modification using butanedione and 3 different 
glyoxals, which rapidly inactivated the enzyme (Daemen and Riordan 1974).  
The nucleotide sequence of the alkaline phosphatase gene of E. coli was 
determined by Chang et al (Chang, et al. 1986).  The function of the arginine 
at position 166 has been investigated by site directed mutagenesis showing 
that this residue is involved in the catalytic mechanism of alkaline phosphatase 
(Chaidaroglou, et al. 1988).  However, in this study the arginine was not 
determined to be essential.  The mutant versions of alkaline phosphatase; 
R166S and R166A had very similar kinetic properties, particularly the kcat, to 
wild type.  The reason given for the inactivation with butanedione is that it is 
bulky and may have sterically hindered catalysis.  However, in conditions 
where transphosphorylation occurs, the Km did differ (Chaidaroglou, et al. 
1988). 
When Ser102 is replaced by Cys, the enzyme turnover can still proceed, which 
is consistent with a phospho-enzyme intermediate using the thiol group instead 
of the hydroxyl group (Butler-Ransohoff, et al. 1988).  When Ser102 is replaced 
with a glycine or an alanine a reduction in excess of 2000-fold in kcat was 
observed (Wang and Kantrowitz 2006). When Ser102 is replaced with a 
threonine (S102T) it shows a reduction in excess of 4000-fold in kcat  and 
effectively traps the enzyme in a covalent intermediate state (Wang and 
Kantrowitz 2006).  Some S102T crystals were soaked with inorganic 
phosphate (Pi), and the structures were determined both with and without Pi.  
The threonine was covalently attached to the phosphate a shift of the 
phosphate by 1.3 Å compared to wild type was observed. The stereochemistry 
of the phosphorus was inverted compared to the wild type enzyme, which is 
probably why this mutation allows the covalent intermediate structure to be 




1.5.2.1 The effects of zinc in E. coli alkaline phosphatase 
Zinc is essential for alkaline phosphatase activity (Schlesinger 1966).  The two 
zinc ions are referred to as Zn1 and Zn2.  Zn1 is penta-coordinate: The 
imidazole nitrogens of His331 and His412, both carboxyl oxygens of Asp327, 
and one of the phosphate oxygens.  Zn2 is tetra-coordinated by the imidazole 
nitrogen of His 370; the carboxyl oxygens of Asp51 and Asp369, and one of 
the phosphate oxygens (Figure 1.15) (Kim and Wyckoff 1991). 
1.5.2.2 Increasing catalytic efficiency 
Chaidaroglou and Kantrowitz (1998) mutated aspartate 101 to alanine 
(D101A) and showed that it had enhanced the catalytic activity in the presence 
of a phosphate acceptor.  In the absence of a phosphate acceptor the turnover 
rate is 37 s-1 compared to 70 s-1 for wild type.  The Km for para-nitrophenyl 
phosphate (pNPP) decreases to 3.7 μM for D101A from 7.4 μM for wild type.  
Therefore, there is little difference in kcat/Km (Chaidaroglou and Kantrowitz 
1989). 
Mandecki et al. (1991) investigated 9 different amino acids which were within 
10 Å of the catalytically important residue Ser 102.  These were residues Val 
99, Thr 100, Thr 101, Ala 103, Ala 104, Ser 105, Ala 106 and Thr 107 along 
with Lys 328.  Approximately 170 mutants were screened and 8 showed an 
increase in specific activity.  These were V99A, T100V, T100I, D101S, A103S, 
A103C, T107V and K328R.  D101S had more than a 4-fold increase in specific 
active over wild type at pH 8.0, and an increase of over 35-fold at pH 10. This 
represented the highest increase in activity of the 8 mutants (Mandecki, et al. 
1991).  Chen et al. successfully crystallised the D101S mutant and determined 
a 3D structure. This structural information and subsequent experiments, where 
both wild type and D101S crystals were soaked with phosphatase, suggested 
that the D101S mutant does not retain the product phosphate to the same 
extent as wild type (Chen, et al. 1992).  It is well documented that alkaline 
phosphatase is inhibited by phosphate (Applebury and Coleman 1969, 
Applebury, et al. 1970) and the release of phosphate is the rate limiting step 
(Hull, et al. 1976) this, explains why the D101S variant is catalytically enhanced 




Alkaline phosphatase does not turn over substrate when monomeric, but only 
when it is in a dimer.  This indicates there is some form of cooperativity 
between the subunits. (Schlesinger 1965, Schlesinger and Barrett 1965).  
Subunit cooperativity could be either conformational selection or induced fit.  
This is poorly understood, and therefore in order to create a stable monomer, 
and to understand the mechanism of control and regulation of AP due to 
subunit interactions, several mutants of the enzyme were constructed (Martin, 
et al. 1999, Boulanger and Kantrowitz 2003, Orhanovic, et al. 2006). 
1.5.3 Mutational studies on the alkaline phosphatase dimeric 
interface. 
The kinetic properties of wild type ECAP and several mutants: R10A, R10K, 
R24A, R24A, R24K, R10A-R24A and T59A were assessed in a study by Martin 
et al. (1999).  The intramolecular interactions on the dimeric interface of R10, 
R24 and T59 are shown in Figure 1.18. The studies were performed in 1.0 M 
Tris, which is a phosphate acceptor, thus the activity being observed is both 
transphosphorylation and hydrolysis.  There is less than a 26% decrease from 
69.5 s-1 in kcat  in all cases and less than a 30 % decrease in Km from 20.6 μM.  
The kinetic parameters for all of the variants were similar to wild type at pH 
8.0, 25o C and 1.0 M Tris using pNPP as a substrate (Martin, et al. 1999).   
The key difference between variants and the wild type was in their stability.  
They were tested at a range of pH values (3.0 – 7.4) to investigate the pH at 
which the dimers would separate into monomers.  A sucrose density profile 
showed the wild type enzyme was monomeric at pH 3, a mixture of species at 
pH 3.5 and a dimer at pH 4 and above.  The same conditions were tested on 
a size exclusion column, and the data agreed with those of the sucrose 
gradient.  A sucrose gradient at pH 4 indicated that all of the mutant proteins 
are monomeric but, as expected, the wild type remained dimeric.  At pH 4.5 
R10A, R24A and R24K are monomeric, R10A-R24A, R10K and T59A show a 
mixed population.  Finally, at pH 5.0, R24K, R24A and R10A-R24A show a 
mixed population whereas T59A and R10A both show dimeric peaks (Martin, 






Figure 1.18 Interactions of R10, R24, T59, and T81 of one subunit (A; 
purple) that are all located at the dimeric interface.  
Hydrogen bonds are shown as blue lines to residues on the other 
subunit (B; cyan).  (a) R10 interacts with backbone carbonyl 
oxygens of V430 and L432.  (b) R24 interacts with side chains of 
T85 and D437.  (c) T59 interacts with the main chain of Q416.  (d) 
T81 interacts with T81 and G431. 
The study (Martin et al., 1999) went on to show transverse urea gradient gel 
electrophoresis (TUGGE).  Folded compact proteins travel with high mobility 
in the absence of urea.  Unfolded chains in high urea will be retarded in the 
gel.  Wild type AP has a distinct pattern with fast moving protein below 2.7 M 
urea and slow moving protein at a higher concentration of urea.  All of the six 
mutants had the same unfolding pattern as each other but different from the 
wild type enzyme.  The mutants unfolded at a lower concentration of urea.  
This demonstrates that each variant forms a less stable dimer than the wild 




As shown in Figure 1.18 the side chain of R10 forms hydrogen bonds to the 
backbone oxygens of L432 and V430.  In this study Martin et al. (1999) 
changed R10 to both an alanine and a lysine. Substituting to an alanine 
negates both of the hydrogen bonds whereas a lysine only negates the 
hydrogen bond to V430.  The side chain of R24 interacts through a hydrogen 
bond with the side chain of T85 and D437, and the backbone of T433.  
Mutating to an alanine negates all three interactions.  Finally, the R group of 
T59 forms a hydrogen bond with the backbone of Glu416 (Martin, et al. 1999).  
The mutations most prone to dissociation were identified as R24A and R24K, 
suggesting that of the three residues studied, R24 is the most important for 
dimer stability.  Further to the quaternary stability, the TUGGE demonstrated 
these mutations also have an effect upon the tertiary structure (Martin, Pastra-
Landis et al. 1999).  
The T81A mutation is also at the subunit interface as shown in Figure 1.18.  It 
has a limited effect on substrate turnover, but as a consequence of the 
mutation the stability was reduced (Orhanovic, et al. 2006).  In this study, the 
T81A mutation was chosen because it interacts with T81 in the opposite 
monomer via a hydrogen bond in the centre of the dimeric interface, and it was 
postulated that it might have some role in dimeric stability.   If there was a small 
conformational change it would not be obvious in a crystal structure, but the β-
sheet stretching underneath the active site to the dimeric interface seems to 
communicate, via a hydrogen bond, between two threonines at position 81 and 
Gln83 (Orhanovic, et al. 2006) . 
The kinetic properties of T81A were compared with the wild type enzyme.  The 
Km for wild type and T81A were 7.8 μM and 7.3 μM respectively.  The assay 
conditions were the same as in the study by Martin et al. (1999). The kcat was 
reduced for T81A to 37.0 s-1 from 61.8 s-1 for wild type AP.  The metal ions 
from wild type and T81A were removed by chelation with EDTA and then were 
re-introduced, and wild type activity was restored but T81A activity was not. 





A mutation that successfully produced a stable monomer was T59R 
(Boulanger and Kantrowitz 2003).  However, this mutant monomer was 
unlikely to ever be capable of associating as a homodimer as there is an 
obvious steric clash and positive charge repulsion (Boulanger and Kantrowitz 
2003). 
 
Figure 1.19  A schematic of the T59R mutation.  
Left; in wild type AP, the hydrogen bond between the side chains 
of Thr 59 and Gln 416 is shown as a dashed line. Right; when 
mutated to Arg 59 the large side chain sterically clashes with Gln 
416, highlighted with a red circle 
Sucrose density gradient analysis showed wild type AP and T59A to be 
dimeric, and T59R to be monomeric.  Size exclusion chromatography showed 
similar retention times for wild type and T59A, whereas T59R had a longer 
retention time.  The Stokes radii were calculated as 3.41 nm for wild type, 3.35 
nm for T59A, and 2.93 nm for T59R.  The kinetics data for wild type, T59A and 
T59R were compared and kcat values were 74.7 s-1, 56.3 s-1and 2.1 x10-4 s-1 
respectively, demonstrating that wild type and T59A are similar whereas the 
T59R cat aonstant was reduced by a factor of ca. 3 x 106.  The Km values were 
21.8 μM, 24.9 μM and 39.2 μM respectively indicating that substrate can bind 
but catalytic turnover is compromised in the T59R enzyme.  Circular dichroism 
(CD) studies on the three enzymes showed that they have almost identical 
secondary structure. CD was also used to indicate thermal stability by 
monitoring ellipticity at 222 nm and revealed that wild type and T59A have a 
Tm  in excess of 90oC whereas T59R had a Tm of only 43oC.  Finally, the metal 




T59A have a normal content of zinc and magnesium, with T59R having only a 
trace amount of both metals (Boulanger and Kantrowitz 2003). 
1.5.4 Current Uses of alkaline phosphatase 
In molecular biology, ECAP is a valuable tool for the removal of terminal mono-
esterified phosphate from both ribo- and deoxyribo-oligonucleotides. For 
example, removing phosphates from a vector helps prevent its re-ligation, thus 
reducing vector-only background during cloning experiments.  ECAP is used 
in laboratory assays as a reporter enzyme, often fused to an antibody or other 
protein of interest.  These fusions can be used in epitope mapping, 
histochemistry, immunoblotting, and ELISA (Sambrook, et al. 1989).  
1.5.5 Substrates of E. coli alkaline phosphatase. 
ECAP has many substrates as it hydrolyses a wide variety of 
phosphomonoesters and also catalyzes transphosphorylation reaction by 
transferring a phosphoryl group to alcohol groups in the presence of certain 
phosphate acceptors (Garen and Levinthal 1960).  
 
1.5.5.1 Chromogenic substrates 
Typically, para-nitrophenyl phosphate (pNPP) is used for chromogenic 
detection of alkaline phosphatase (Coleman 1992).  It is a colourless 
substance which turns yellow when the phosphate is removed.  This colour 
change can be observed visually, but accurate measurements are made using 
a spectrophotometer at 405 nm. 
 
1.5.5.2 Electrochemical substrates 
4-amino-1-naphthyl phosphate (4ANP) can be used as a substrate for alkaline 
phosphatase and detected electrochemically.  Alkaline phosphatase releases 
the phosphate, giving 4-amino-1-naphthol-HCl (4AN), 4AN is oxidised to 
produced 1,4-naphthoininoquinone (4NIQ). The product, 4NIQ releases 2 





1.6 Aims of this work 
The overall aim was to create a novel, electrochemically active split-enzyme 
for use in a biosensor.  This was to be achieved through a series of 
investigations, including:  
• Splitting β-lactamase and producing purified N- and C-terminal 
fragments, then exploring whether these fragments can be functionally 
associated in an in vitro assay. 
• Mutational studies on the dimeric interface of alkaline phosphatase in 
order to create a stable monomeric alkaline phosphatase, followed by 
exploring whether the monomers can be brought back together and 
catalyse substrate turnover. 
• Preparing relevant Affimers that can bind a target molecule at two 
separate epitopes. Generating fusions between the split enzyme 
monomers and investigating if this interaction can be used to 
regenerate a functional enzyme. 
Splitting β-lactamase was a proof of concept as it had been used in previous 
protein complementation assays. Chapter 3 describes how the β-lactamase 
coding fragments were cloned, produced, and purified and used in basic 
assays to assess functional reconstitution.  
Chapter 4 deals with alkaline phosphatase and details the residues at the 
dimer interface that were selected for alteration with the intention of generating 
a stable monomer.  Starting with the known mutant T59R, which forms a stable 
monomer but cannot interact to dimerise, this residue was further investigated 
by a saturation mutagenesis approach.  A modest alanine substitution library 
of residues along the dimeric interface was also created. R10, R24, T59, and 
T81 were all included as they have been shown to increase instability in the 
enzyme.  Bioinformatics analysis was also used to select D28, R34, R62, and 
Y98.  Single and double mutants of these alanine substitutions were created 
and assayed for activity.  One particular residue, R62, was investigated further 




used to investigate possible residues to determine whether any variants were 
more stable than the leading double mutant from the alanine library studies. 
Chapter 5 describes further characterisation of the most promising mutants 
from the work reported in Chapter 4. Initially, CD and Optim instruments were 
used to assess the stability of the proteins, followed by size exclusion 
chromatography (SEC) and analytical ultracentrifugation (AUC) to assess their 
monomeric or dimeric state. Complementary coiled-coil sequences fused to 
the N-terminal of the mutant protein were used to drive association of the 
mutant forms of the monomers.  Further investigations were undertaken into 
the stability and the secondary structure of the coiled-coil mutant forms.  
 
Chapter 6 describes how Affimers directed to two different epitopes on the 
model protein GFP were produced.  The Affimers were characterised and used 
in ELISA and sandwich ELISA to show that they can be used with alkaline 
phosphatase and that two distinct binding sites were recognised.  The split 
alkaline phosphatase was also tested using these two model proteins.   





Chapter 2  





2.1 Standard Buffers, Reagents, and Media. 
2.1.1 Buffers/reagents 
2.1.1.1 Tris-acetate-EDTA (TAE)  
40 mM Tris-acetate,  
1 mM ethylenediaminetetraacetic acid (EDTA),  
made up as a 50 x stock, pH 8.0 
2.1.1.2 Tris-borate-EDTA (TBE) 
220 mM Tris pH 8.3 
180 mM Borate 
5 mM EDTA 
2.1.1.3 Buffers for chemically competent cell preparation 
TFB1     TFB2 
3 mM potassium acetate,   10 mM RbCl2 
100 mM RbCl2   75 mM CaCl2  
50 mM MnCl2   10 mM MOPS, 
10 mM CaCl2   15% (v/v) glycerol 
15% (v/v) glycerol 
TFB1 pH adjusted to 5.8 with acetic acid and filter sterilised through a 0.2 μm 
membrane.  TFB2 pH was adjusted to 6.5 with potassium hydroxide and filter 
sterilised through a 0.2 μm membrane), 
 
2.1.1.4 IMAC buffers for Affimer and Alkaline Phosphatase purification 
LYSIS buffer:  
 Affimers    Alkaline phosphatase 
50 mM NaH2PO4, pH 7.4  50 mM Tris pH 8.0 
300 mM NaCl   300 mM NaCl 






WASH BUFFER:  
 Affimers    Alkaline phosphatase 
50 mM NaH2PO4, pH 7.4  50 mM Tris pH 8.0 
500 mM NaCl   300 mM NaCl 




 Affimers    Alkaline phosphatase 
50 mM NaH2PO4 pH 7.4  50 mM Tris pH 8.0 
500 mM NaCl    300 mM NaCl 
300 mM Imidazole,    300 mM Imidazole 
 
2.1.1.5 Buffers for Zif- Alkaline Phosphatase purification 
 Lysis buffer:     Binding buffer:  
500 mM Tris pH 8.0   500 mM Tris pH 8.0 
300 mM NaCl   300 mM NaCl 
      
Elution Buffer   Regeneration buffer 
50 mM Tris pH 8.0   50 mM Tris pH 8.0 
300 mM NaCl   300 mM NaCl 






2.1.1.6 SDS PAGE Buffers 
 SDS PAGE gel loading buffer (4x) 15% resolving gel 
200 mM Tris-HCl pH 6.8    15% (v/v) acrylamide (Severn 
20% (v/v) glycerol     Biotech Ltd.),  
8% (w/v) SDS    375 mM Tris-HCl, pH 8.8 
0.4% (w/v) bromophenol blue  0.1% (w/v) SDS 
20% (v/v) β-mercaptoethanol  0.1% (w/v) ammonium  
      persulfate (APS) 
      0.04% (v/v) N,N,N’,N’,- 
      tetramethylethylenediamine 
      (TEMED) 
 
5% SDS PAGE stacking gel  SDS-PAGE running buffer  
5% (v/ v) acrylamide (Severn   25 mM Tris pH 8.3 
Biotech Ltd.)     250 mM glycine 
125 mM Tris-HCl, pH 6.8   0.1% (w/v) SDS 
0.1% (w/v) SDS  
0.1% (w/v) APS  
0.1% (v/v) TEMED 
2.1.1.7 Buffer for western blots 
 Transfer buffer  Tris buffered saline with Tween (TBST) 
0.1 M Tris    50 mM Tris 
0.192 M Glycine   150 mM NaCl 
20 % Methanol   0.1% Tween 20 







2.1.2.1 LB & LB Agar 
Tryptone (10 g/L) 
Yeast extract (5 g/L)  
NaCl (10 g/L)  
2.1.2.2 2TY & 2TY Agar 
Tryptone (16 g/L) 
Yeast extract (10 g/L)  
NaCl (5 g/L)  
Agar (12g/L) 
2.1.2.3 SOC  
Tryptone (20 g/L),   10 ml 1 M MgCl2 (0.1 M), 
Yeast extract (5 g/L)   10 ml MgSO4 (0.1 M)  
NaCl (0.5 g/L)    1 ml 2 M D-glucose (20 mM).  
2.1.2.4 Terrific Broth (TB)  
Tryptone (12.0 g/L) 
Yeast Extract (24.0 g/L) 
Potassium phosphate, Dibasic = 9.4g Potassium phosphate, 
Monobasic = 2.2 g Final pH 7.2 ± 0.2 at 25C  
2.1.2.5 Super Broth (SB) 
Tryptone (35 g/L)  
Yeast extract (20 g/L) 
NaCl (5 g/L) 
1 M NaOH (5 ml/L) 
The ingredients above were dissolved in deionised water, (for agar recipe 
-12 g/L agar was added) and the volume adjusted before the solution was 
autoclaved at 121 °C, 15 psi for 20 min. After autoclaving, the solution was 
cooled in a 50 °C water bath for 30 min before addition of antibiotic to the 




approximately 20 ml per petri dish. For TB and SOC the salt and glucose 
were added after autoclaving 
2.2 Bacterial strains  
Different E. coli strains were used for replication, purification of DNA and 
protein production, depending on the protein being produced.  
2.2.1 XL-1-Blue 
Genotype: recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [F ́ proAB 
lacIqZΔM15 Tn10 (Tetr)]  Source: Agilent   
XL1-blue cells were used for DNA manipulation because they are recA 
deficient which improves insert stability and endA deficient, which is an 
endonuclease, thus improves the quality of the miniprep DNA.  The hsdR 
mutation also prevents cleavage of cloned DNA by the EcoK endonuclease 
system.  Termination of translation is reduced by the supE44 mutation. The 
other mutations in the genotype were not necessary, as blue/white selection 
was not used in this study.  
2.2.2 One shot BL21 (DE3) Star 
Genotype: F- ompT hsdSB (rB-mB-) gal dcm rne131 (DE3) Source: 
ThermoFisher 
BL21 Star (DE3) cells were used for general protein expression because they 
are engineered to reduce the degradation of recombinant proteins.  The cells 
also carry the gene for T7 RNA polymerase, therefore, can be used with a T7 
promoter.  The mRNA is more stable due to a mutation in the RNaseE gene 
(rne131).  The levels of endogenous RNases are reduced, which in turn 
increases the stability of mRNA, making the transcripts more available for the 
ribosome. 
2.2.3 SHuffle T7 Express 
Genotype: F´ lac, pro, lacIq / Δ(ara-leu)7697 araD139 fhuA2 lacZ::T7 gene1 
Δ(phoA)PvuII phoR ahpC* galE (or U) galK λatt::pNEB3-r1-cDsbC (SpecR, 




Shuffle T7- Express cells were used for alkaline phosphatase expression as 
they have been optimized by a number of mutations.  This strain is engineered 
to promote disulphide bond formation in the cytoplasm as it 
constitutively expresses a chromosomal copy of the disulfide bond isomerase 
DsbC.  DsbC promotes the correction of mis-oxidized proteins into their correct 
form.  Furthermore, this strain is deficient in the phoA gene and therefore does 
not produce any endogenous alkaline phosphatase.  
2.2.4 ArcticExpress (DE3)  
Genotype: E. coli B F- ompT hsdS (r8 - m8 - ) dcm+ Tetr gal λ(DE3) endA [cpn 
10 cpn 60 Gent’] source: Agilent 
ArcticExpress cells were used to produce a mutant (T59A-R62A) alkaline 
phosphatase which was fused to a zinc finger (zifAPT59AR62A). The cells were 
derived from E. coli B which naturally lacks the Lon protease and are 
engineered to remove the OmpT protein which is also a protease; this reduces 
the degradation of recombinant proteins, similar to that in BL21 (DE3) cells. 
Transformation efficiency was increased by the presence of the Hte 
phenotype.  Cpn10 and Cpn60 are constitutively expressed from a plasmid 
that contains a gentamycin-resistance gene. These are the antarctica 
chaperonins which help proteins fold at temperatures of 4-12 oC. The other 
mutations in the genome were not necessary for this study. 
2.3 Production of competent E. coli cells 
A LB agar plate containing an appropriate antibiotic was streaked with a 
commercial stock of the appropriate bacterial strain and incubated overnight 
in a static incubator at 37 °C. A single colony was picked and used to inoculate 
5 ml 2TY broth that was incubated overnight at 37 °C with shaking at 220 rpm. 
A 1 ml aliquot of the overnight culture was used to inoculate 50 ml pre-warmed 
2TY broth that was then incubated in a shaking incubator at 37 °C with shaking 
at 220 rpm until an OD600 of 0.4 - 0.6 was reached. The cells were then 
transferred to a sterile 50 ml Falcon tube and chilled on ice for 5 min. After 
centrifugation at 4 °C for 10 min at 4000 x g in a Hermle Z400 K centrifuge with 




buffer and chilled on ice for 5 min. The cells were then centrifuged again for 
10 min at 4000 x g, the supernatant discarded, and the tube wiped dry with 
tissue. The cells were resuspended in 2 ml ice-cold TFB2 buffer chilled on ice 
for 15 min and then 200 μl aliquots pipetted into sterile pre-chilled 1.5 ml 
microcentrifuge tubes. The aliquots were flash frozen in liquid nitrogen and 
stored at -80 °C.  
2.4 Transformation of E. coli  competent cells 
A 50 μl aliquot of competent cells (Section 2.2.4) was defrosted on ice for at 
least 10 min before addition of 10-50 ng plasmid DNA in a total volume of no 
more than 5 μl. The mixture was gently mixed and incubated on ice for 30 min 
before transfer to a 42 °C water bath for 45 s. The microcentrifuge tube was 
then transferred immediately to ice for a minimum of two min before addition 
of 1 ml 2TY broth, pre-warmed to 37 °C. The culture was then placed in a 
shaking incubator at 37 °C with shaking at 220 rpm to permit recovery and 
expression of the antibiotic resistance protein. After one hour, a 100 μl aliquot 
was plated onto an agar plate containing the appropriate antibiotic and the 
remaining culture was centrifuged at 4000 rpm for 4 min in a microcentrifuge. 
All but 100 μl of the supernatant was discarded and the remaining broth used 
to resuspend the bacterial pellet which was then plated out onto a second agar 
plate containing the appropriate antibiotic. Both plates were incubated at 37 





2.5 Molecular Biology 
2.5.1 Cloning 
2.5.1.1 TEM-1 β-lactamase fragment cloning 
Fragment A of the coding region of the β-lactamase gene was amplified using 
PCR.  The PCR reaction contained 50 ng of template DNA, 2.5 µl 10x Phusion 
buffer (NEB), 2 μl of 10 mM dNTPs, 2 μl of 10 nM forward and reverse primer, 
200 U Phusion polymerase (NEB), and double distilled water (ddH2O) to 25 µl.  
The PCR products were digested for 3 h with NdeI and EcoRI, according to 
the manufacturer’s instructions (New England Biolabs - NEB).   A 2 μl aliquot 
of digested DNA was analysed on an agarose gel to check for a correct size 
product.  The remaining DNA was purified using a QIAGEN PCR purification 
kit.  The digested fragment insert was ligated into a pET28c vector digested 
with appropriate restriction enzymes and treated with Antarctic phosphatase 
(NEB).  The ligation reaction contained 40 ng of linearised, phosphatase-
treated pET28c, a 3-fold molar excess of the fragment insert, 1 µl 10x T4 DNA 
ligase buffer (Roche), 200 U T4 DNA ligase (Roche), and ddH2O to 10 µl.  The 
reaction was incubated at 16°C for 16 h, followed by transformation into XL-1 
Blue competent cells and screening using colony PCR, followed by agarose 
gel electrophoresis.  The identity of clones was confirmed by DNA sequencing  
The PCR reaction for fragment B contained 50 ng of template DNA, 5.0 µl 10x 
KOD buffer (Novagen), 5 μl of 0.2 mM dNTPs, 5 μl of 10 nM forward and 
reverse primer, 0.02 U KOD polymerase (Novagen), and ddH2O to 50 µl.  The 
PCR products were digested for 3 h with NcoI and XhoI, according to the 
manufacturer’s instructions (NEB).  2 μl of digested DNA were run on an 
agarose gel to check for a correct size band.  The remaining DNA was purified 
using a QIAGEN PCR purification kit.  The digested fragment was ligated into 
a pET28c vector digested with appropriate restriction enzymes and treated 
with Antarctic phosphatase (NEB).  The ligation reaction contained 40 ng of 
linearised, phosphatase-treated pET28c, a 10-fold molar excess of the insert 
fragment, 1 µl 10x T4 DNA ligase buffer (Roche), 200 U T4 DNA ligase 
(Roche), and ddH2O to 10 µl.  The reaction was incubated at 16°C for 16 h, 




colonies screened by colony PCR, followed by agarose gel electrophoresis.  
The identity of clones was confirmed by DNA sequencing  
2.5.1.2 Site-directed mutagenesis 
To introduce a point mutation(s), two complementary oligonucleotide primers 
containing the mutation(s), and designed to bind to complementary strands of 
the plasmid, were synthesised. Using the pECAP-sort plasmid (see Figure 4.1) 
as a template, a linear amplification temperature cycling was carried out with 
KOD DNA polymerase to extend the two primers.  Typical conditions were: 
Step 1  95oC   Initial denaturation  2 minutes 
Step 2  95oC   Denaturation   1 minute 
Step 3  55oC   Annealing   1 minute 
Step 4  70oC   Extension   1minute/kb 
Step 5  Cycle back to step 2 29 times (30 cycles total) 
Step 6  70oC   Final extension  10 minutes 
 
Following temperature cycling, the methylated template DNA which did not 
contain the mutation was digested by DpnI leaving the non-methylated nicked 
plasmid containing the introduced mutation(s) on both strands. This was then 
transformed into XL-1 Blue cells, the resulting plasmid DNA purified from 
transformants, and the mutation confirmed by DNA sequencing. The following 
primers were used to introduce mutations during these studies. 
T59X alkaline phosphatase 
T59A FOR  5’ GATAGCGAGATTGCAGCAGCGCGCAATTAC 3’ 
T59A REV  5’ GTAATTGCGCGCTGCTGCAATCTCGCTATC 3’ 
T59D FOR  5’ GATAGCGAGATTGATGCAGCGCGCAATTAC 3’ 
T59D REV  5’ GTAATTGCGCGCTGCATCAATCTCGCTATC 3’ 
T59E FOR  5’ GATAGCGAGATTGAAGCAGCGCGCAATTAC 3’ 
T59E REV  5’ GTAATTGCGCGCTGCTTCAATCTCGCTATC 3’ 
T59F FOR  5’ GATAGCGAGATTTTTGCAGCGCGCAATTAC 3’ 
T59F REV  5’ GTAATTGCGCGCTGCAAAAATCTCGCTATC 3’ 
T59G FOR  5’ GATAGCGAGATTGGCGCAGCGCGCAATTAC 3’ 
T59G REV  5’ GTAATTGCGCGCTGCGCCAATCTCGCTATC 3’ 
T59H FOR  5’ GATAGCGAGATTCATGCAGCGCGCAATTAC 3’ 
T59H REV  5’ GTAATTGCGCGCTGCATGAATCTCGCTATC 3’ 
T59I FOR  5’ GATAGCGAGATTATTGCAGCGCGCAATTAC 3’ 
T59I REV   5’ GTAATTGCGCGCTGCAATAATCTCGCTATC 3’ 
T59K FOR   5’ GATAGCGAGATTAAAGCAGCGCGCAATTAC 3’ 
T59K REV   5’ GTAATTGCGCGCTGCTTTAATCTCGCTATC 3’ 




T59L REV   5’ GTAATTGCGCGCTGCCAGAATCTCGCTATC 3’ 
T59M FOR   5’ GATAGCGAGATTATGGCAGCGCGCAATTAC 3’ 
T59M REV   5’ GTAATTGCGCGCTGCCATAATCTCGCTATC 3’ 
T59N FOR   5’ GATAGCGAGATTAACGCAGCGCGCAATTAC 3’ 
T59N REV   5’ GTAATTGCGCGCTGCGTTAATCTCGCTATC 3’ 
T59P FOR   5’ GATAGCGAGATTCCGGCAGCGCGCAATTAC 3’ 
T59P REV   5’ GTAATTGCGCGCTGCCGGAATCTCGCTATC 3’ 
T59Q FOR   5’ GATAGCGAGATTCAGGCAGCGCGCAATTAC 3’ 
T59Q REV   5’ GTAATTGCGCGCTGCCTGAATCTCGCTATC 3’ 
T59R FOR  5’ GATAGCGAGATTCGCGCAGCGCGCAATTAC 3’ 
T59R REV  5’ GTAATTGCGCGCTGCGCGAATCTCGCTATC 3’ 
T59S FOR   5’ GATAGCGAGATTTCTGCAGCGCGCAATTAC 3’ 
T59S REV   5’ GTAATTGCGCGCTGCAGAAATCTCGCTATC 3’ 
T59V FOR   5’ GATAGCGAGATTGTGGCAGCGCGCAATTAC 3’ 
T59V REV   5’ GTAATTGCGCGCTGCCACAATCTCGCTATC 3’ 
T59W FOR   5’ GATAGCGAGATTTGGGCAGCGCGCAATTAC 3’ 
T59W REV   5’ GTAATTGCGCGCTGCCCAAATCTCGCTATC 3’ 
T59Y FOR   5’ GATAGCGAGATTTATGCAGCGCGCAATTAC 3’ 
T59Y REV   5’ GTAATTGCGCGCTGCATAAATCTCGCTATC 3’ 
R62X alkaline phosphatase 
R62A FOR  5’ GATTACCGCAGCGGCCAATTACGCCG 3’ 
R62A REV  5’ CGGCGTAATTGGCCGCTGCGGTAATC 3’ 
R62D FOR   5’ GATTACCGCAGCGGATAATTACGCCG 3’ 
R62D REV   5’ CGGCGTAATTATCCGCTGCGGTAATC 3’ 
R62E FOR   5’ GATTACCGCAGCGGAAAATTACGCCG 3’ 
R62E REV   5’ CGGCGTAATTTTCCGCTGCGGTAATC 3’ 
R62F FOR   5’ GATTACCGCAGCGTTTAATTACGCCG 3’ 
R62F REV   5’ CGGCGTAATTAAACGCTGCGGTAATC 3’ 
R62G FOR   5’ GATTACCGCAGCGGGCAATTACGCCG 3’ 
R62G REV   5’ CGGCGTAATTGCCCGCTGCGGTAATC 3’ 
R62H FOR   5’ GATTACCGCAGCGCATAATTACGCCG 3’ 
R62H REV   5’ CGGCGTAATTATGCGCTGCGGTAATC 3’ 
R62I FOR   5’ GATTACCGCAGCGATTAATTACGCCG 3’ 
R62I REV   5’ CGGCGTAATTAATCGCTGCGGTAATC 3’ 
R62K FOR   5’ GATTACCGCAGCGAAAAATTACGCCG 3’ 
R62K REV  5’ CGGCGTAATTTTTCGCTGCGGTAATC 3’ 
R62L FOR   5’ GATTACCGCAGCGCTGAATTACGCCG 3’ 
R62L REV   5’ CGGCGTAATTCAGCGCTGCGGTAATC 3’ 
R62M FOR   5’ GATTACCGCAGCGATGAATTACGCCG 3’ 
R62M REV   5’ CGGCGTAATTCATCGCTGCGGTAATC 3’ 
R62N FOR   5’ GATTACCGCAGCGAACAATTACGCCG 3’ 
R62N REV   5’ CGGCGTAATTGTTCGCTGCGGTAATC 3’ 
R62P FOR   5’ GATTACCGCAGCGCCGAATTACGCCG 3’ 
R62P REV   5’ CGGCGTAATTCGGCGCTGCGGTAATC 3’ 
R62Q FOR   5’ GATTACCGCAGCGCAGAATTACGCCG 3’ 
R62Q REV  5’ CGGCGTAATTCTGCGCTGCGGTAATC 3’ 
R62S FOR   5’ GATTACCGCAGCGTCTAATTACGCCG 3’ 
R62S REV   5’ CGGCGTAATTAGACGCTGCGGTAATC 3’ 
R62T FOR   5’ GATTACCGCAGCGACCAATTACGCCG 3’ 
R62T REV   5’ CGGCGTAATTGGTCGCTGCGGTAATC 3’ 
R62V FOR   5’ GATTACCGCAGCGGTGAATTACGCCG 3’ 
R62V REV   5’ CGGCGTAATTCACCGCTGCGGTAATC 3’ 




R62W REV   5’ CGGCGTAATTCCACGCTGCGGTAATC 3’ 
R62Y FOR   5’ GATTACCGCAGCGTATAATTACGCCG 3’ 
R62Y REV   5’ CGGCGTAATTATACGCTGCGGTAATC 3’ 
Point mutation for alkaline phosphatase 
R10A FOR  5’ GTGCTGGAGAATGCGGCAGCGCAGGGTG 3’ 
R10A REV  5’ CACCCTGCGCTGCCGCATTCTCCAGCAC 3’ 
R24A FOR  5’ GGTGGCGCACGTGCGCTGACCGGCGACC 3’ 
R24A REV  5’ GGTCGCCGGTCAGCGCACGTGCGCCACC 3’ 
D28A FOR  5’ CTGACCGGCGCCCAAACCGCGGC 3’ 
D28A REV  5’ GCCGCGGTTTGGGCGCCGGTCAG 3’ 
R34A FOR  5’ CGCGGCACTGGCCGACAGCCTGA 3’ 
R34A REV  5’ TCAGGCTGTCGGCCAGTGCCGCG 3’ 
T81A FOR  5’ GCTCTGCCTCTGGCGGGTCAGTATACC 3’ 
T81A REV  5’ GGTATACTGACCCGCCAGAGGCAGAGC 3’ 
Y98A FOR  5’ CAAACCGGATGCTGTTACGGATAG 3’ 
Y98A REV  5’ CTATCCGTAACAGCATCCGGTTTG 3’ 
 
Double point mutation for alkaline phosphatase 
T59A-R62A FOR 5’ GATAGCGAGATTGCAGCAGCGGCCAATTACGCC 3’ 
T59A-R62A REV 5’ GGCGTAATTGGCCGCTGCTGCAATCTCGCTATC 3’ 
Addition of a cysteine for alkaline phosphatase 
E407C FOR  5’ GGTAATAGCGAATGTGATAGCCAAGAGC 3’ 
E407C REV  5’ GCTCTTGGCTATCACATTCGCTATTACC 3’ 
 
2.5.1.3 Introducing the K4 coiled coil into pECAP-Sort. 
A plasmid containing the genetic information for the K4 coiled coil was supplied 
by the Wälti laboratory and was used as a template to amplify a ‘megaprimer’. 
This ‘megaprimer’ was generated using K4 For and K4 Rev primers and 
contained a coiled coil coding region: 
 
K4 For:  5’ CCCCGGTGACCAAGGCACGTGGTGGTCAGAAACTGG  3’ 
K4 Rev:  5’ CAGCACCGGCATCTCAGGGGTACCACCTTTGATAGCAGC 3’ 
 
The ‘megaprimer’ contains overlapping regions with the pECAP coding 
sequence to facilitate insertion of the K4 coiled coil DNA into the pECAP 
plasmid. This resulted in a plasmid with the DNA encoding the coiled coil being 
introduced between a linker region and the alkaline phosphatase gene.  The 




used.  The introduction of the coiled coil sequence was confirmed by DNA 
sequencing. The resulting plasmid was called pK4_ECAP-sort. 
 
2.5.1.4 Subcloning Affimers from pDHIS into pET11 and pET11AP 
pDHIS phagemids containing the open reading frame of each of the Affimers 
were transformed into XL-1 Blue cells and were cultured for 16 h at 37°C.  
These colonies were used to inoculate 5 ml each of 2TY with ampicillin (amp) 
in a 50 ml falcon tube, and incubated for ca. 16 h at 37°C with shaking (220 
rpm).  Small-scale isolation of the plasmid DNA was performed using a 
QIAGEN miniprep kit.  The plasmid DNA was digested for 3 h with NotI and 
NheI according to the manufacturer’s instructions (NEB).  The digested DNA 
was separated on an agarose gel and the correct size band was excised and 
purified using a QIAGEN gel extraction kit.  The Affimer insert was ligated into 
a pET11a vector, which had previously been modified to include extra 
restriction sites, digested with NotI and NheI, and treated with Antarctic 
phosphatase.  The ligation reaction contained 40 ng of linearised, 
phosphatase-treated pET11a, a 3-fold molar excess of the Affimer insert, 1 µl 
10x T4 DNA ligase buffer (Roche), 200 U T4 DNA ligase (Roche), and ddH2O 
to 10 µl.  The reaction was incubated at 16°C for 16 h, followed by 
transformation into XL-1 Blue competent cells.  Both 50 µl and 250 l aliquots 
of the transformation reaction were plated onto each of two 2TY/amp agar 
plates, then incubated at 37°C for 16 h.  Plasmid DNA was prepared from 
several colonies using a QIAGEN miniprep kit and the clones were screened 
for successful ligation by colony PCR followed by agarose gel electrophoresis.  
The recombinant clones were confirmed by DNA sequencing.  
2.5.2 Agarose gel electrophoresis of DNA 
The agarose gel was prepared and operated using an HU6 Mini or HU10 Mini-
Plus horizontal gel unit (Scie-Plas, Harvard Bioscience). The gel was prepared 
by combining the appropriate volume of TAE with agarose in a 250 ml flask, 
and heating in a microwave for 2 min until the agarose completely dissolved.  
The agarose solution was cooled under running cold water with agitation 




The molten agarose was then poured into the casting tray in a casting unit, a 
comb added and the gel left to set at room temperature.  
For use, the casting tray containing the agarose gel was removed from the 
casting unit and placed into the gel running chamber. The comb was removed 
and TAE buffer was added until the gel was submerged. DNA samples were 
prepared by addition of 6 x gel loading dye (NEB) and then loaded into the 
wells of the agarose gel. A 1 μl aliquot of the appropriate DNA size ladder was 
also combined with 1 μl 6 x gel loading dye and added to a well. Either 1 kb or 
or 100 bp DNA size ladders (NEB) were used.  
Once samples were loaded, the running chamber was connected to the power 
unit and a voltage of 70 V applied for 40 min. After completion, DNA was either 
visualised under UV light and photographed, or, if it was to be used for 
downstream applications, was visualised using a Safe Imager (Invitrogen), 
which is a blue light transilluminator and does not lead to DNA damage as 
does UV light, allowing excision of bands from the gel.  
2.5.2.1 Gel extraction and ethanol precipitation 
The DNA was isolated by gel extraction using the dialysis tube/electrophoresis 
method due to the low levels of product and potential 50% losses seen for 
product recovery from gel extraction kits.  In this method, DNA was loaded into 
a 0.7 % agarose gel and separated using a HU6 Mini or HU10 Mini-Plus 
horizontal gel unit. The gel was visualised on a Safe Imager with Safe Imager 
glasses and a piece of agarose with the correct band of DNA was cut out using 
a sterile scalpel, and placed in a piece of dialysis tubing with 0.5 ml TAE.  The 
ends of the dialysis tubing were sealed and placed back in the HU6 Mini or 
HU10 Mini-Plus horizontal gel unit and a voltage of 70 V was applied for 20 
min.  The gel was visualized again to make sure that the DNA had migrated 
out of the gel and into the solution.  The DNA was then desalted and 
concentrated by ethanol precipitation.  A 10 % volume of 3 M sodium acetate 
(pH 5.2) and a 200 % volume of absolute ethanol were added to the eluted 
DNA solution and the mixture was incubated on ice for 15 min. This was 
followed by centrifugation at 13,000 x g for 30 min at room temperature.  The 




μl 70% ethanol followed by centrifugation at 13,000 x g for 15 min. The 
supernatant was discarded again and left to air dry for 10 min, and then the 
pellet was dissolved initially in 30 μl of water. 
 
2.5.3 Colony PCR screening of bacterial colonies or cultures 
It is possible to directly analyze colonies to determine whether they contain a 
desired recombinant plasmid, and, at the same time, to set up overnight 
cultures from the colonies to allow isolation of recombinant plasmids for further 
study.  
3 ml aliquots of SOC medium containing the appropriate antibiotic in 50 ml 
falcon tubes were prepared.  100 μL aliquots of sterile water were pipetted into 
0.2 ml PCR tubes.  Using a toothpick, a colony was collected from the agar 
plate and swirled gently in the sterile water aliquot; the toothpick was then used 
to inoculate a tube containing SOC medium. This was repeated for each of the 
colonies to be screened. 
 
Table 2-1 Colony PCR premix 
Component Vol (μl) Final concentration 
5X Green GoTaq Flexi buffer 5 1X 
MgCl2 (25 mM) 2 2 mM 
PCR nucleotide mix (10 mM each) 0.5 0.2 mM each 
Primer (10 pmol/μl) 0.5 0.2 pmol/μl 
Primer (10 pmol/μl) 0.5 0.2 pmol/μl 
GoTaq Hotstart polymerase (5 U/μl) 0.125 0.025 U/μl 
dH2O 15.375  








The tubes containing the water and dispersed bacterial suspension were 
placed in a thermal cycler and heated to 99 oC for 5 min, and then cooled to 
20 oC, followed by centrifugation for 5 min at 13,000 g in a microcentrifuge to 
pellet the cell debris.  A 24 μL aliquot of the PCR premix, as detailed in Table 
2-1, was added to a PCR tube together with 1 μL of the DNA solution from the 
bacterial colony.  The PCR was performed using the following conditions; 
• 94oC, 5 min initial denaturation 
• 94 oC, 30 sec;  
• 55 oC, 30 sec;    for 30 cycles 
• 72 oC, 2 min  
• 72 oC, 5 min 
A 5 μL sample was analysed on an agarose gel whilst the inoculated cultures 
were placed in an orbital incubator at 37 oC to allow growth for the culture for 
subsequent plasmid isolation from PCR positive colonies. 
2.5.4 QIAgen miniprep 
The QIAprep Spin miniprep kit (Qiagen) was used to purify DNA from E. coli 
cultures. A single colony containing the plasmid to be purified was used to 
inoculate 5 ml 2TY broth containing the appropriate antibiotic, then incubated 
overnight at 37 °C in a shaking incubator at 220 rpm. The cells were harvested 
by centrifugation at 7500 x g for 5 min in a Hermle Z400 K centrifuge with a 
220 97 VO2 rotor and the supernatant drained by inverting the tube. The pellet 
was completely resuspended in 250 μl buffer P1 (50 mM Tris-HCl, pH 8.0, 10 
mM EDTA, 100 μg/ ml ribonuclease A, 1 μl/ ml LyseBlue reagent), using a 
vortex, before being transferred to a 1.5 ml microcentrifuge tube. A 250 μl 
aliquot of lysis buffer P2 (200 mM NaOH, 1% (w/v) SDS) was added and the 
solution mixed by inversion until a homogeneous blue colour was achieved. 
Then 350 μl neutralisation buffer N3 (4.2 M guanidinium chloride, 0.9 M 
potassium acetate, pH 4.8) was added and immediately mixed by inversion 
until all the blue colour had disappeared indicating that the SDS had 
precipitated and the solution had been neutralised. The tube was then 
centrifuged at 13000 rpm in a microcentrifuge for 15 min to pellet all of the cell 




a silica gel membrane that can bind up to 20 μg DNA in the presence of high 
concentrations of chaotropic salts, such as guanidinium chloride, and 
centrifuged for 45 s. The flow-through was discarded and the silica gel 
membrane was washed to remove impurities by addition of 750 μl buffer PE 
(10 mM Tris-HCl, pH 7.5, 80% (v/v) ethanol) and centrifuged for 45 s. The flow-
through was discarded and the spin column with DNA was centrifuged for a 
further 60 s to remove any residual ethanol which would prevent loading of the 
sample onto an agarose gel and inhibit any future enzymatic reactions. The 
column was transferred to a sterile 1.5 ml microcentrifuge tube, 50 μl of 
deionised water were carefully pipetted onto the membrane and after 60 s the 
column was centrifuged for 2 min to elute the DNA, which was then stored at 
-20 °C. 
2.6 Protein Production 
In the work described in Chapter 3 there were only three proteins of interest: 
β-lactamase and two different β-lactamase fragments.  In the work described 
in Chapter 4 there were over one hundred proteins produced due to several 
small mutagenesis libraries of alkaline phosphatase mutants. Chapter 6 
includes several Affimers and three different targets. Each set of proteins was 
produced differently and the different protocols are detailed in the sections 
below. 
2.6.1 β-lactamase and -lactamase fragments 
β-lactamase was provided in pET28c and was transformed into BL21 star 
(DE3) cells.  The newly cloned, pET28cFragB, C-terminal fragment of -
lactamase (fragment B) was transformed into BL21 star (DE3) cells.  A single 
colony was used to inoculate 5 ml of 2TY medium supplemented with 60 ng/ml 
kanamycin.  This culture was used to inoculate 400 ml of 2TY medium, for both 
full-length and fragment B, then incubated at 37oC with shaking until an OD600 
of 0.6 was reached.  0.5 mM IPTG was added and incubated for a further 8 h.  





The newly formed pET28cFragA was used for -lactamase fragment A 
expression.  This vector was transformed into BL21 star (DE3) cells.  A single 
colony was used to inoculate 5 ml of 2TY medium supplemented with 60 ng/ml 
kanamycin.  This culture was used to inoculate 500 ml of auto TB medium 
(Formedium) and incubated at 25 oC for 48 hrs.  The cells were pelleted by 
centrifugation at 3600g for 10 min at 4oC. 
2.6.2 Alkaline phosphatase and Alkaline phosphatase mutants 
pECAP-sort, pECAP-sort incorporating a mutation, and pK4_ECAP-sort, were 
transformed into E. coli SHuffle competent cells. A single colony was used to 
inoculate 5 ml of 2TY medium supplemented with 60 ng/ml kanamycin and 
grown overnight at 37 oC with shaking at 220 rpm to produce a booster culture.  
A 5 ml aliquot of the booster culture was used to inoculate 500 ml of 2TY 
medium, then incubated at 25 oC with shaking until an OD600 of between 0.4 
and 0.8 was reached. Rhamnose was added to 0.01 % and incubated for a 
further 4 h, 6 h or overnight.  The cells were pelleted by centrifugation at 3600g 
for 10 min at 4oC and frozen for storage.   
2.6.3 Zinc-finger alkaline phosphatase fusion protein 
pZifAP or pZifAPT59A-R62A were transformed into ArcticExpress cells.  A single 
colony was used to inoculate 1 ml aliquots of LB broth containing 20 ng/ml of 
gentamycin (to maintain the chaperone proteins: Cpn10 and Cpn60 which are 
constitutively expressed), and 50 ng/ml carbenicillin. These cultures were 
incubated at 37°C with shaking at 220 rpm overnight.  A 50 μl aliquot of this 
culture was added to 50 ml of LB broth containing no selection antibiotics, and 
incubated at 30°C with shaking at 220 rpm for 3 h.  Next, the culture was 
transferred to 10 °C and incubated with shaking at 220 rpm for approximately 
10 min to equilibrate the culture, IPTG was added to each flask to a final 
concentration of 1 mM and incubated at 10 °C, with shaking at 220 rpm, for 24 
h. The cells were pelleted by centrifugation at 3600 g for 10 min at 4oC and 
frozen for storage.   
2.6.4 Affimers 
The pET11a plasmid containing the coding region for the Affimer was 




5 ml of 2TY medium supplemented with 50 ng/ml carbenicillin and incubated 
overnight at 37 oC with shaking (220 rpm).  A 1 ml aliquot of this booster culture 
was used to inoculate 400 ml TB auto-induction media (Formedium) 
supplemented with 50 ng/ml carbenicillin, 1 x lactose (LAC), and 25 mM 
succinate.  This culture was incubated for approximately 48 h at 25oC with 
shaking (220 rpm).  The cells were pelleted at 3600 g for 10 min at 4oC.  
2.7 Purification of Proteins 
Several protocols for purification of the different proteins used in this study are 
detailed. 
2.7.1 β-lactamase  
The E. coli pellet from 50 ml of culture was re-suspended in 10 ml of lysis buffer 
(section 2.1.1.5).  The suspension was vortexed for 5-10 min and left to lyse 
at 4oC whilst rolling for 1.5 h.  The soluble fraction of the sample was separated 
by centrifugation at 25000 g for 30 min.  The supernatant was filtered (0.22 
μm) and poured onto a HisPur Ni-NTA column which had been equilibrated 
with binding buffer (section 2.1.1.5) at 4 oC followed by 5 column volumes of 
wash buffer (section 2.1.1.5), and then eluted with 2 column volumes of β-
lactamase elution buffer (section 2.1.1.5). 
2.7.1.1 Purifying N terminal fragment of β-lactamase (fragment A) 
The N-terminal fragment of β-lactamase is insoluble.  An inclusion-body prep 
was carried out by first thawing the cell pellet on ice, followed by re-suspension 
in 20 ml re-suspension buffer. The cells were lysed by sonication – 6x1 min 
bursts with 1 min cooling on ice in between each sonication.  The insoluble 
fraction was pelleted (25000 g, 30 min, 4 °C) and the supernatant was 
discarded.  The insoluble pellet was re-suspended in 20 ml detergent wash 
buffer and incubated for 1 h at room temperature on a see-saw rocker.  The 
insoluble fraction was pelleted (25000 g, 30 min, 4 °C) and the supernatant 
was discarded.  The pellet was washed twice by resuspending in 50 mM 
Tris.HCl pH 8.0 and incubated for 1 hour at room temperature on a see-saw 
rocker.  The purified inclusion bodies were pelleted (25000 g, 30 min, 4 °C) 




Purification and re-folding of the N-terminal fragment was accomplished on a 
Ni2+NTA column (Pierce).  The column was equilibrated with equilibration 
buffer.  The inclusion bodies were re-suspended in re-suspension buffer and 
incubated for 1 hour at 4oC, followed by filtration (0.22 μm) to remove large 
impurities.  This was poured onto the equilibrated column, followed by 10 
column volumes (CV) re-suspension buffer.  Then 50 CV of wash buffer were 
added, and, since the wash buffer does not contain denaturant, the protein 
should re-fold on the column.  The fragment was eluted in 3 CV of elution 
buffer. 
 
2.7.1.2 Purifying the C terminal fragment of β-lactamase (fragment B) 
The C-terminal fragment was, at least in part, in the soluble fraction.  The pellet 
was lysed using lysis buffer followed by centrifugation of 25000 x g for 35 min.  
The resin was equilibrated with 5 CV of wash buffer and the filtered 
supernatant (0.22 μm) added to the column.  Then 10 CV of wash buffer were 
added to the column and the protein was eluted in 3 CV of elution buffer. 
 
2.7.2 Alkaline phosphatase and alkaline phosphatase mutants 
The cell pellet containing alkaline phosphatase, or alkaline phosphatase 
mutant, was thawed at room temperature and mixed with 10 ml of lysis buffer 
(section 2.1.1.4) per gram of cells.   The lysate was pelleted  at 25000 x g at 4 
oC for 30 min. The supernatant was filtered (0.22 μm) and then incubated with 
Ni2+ NTA resin (Amintra) for 40 min before being poured into a Pierce, 
disposable plastic column and washed with 20 ml of wash buffer (section 
2.1.1.4), or until the OD280 was less than 0.1.  The protein was eluted in 0.5 ml 






2.7.3 ZifAP and zifAP Mutants 
The cell pellet containing Zif-alkaline phosphatase, or a Zif-alkaline 
phosphatase mutant, was thawed at room temperature and mixed with 10 ml 
of lysis buffer (section 2.1.1.4) per gram of cells, for 40 min. The streptavidin 
resin and buffers were equilibrated to room temperature, during the lysis 
incubation, and then packed into a column.  The column was equilibrated with 
three column volumes of binding buffer.  The sample was added to the column 
and allowed to enter the resin bed, and was left to exit the column by gravity 
flow.  The flow-through was put through the column a further two times.  The 
column was washed with 10 CV of binding buffer (section 2.1.1.4), and the last 
CV was kept for analysis. The bound protein was an eluted sample with 3 CV 
of elution buffer (section 2.1.1.4), collected in 0.5-1 ml fractions.   After analysis 
on SDS PAGE gels, the protein was immediately desalted or dialyzed.  The 
column was regenerated with 5 CV of regeneration buffer followed by 5 CV of 
binding buffer.  If the column needed to be stored this was done in 20% 
ethanol. 
 
2.7.4 Affimers  
E. coli pellets from 400 ml of culture were suspended in 40 ml lysis buffer 
(Section 2.1.1.4) supplemented with 2 mg/ml lysozyme, cOmplete protease 
inhibitor tablet (Roche) and 200 U OmniCleave (Epicenter), and incubated at 
room temperature whilst rolling for 2 h.  The cell lysate was then incubated at 
50 oC for 20 min followed by centrifugation at 25000 x g for 35 min.  The 
supernatant was then filtered (0.22 μm) to remove any large impurities.  The 
soluble fraction of the cell lysate was incubated for 1.5 h with HisPur Ni-NTA 
resin (Pierce) whilst rolling at room temperate.  The cell lysate and resin mix 
were then put through an empty column to collect the resin and leave the flow 
through.  The resin was removed from the column and incubated with 10 ml of 
wash buffer for 10 min whilst rolling at room temperature.  The wash buffer 
(section 2.1.1.4) was removed and the resin was further washed with 20 
column volumes of wash buffer followed by elution with 6 column volumes of 




2.8 Modification of Proteins 
Proteins can be modified chemically, often at the thiol on a cysteine residue. 
2.8.1 Reduction of disulfides on cysteines 
A Tris [2-carboxyethyl] phosphine hydrochloride (TCEP) disulfide reducing gel 
(Thermo Scientific) was used to reduce the thiol on cysteine residues.  A 
volume of between 100-500 μl of TCEP reducing gel slurry was added to a 
microcentrifuge tube and centrifuged at 1000 × g for 1 min so that the 
supernatant was removed.  An equal volume of protein (1 mg/ml) was added 
to the gel, and the tube vortexed and incubated with agitation for 1 h. The tube 
was centrifuged at 1000 x g for 1 min. The supernatant containing the reduced 
protein was recovered and used immediately in a biotinylation reaction. 
 
2.8.2 Biotinylation 
EZ-link BMCC-biotin (Thermo Scientific) was used to biotinylate the reduced 
protein.  An 8 mM stock solution of BMCC-Biotin was prepared by dissolving 
2.1 mg in 500 μl of DMSO.  2 μl of 8 mM stock solution were added to 50 μl of 
reduced protein (1 mg/ml) and incubated at room temperature for 2 h. The 
labelled protein was purified from non-reacted BMCC-Biotin by desalting or 
dialysis.  
2.9 Protein characterisation 
2.9.1 SDS PAGE Analysis  
Protein samples were separated according to their size by SDS-
polyacrylamide gel electrophoresis (PAGE).  To make sure protein samples 
were denatured, and for easy loading, soluble samples were mixed with gel 
loading buffer (section 2.1.1.6) and heated at 95 °C for 3 min.  The insoluble 
fraction was resuspended in 20 % lysis buffer and incubated for 20 min at room 
temperature, with agitation, and centrifuged at 13000 rpm in a microcentrifuge 




in 20% lysis buffer. The pellet was resuspended in 4 x loading buffer then 
heated at 95 °C for 3 min.  
A 15% resolving gel was poured between Bio-Rad PROTEAN casting plates 
and allowed to polymerise.  To ensure a flat interface between the resolving 
and stacking gel it was overlaid with water.  A 5% stacking gel (section 2.1.1.6) 
was added to the top of the resolving gel, followed by a comb to create wells. 
Protein samples were loaded along with either PageRuler Unstained Protein 
Size Ladder (Fermentas) or Pageruler Prestained Protein Ladder (Fermentas). 
Gels were run at 150 V in SDS-PAGE running buffer (Section 2.1.1.6) for 55 
min.  
2.9.2 Protein concentrations 
The concentration of an enzyme is central to enzyme activity assays. To 
ensure accuracy, two different methods for calculating protein concentration 
were employed: Absorbance at 280 nm and a colourimetric assay; either BCA 
or Bradfords assay. 
2.9.2.1 Absorbance of proteins 
The absorbance at 280 nm is based on Beer-Lambert equation: A= cl, where 
A is the absorbance value, is the molecular extinction coefficient, c is the 
analyte concentration in moles/litre or molarity (M) and l is the path length in 
centimetres.   Protein concentrations were determined using a NanoDrop Lite 
Spectrophotometer (Thermo Scientific), which gives the absorbance reading 
at 1 cm absorbance equivalent, therefore the path length is 1.  A 3 l aliquot 
of ddH2O was loaded onto the instrument and ‘blank’ was selected from the 
menu, followed by a repeat with ddH2O.  A 3 l aliquot of the protein buffer 
was then measured. If the absorbance was less than 0.04 AU at 280 nm then 
a 3 l aliquot of the sample protein was used for the measurement. The 
molecular extinction coefficients were calculated using the ExPASy protparam 
tool. For β-lactamase the coefficient is 27880 M-1 cm-1 and for alkaline 
phosphatase it is 32890 M-1 cm-1.  To determine the concentration, the 
absorbance was divided by the molecular extinction coefficient.  To convert to 




molecular weight, because concentration (moles per litre) x molecular weight 
(grams per mole) = grams per litre.  
2.9.2.2 Bicinchoninic acid (BCA) assay  
The reduction of Cu2+ ions from the copper(II) sulfate to Cu+ by the peptide 
bonds is proportional to the amount of protein present in a sample. Each Cu+ 
ion is chelated by two molecules of Bicinchoninic acid (BCA) forming a 
complex that strongly absorbs light at 562 nm and is purple in colour. 
A micro BCA protein assay kit from Thermo Scientific was used to examine 
the concentration of protein samples.  Mixing 24 parts of reagent MA with 24 
parts of reagent MB, and 1 part reagent MC, prepared a working reagent.  150 
μl of each standard, or unknown sample, were pipetted into a 96 well plate. 
150 μl of the working reagent were added to each well and incubated at 37 °C 
for 2 h.  The plate was left to cool to room temperature and the absorbance 
was measured at 562 nm on a Tecan Spark (Tecan) plate reader.  The average 
absorbance measurement of the blank standard was subtracted from all the 
standard and unknown sample replicates.  A standard graph was prepared by 
plotting the average absorbance for each BSA standard vs. its concentration 
in μg/ml, and a linear equation for the line was established.  This was used to 
calculate the protein concentration of each unknown sample.  
2.9.2.3 Bradford Assay 
The Bradford assay was performed with a Coomassie (Bradford) Protein 
Assay Kit.  When Coomassie dye binds with a protein there is an immediate 
shift in absorption from 465 nm to 595 nm with a colour change from brown to 
blue.  
50 μl of each standard or unknown sample was added to a 1 ml cuvette, and 
950 μl of the Coomassie reagent was added to each cuvette.   These were 
mixed and incubated for 10 min at room temperature.  Using a UV-2401PC 
spectrophotometer (Shimadzu), controlled by UV Probe v.2.2 software set to 
595 nm, the instrument was zeroed on a cuvette filled only with water.  The 
absorbance of all the standards and samples were measured.  The average 
measurement for the blank replicates was subtracted from the measurements 




plotting the average measurement for each BSA standard vs. its concentration 
in μg/ml. A linear equation for the line was established which was then used to 
calculate the protein concentration of each of the unknown samples.  
2.9.3 Kinetics analysis of enzyme activity 
Enzyme kinetic parameters were used to assess if the newly produced 
recombinant enzymes in this study were as active as previously reported in 
the literature, as well as to assess mutants of the enzymes 
 
2.9.3.1 β-lactamase and fragments  
In order to measure the kinetic parameters for β-lactamase and β-lactamase 
fragments, a nitrocefin assay was carried out in which nitrocefin turns from 
yellow to red upon hydrolysis of the β-lactam ring.  Hydrolysed nitrocefin has 
a λmax of 492 nm.  A working solution of 0.5 mg/ml (968 μM) nitrocefin was 
prepared by adding 5 mg of nitrocefin to 500 μl of DMSO and 1.9 ml of 200 
mM phosphate buffer.  50 μl of β-lactamase or β-lactamase fragments at an 
appropriate concentration were added to a cuvette with nitrocefin, and made 
up to 1 ml with 200 mM phosphate buffer.  The cuvette was immediately 
covered with Parafilm, inverted, and then placed into a UV-2401PC 
spectrophotometer (Shimadzu). Absorbance at 492 nm was measured for 60 
s using the UV Probe v.2.2 software and the plot of A486 against time was used 
to determine the rate in absorbance units per s.  The extinction coefficient of 




, the rate in absorbance units 
per s was divided by 20500 and then multiplied by 10
6 
to convert the units to 
μM per s.  
 
2.9.3.2 Alkaline phosphatase and alkaline phosphatase mutants 
To determine the kinetic parameters for alkaline phosphatase, and alkaline 
phosphatase mutants, p-nitrophenyl phosphate (pNPP) (NEB) was used. 15 
nM enzyme was added to a cuvette with pNPP and made up to 1 ml with either 




immediately covered with Parafilm, inverted, and then immediately placed into 
the UV-2401PC spectrophotometer (Shimadzu). Absorbance at 405 nm was 
measured for between 30 s and 10 min using the UV Probe v.2.2 software and 
the plot of A405 against time was used to determine the rate in absorbance 





, so the rate in absorbance units per s was divided by 18000 
and then multiplied by 10
6 
to convert the units to μM per s. 
Kinetic parameters for all enzymes were determined by measuring activity over 
a range of substrate concentrations and fitting the plot of rate against substrate 
concentration to the Michaelis-Menten equation using non-linear regression in 
OriginPro 9.0: Rate = (Vmax[S])/ (KM+[S]).  Where Vmax (μM hydrolysed 
nitrocefin/sec) is the maximum rate of the enzyme, [S] (mM) is the substrate 
concentration and the Michaelis constant, KM (mM) is the [S] at half Vmax and 
can give an indication of the affinity of the enzyme for the substrate. The 
turnover number, kcat (s-1) was determined using the equation: kcat = Vmax / ET 
where ET is the total amount of enzyme. 
2.9.3.2.1 Alkaline phosphatase specific activities 
Specific activities were used as a high-throughput approach to assess a large 
number of mutants.  The assay to determine specific activities of the mutants 
was performed in the same way as kinetic analysis (section 2.9.3.2) but only 
one measurement at one substrate concentration was taken.  The rate was 
divided by the mg of alkaline phosphatase added and then divided by 1000 ml 
to convert to units of μmol pNP /min/mg alkaline phosphatase.  
2.9.3.2.2 Activity Assays 
Assay to examine changes before and after addition of a mediator using the 
activity level of an enzyme is a common theme in this thesis. 
2.9.3.2.3 Coiled coil  activity assay  
The activity of K4-AP and K4-AP mutants at a final concentration of 0.4 nM in 
1 M Tris pH 8.0 was detected using pNPP (2 mM final concentration) and the 
assay was stopped after 30 min with 50 μl 5 M NaOH.  The resulting 




2.9.3.2.4 Coiled coil inhibition assay 
A final concentration of 0.4 nM K4-T59A-R62A protein was incubated with K4 
peptide in a concentration range from 25 pM to 20 nM for 2 h in 1 M Tris pH 
8.0.  The activity was detected using 100 μl (2 mM final concentration) of 
pNPP, and the assay was stopped after 5 min with 50 μl 5 M NaOH.  The A405 
was converted to the product amount using the Beer-Lambert law as described 
in Section 2.9.3.2.  The amount of product (pNP) was plotted against the Log10 
of the concentration of K4 peptide 
2.9.4 Circular dichroism 
Far UV CD was used to analyse the secondary structure of the mutants. The 
activity of alkaline phosphatase mutants was performed in 1 M Tris-HCl pH 
8.0, and it was important to know what was happening with the secondary 
structure in this buffer.  Buffers which contain chloride ions absorb light 
strongly below 200 nm (Kelly, et al. 2005), and therefore the data were 
processed between 200 nm to 260 nm.  Wild-type alkaline phosphatase was 
investigated as a positive control and it was expected to be folded correctly, 
and therefore the spectra could be used as a comparison. 
CD experiments were performed on a Jasco J715 spectropolarimeter and the 
spectra were recorded in a 0.02-cm path length using a scan speed of 50 
nm/min, a time constant of 0.5 s, and a bandwidth of 2 nm. 3 scans were 
performed. The Jasco J715 spectropolarimeter gives its raw output in 
ellipticity, with the symbol θ measured in millidegrees (mdeg). To compare the 
data with those of others, θ was converted to molar ellipticity, this is given the 
symbol [θ] and is in units of degrees.cm2 per decimole.  Hence, [θ] = θ / (10 x 
c x l) where c is the molar concentration of the sample and l is the path length 
in cm. 
To investigate the thermal stability of the T59A-R62A mutant, both with and 
without the K4 coiled coil, a thermal melt experiment using CD was performed. 
The intensity of the CD signal at 220 nm was recorded. A 0.02-cm path length 
cuvette was used with a scan speed of 50 nm/min, a time constant of 0.5 s, 




2.9.5 Static light scattering and intrinsic fluorescence (Optim)  
Simultaneous SLS and intrinsic fluorescence measurements were conducted 
using an Optim 1000 (Avacta Analytical) to analyse the rate of aggregation of 
the Affimer and give an indication of their stability.  Colloidal stability was 
measured using SLS at 266 nm, and the data output was given as the onset 
of aggregation temperature (Tagg).  Thermal stability was assessed by 
measuring the intrinsic fluorescence of Tryptophans, which were excited at 
266 nm, and extrinsic fluorescence was measured at a range from 300 to 400 
nm. The data were reported as a barycentric mean (BCM), The melting 
temperature (Tm) was calculated using the BCM as a function of temperature.  
A stepped thermal ramp program was used, set between 20 oC and 95 oC using 
1 °C increments, with an equilibration time of 30 s.  Aliquots of 8.8 μl of each 
protein (1 μg/ml) were measured in triplicate, and the analysis software 
provided with the Optim 1000 was used to process the data. 
2.9.6 Oligomerisation 
2.9.6.1 Size Exclusion Chromatography (SEC) 
Preparative SEC was performed on a HiPrep 16/60 Sephacryl S-100 HR 
preparative column, so the protein could be recovered for other assays.  The 
flow rate of buffer was set to 0.5 ml/min in an isocratic fashion on a ÄKTA 
FPLC and the eluent was collected in 2 ml fractions for 1.25 column volumes. 
To begin with, five protein standards: β-amylase, alcohol dehydrogenase, 
albumin, carbonic anhydrase, and cytochrome c, were separated on the SEC 
column for calibration purposes.  The sample proteins were loaded onto the 
column after their first step in purification in as high a concentration as 
possible. 
2.9.6.2 Analytical SEC 
A Superdex 200 10/300 GL column was used to analyse the multimeric state 
of Affimers.  The column was equilibrated with PBS with 10% glycerol and 1.2 
ml of 2 mg/ml Affimers were added separately to the column. This was eluted 
in an isocratic fashion using PBS with 10 % glycerol.  The flow rate of buffer 
was set to 0.5 ml/min in an isocratic fashion on a ÄKTA FPLC and the eluent 




2.9.6.3 Analytical Ultracentrifugation (AUC) 
All of the protein had an A280 of between 0.3 and 0.5, and were exhaustively 
dialysed against 50 mM Tris pH 8.0 using 4 buffer changes, the first two after 
2 h each and then changed for overnight incubation, followed by a further 
change and being left for a further 2 h the next day.  A XL-I machine from 
Beckman Coulter was used, and after the AUC cells were filled and 
assembled, a centrifugation scan from 3000 rpm to 30000 rpm was run to 
indicate if any of the cells were leaking.  A continuous scan from 5.8 to 7.3 cm 
at 30000 rpm was set up and data were recorded for every third scan.  200 
scans were recorded in total at a constant temperature of 19.8 oC. The data 
were fitted using the SEDPHAT and SEDFIT programs (Schuck 2000).  
SEDPHAT was used to calculate the density and viscosity from the buffer 
ingredients.  The partial specific volume ‘v bar’ was calculated using the same 
software for each of the proteins from the amino acid sequence.  The 200 data 
scans were loaded into the SEDFIT program, continuous c(S) distribution was 
selected and the parameters calculated from the SEDPHAT program were 
entered. The SEDFIT program was used to fit the data using the Marquardt 
Levenberg algorithm.  To check the fitting, SEDFIT was used to fit the data 
again using a Simplex algorithm.  If the root mean square deviation (rmsd) was 
=< 0.05, and the Z (stddev) =< 15, this was considered a reliable fit. 
2.9.7 Distance dependence of Zif-AP 
2.9.7.1 TEV cleavage 
20 μg of the fusion protein in 1M Tris pH 8.0 and 10 units of TEV protease 
were incubated at 30 oC for 2 h. The protein was analysed by SDS PAGE. 
2.9.7.2 Annealing DNA 
The zinc finger ‘Zif 268’ has three fingers and each finger binds a specific 
sequence of DNA.  The recognition sequence for  Zif 268 is: 
5’ GCG TGG GCG T 3’ 
3’ CGC ACC CGC A 5’ 
Each coloured highlight represents where each of the fingers binds.  Single-




sites, with a spacer in between of zero, 5 and 10 base pairs.  In each case 
reverse oligos were designed as a whole oligo or in two parts; thus, a nick 
would be introduced once the three pieces of DNA were annealed together.  
Each of the oligos is listed below: 
Zif_H2H_0_Fwd 5’ GTGAACTGCGTGGGCGTACGCCCACGCGACGAGC 3’ 
Zif_H2H_0_Rev_Whole 5’ GCTCGTCGCGTGGGCGTACGCCCACGCAGTTCAC 3’ 
Zif_H2H_0_rev_nick1 5’ GCTCGTCGCGTGGGCGT 3’ 
Zif_H2H_0_rev_nick2 5’ ACGCCCACGCAGTTCAC 3’ 
Zif_H2H_5_Fwd 5’ GTGAACTGCGTGGGCGTGCTCAACGCCCACGCGACGAGC 3’ 
Zif_H2H_5_Rev_Whole 5’ GCTCGTCGCGTGGGCGTTGAGCACGCCCACGCAGTTCAC 3’ 
Zif_H2H_5_Rev_nick1 5’ GCTCGTCGCGTGGGCGTTGAG 3’ 
Zif_H2H_10_Fwd 5’ GTGAACTGCGTGGGCGTGCTCAGTTCAACGCCCACGCGACGAGC 3’ 
Zif_H2H_10_Rev_Whole 5’ GCTCGTCGCGTGGGCGTTGAGCTGAGCACGCCCACGCAGTTCAC 3’ 
Zif_H2H_10_Rev_nick1 5’ GCTCGTCGCGTGGGCGTTGAGCTGAGC 3’ 
 
Different 20 nM samples of single stranded of DNA were mixed together in a 
PCR tube in a total volume of 60 μl, which was heated to 95 oC for 10 min and 
brought back down to room temperature in 1 oC steps per min.  The resulting 
duplex DNA was analysed on 4% agarose gels (NuSieve GTG -Lonza) made 
with TBE buffer. 
2.9.7.3 Zinc Finger Assay 
Zinc finger-enzyme fusion protein (15 nM) and 15 nM of oligo were added to a 
96 well plate.  Wild-type alkaline phosphatase was used as a positive, and 
T59R as a negative control. pNPP was added to 2 mM and the absorbance at 
405 nm was measured after 24 h. 
2.9.8 Protein – Protein Interactions 
2.9.8.1 Bilayer interferometry analysis (BLItZ) 
Bilayer interferometry was used to measure binding affinity.  The software fits 
a trend line to the on and off rate, and calculates a dissociation constant (KD).  
The chips used on the BLItz system (fortéBIO) are streptavidin chips and so 
the proteins required biotinylation.  The protein was biotinylated using (+)-




DMSO (5 mg/ml).  A 100 μl aliquot of dissolved biotin linker was mixed with 
100 μl of protein (1 mg/ml) and incubated for 2 h at room temperature followed 
by desalting on a Zeba column with a MWCO of 7 kDa (Thermo scientific).  
The streptavidin chips were hydrated in PBS for 10 min and a baseline was 
taken for 30 s.  The biotinylated protein was loaded onto a chip by incubating 
the chip with the biotinylated protein for 2 min, followed by another 30 s 
baseline.  Association was then calculated for 2 min by incubating with the 
binding partner. Finally, dissociation was calculated for 2 min by incubation in 
PBS  
2.9.8.2 Enzyme-linked immunosorbent assay (ELISA) 
ELISA is a technique for detecting the presence of molecules such as proteins. 
In an ELISA, a protein is immobilized on a solid surface, usually in a 96 well 
plate. Then, an antibody that is linked to an enzyme is incubated with the 
protein of interest. Detection is accomplished by enzyme activity with a 
substrate to produce a measurable signal. Variations of a simple ELISA 
included in this study are a phage ELISA, and a sandwich ELISA. 
2.9.8.2.1 Sandwich Phage ELISA  
In a 96-well Nunc plate, 50 μl of Adhiron 21 (1 μg/ml) was placed in 32 
(columns 1-4) of the 96-well plates, another 32 (columns 5-8) were left blank 
and incubated at 4 oC overnight.  The plate was then washed twice with PBS, 
blocking buffer was added to each of the wells and incubated overnight at 
25oC. 50 μl of mGFP (1 μg/ml) was then added to columns 1-4 and incubated 
at 4 oC overnight.  The plate was washed twice with PBS, 10 μl of blocking 
buffer and 40 μl of the supernatant from the phage growth was added to each 
well.  This was incubated at room temperature for 1 hour followed by a single 
wash with PBS.  The enzyme-linked antibody was added, followed by 10 
washes with PBS and finally 50μl 3,3',5,5'-Tetramethylbenzidine (TMB) was 





2.9.8.3 Enzyme-Linked Affimer assay 
Biotinylated Affimers were immobilized onto strep-activated plates (Pierce) at 
a concentration of 100 μg/ml in phosphate buffered saline (PBS) and incubated 
at 4 °C overnight. Alternatively, Polysorp microtiter plates (Nunc) were coated 
with Affimers at 37 °C for 2 h. Plates were washed three times with PBS before 
blocking non-specific sites with 5% skimmed milk in PBS overnight at 4 oC.  
Plates were then washed three times with PBS with 0.05% Tween-20 (PBST).  
Dilutions of the target protein (GFP) were prepared in 1% skim milk/PBST, 
added to wells in duplicate and incubated for an additional hour at room 
temperature, followed by 6 more washes with PBST. The alkaline phosphatase 
linked Affimer was added and incubated for 2 h at room temperature and 
washed 6 times with PBST. Activity was measured after incubation with 100 l 
of pNPP (2 mM final concentration) for 30 min at room temperature.   The 
reaction was halted by the addition of 50 μl, 3 M NaOH, and the absorbance 












3.1 Introduction – split β-lactamase: 
Split β-lactamase was generated for use in protein complementation assays 
(PCA) (Galarneau, et al. 2002, Wehrman, et al. 2002) to measure the 
interaction of two proteins through the restoration of beta-lactamase enzymatic 
activity (Galarneau, et al. 2002, Wehrman, et al. 2002).  The DNA sequences 
encoding N- and C-terminal fragments of β-lactamase (Figure 3.1) were fused 
to coding regions for interactive protein partners and the resulting plasmids 
were co-transfected into Cos-7 or HEK 293 cells.  Proof of principle 
experiments were carried out by (Galarneau, et al. 2002) who used Bad and 
Bcl2, two apoptotic proteins with high affinity for each other.  These two 
proteins were both fused to the N-terminal and C-terminal fragments of β-
lactamase. Galarneau et al also repeated this experiment showing that the 
PCA principle could be used with a coiled coil interaction between GCN4 
leucine zipper, and the homodimerisation domain of Smad3.  Wehrman et al 
(2002) did some similar experiments but used the Fos and Jun coiled-coils to 
bring the enzyme fragments together.  The Bad/Bcl2 or Fos/Jun interactions 
facilitated association of the fragments of β-lactamase, and subsequent 





Figure 3.1 The β-lactamase (PDB ID 1ZG4) structure shown in a ribbon 
format.  
The complementing fragments A (N-terminal; blue) and B (C-
terminal; green) are shown with the red arrow indicating the 
position of the split site.  
Figure 3.2 highlights the loop (red arrow) that was effectively split by cloning 
two DNA fragments to create the two β-lactamase fragments, both in literature 
and in this study.  In this study, as a control, a full length functional mature β-
lactamase protein, without the signal sequence, was expressed and purified.  
Furthermore, two β-lactamase fragments, one comprising the N-terminal 
fragment and one comprising the C-terminal fragment, needed to be cloned, 
expressed and purified.  It is important to note that the majority of split-β-
Lactamase assays are performed in fixed cells or cell lysates (Remy, et al. 
2007).  In order to use split β-lactamase in this study it was necessary to 
determine if the enzyme fragments could be produced and purified for use in 




could complement in vitro.  In this study (de las Heras, et al. 2008), purified 
fragments of β-lactamase.  The fragments had His tags at appropriate sites for 
nickel or anti-His antibody binding, which would bring the fragments back into 
association with one another, as described in Chapter 1 Section 1.4.3.  This 
study demonstrated that an in vitro approach should prove feasible and that 
the association could be mediated by distinct moieties; ionic nickel and an anti-
His antibody (de las Heras, et al. 2008).   
 
3.1.1 Full length β-Lactamase 
The full-length gene for β-lactamase in the expression vector pET28a was 
kindly provided by the Radford laboratory (University of Leeds).  The 
pET28awtBla plasmid containing mature full-length β-lactamase without a 
signal sequence was used as a template to generate the various DNA 
fragments. To confirm the identity of plasmid pET28awtBla the β-lactamase 
coding region was confirmed by DNA sequence analysis and a diagram of the 





Figure 3.2 Vector map of pETawtBla plasmid containing wild type β-
lactamase.  
A schematic diagram of pET28awtBla, showing the alignment of 
wtBLA-1_T7P_16 gene (green strip arrow) with a reference wtBla 
(solid green arrow).  The wtBla gene produces the enzyme.  Kan 
confers kanamycin resistance for bacterial selection and the lac I 
gene produces the lac repressor which represses wtBla 
expression until an inducer is added.  The red arrow indicates the 
position of the T7 promoter and the solid green arrow the β-
lactamase coding region and direction of transcription/translation, 
while the white circle represents the transcription terminator.   
The pET28awtBla plasmid was used to produce β-lactamase protein and was 
also used as a template DNA to PCR amplify the coding region fragments for 
subcloning into pET28c.  The fragments were amplified by PCR and 
appropriate restriction enzyme sites were added by 5’ extensions on the PCR 
primers.  The N-terminal β-lactamase encoding peptide was designated 
fragment A, and the C-terminal encoding fragment was designated fragment 




3.1.2 β-Lactamase fragments 
Figure 3.3 illustrates the approach for the amplification of the β-lactamase 
fragments.  Each of the fragments was amplified from the full-length coding 
region using primers which introduced 5’ restriction sites.  Block arrows 
represent the β-lactamase gene and gene fragments, and the primers are 
represented by coloured arrows. The restriction sites added to fragment A 
were 5’ Nde I and 3’ Eco RI, and for fragment B were 5’ Nco I and 3’ Xho I.  
The pET28c vector and PCR gene fragments were digested with the 
appropriate restriction enzymes, and then ligated.  As different enzymes were 
used at the 5’ and 3’ ends, the PCR product could be directionally cloned into 
the vector.  
 
  
Figure 3.3 Schematic of the strategy for the amplification of the 
fragments of β-lactamase.   
The red and yellow arrows represent primers for fragment A and 








3.1.2.1 PCR amplification 
Figure 3.4 shows the PCR products for fragment A and B, which were 
calculated to be 513 and 273 base pairs respectively.  Figure 3.4A shows that 
fragment A was amplified successfully in good yield, whereas little 
amplification was observed for fragment B indicating that it was not well 
amplified.  Both fragments were used for ligation reactions and transformed 
into competent E. coli cells.  Plasmid DNA was isolated from colonies picked 
from the Fragment A transformation. Unfortunately, there were no colonies 
from the fragment B transformation, therefore PCR amplification was 
optimised.  Three different proof reading DNA polymerases: Pfu Turbo, KOD 
and Phusion were used. An annealing temperature gradient from 57 oC to 69 
oC was used to investigate the best annealing temperature (Figure 3.4B). 
Figure 3.4B shows that Turbo did not produce any products of the correct size. 
KOD produced products of the correct size, which increased in yield with 
temperature, although a downside of this is that at higher temperatures a 
second larger product appears.  The PCR using Phusion also produced two 
products at all the temperatures tested.  There is an increase in intensity with 
temperature, which then decreases after 65oC.  The highest intensity of the 






Figure 3.4 Agarose gel (1%) analysis of PCR products for fragment A and 
fragment B of β-lactamase.  
(A) Fragment A showed good yield compared with Fragment B. 
Two different markers were used; a 100 bp ladder and 1000 bp 
ladder. The numbers at the side of the gel indicate the size in bps 
of that band (B). Optimisation of PCR of fragment B over annealing 
temperatures of 57 to 69 oC with three different DNA polymerases: 
Turbo, KOD and Phusion.  Using Turbo did not result in any correct 
size bands.  KOD and Phusion show that there are two product 
bands; the bottom band is the correct size for Fragment B.  The 
marker used was 100 bp ladder and the number on the side of the 




The conditions chosen for a larger scale amplification were 65oC with KOD 
polymerase. The reaction was set up as 5 X 50 μl aliquots giving 250 μl in total.  
The PCR amplification products were separated on a 1.2% agarose gel, which 
is a higher than usual percentage, to aid separation of the two products.  The 
lower band was then gel purified. 
3.1.2.2 Ligation optimisation 
Fragment B was digested with Nde I and Eco RI for 3 h at 37 oC and a ligation 
reaction with pET28 was set up at 16oC overnight. This ligation reaction was 
then introduced into competent E. coli XL-1 blue cells by transformation.  
However, no colonies grew over a 16 h period.  There was sufficient digested 
vector and insert to set up further ligation reactions, therefore, several ligation 
conditions were tested to find optimal conditions. 
 
Figure 3.5 Vector (pET28c) and fragment B insert for the ligation reaction.   
Two separate vector purification and digestion reactions were set 
up and separated in the two lanes labelled vector. Two separate 
samples of digested PCR products were also separated in the 












































The absorbance at 260 nm was used to determine the vector and insert 
concentrations.  Each of the two aliquots of insert and vector were also 
separated on an agarose gel at the same amount of DNA to ensure the 
intensities were approximately the same as shown in Figure 3.5. Table 1 
displays the different conditions used to ligate fragment B insert and pET28c 
vector.  Both the ratio of insert to vector and the temperature was varied. 
 
Table 3-1 Ligation reaction conditions tested to ligate fragment B of β-
lactamase into the pET28c vector.  Each ligation reaction was 
incubated over a 16-hour period. 
Temperature Ratio of Insert to 
Vector 
Ratio of Insert to 
Vector 
Ratio of Insert to 
Vector 
4oC 1:1 3:1 10:1 
16oC 1:1 3:1 10:1 
20-25 oC 1:1 3:1 10:1 
 
There were several colonies recovered from the transformation of the ligations 
conducted at 16 oC.  Whilst colonies grew for samples from all three ratios, the 
greatest difference between vector only and the test sample was on the 10:1 
plate that showed 6 and 50 colonies respectively.  Five colonies were picked 
and colony PCR was performed to identify a colony that contained a 
recombinant plasmid.  Figure 3.6 confirms that all 5 colonies contained 
recombinant plasmids with an insert of approximately the correct size.  The 
positive control used pET28wtBla (Figure 3.2) while the negative control used 







Figure 3.6 Colony PCR to identify correctly cloned fragment B of β-
lactamase in pET28c.    
The DNA for fragment A or fragment B cloned into pET28c was subjected to 
DNA sequence analysis to confirm their integrity, and the corresponding amino 
acid sequences are shown in Figure 3.7.  This plasmid was used to produce 





Figure 3.7 Amino acid sequence alignment for fragment A and B of β-Lactamase.  
The DNA sequences were translated into a protein sequence for both fragment A and B and aligned against the full-
length sequence of β-Lactamase.  Fragment A has a N-terminal His tag followed by a small linker region and fragment 
B has a C-terminal His tag, with three preceding amino acids used as a small linker.  White residues are aliphatic, red 
residues are negatively charged amino acids, blue residues are positively charged amino acids and purple resides 




3.2 Protein production of β-Lactamase and β-Lactamase 
fragments 
The vector pET28AwtBla (Figure 3.2) has a T7 promoter, and therefore 0.5 
mM IPTG was used to induce expression of full-length β-lactamase in E. coli 
BL21 (DE3) star cells as described in Chapter 2 Section 2.2.2.  Samples were 
taken before induction, then after 4, 8 and 16 h.  The samples are shown in 
Figure 3.8A and indicate β-lactamase was expressed in the soluble fraction.  
It expressed at the highest yield after 8 h and did not improve further after 16 
h.  There was sufficient protein for further studies and so the expression was 
not optimised further. 
Several attempts were made to obtain Fragment A in the soluble fraction.  
Three different E. coli cell strains were tested: BL21(DE3) Gold, BL21(DE3) 
Star and SHuffle; these did not show any difference, and there was a band 
representing the protein of interest only in the insoluble fraction.  Lower 
induction temperatures of 30oC, 25 oC, 20oC and 18 oC were tested in four 
different media, LB, 2TY, TB and SB. In each case a small band was observed 
in the insoluble fraction, but again there was nothing present in the soluble 
fraction.  Finally, auto-induction was tried using auto LB, auto TB and auto SB 
media.  Once again, the protein produced was only in the insoluble fraction.  
However, there was a large band shown on the insoluble protein gel, with auto 
TB producing the most protein.  These expression trials were conducted in 2 
ml volumes in a 24 well plate.  Fragment A expression was reproduced in a 
500 ml volume, and again, as expected, the protein fragment expressed 
almost completely in the insoluble fragment as shown in Figure 3.8B.  It was 






Fragment B was expressed using 0.5 mM IPTG induction in BL21(DE3) star 
E. coli cells.  Figure 3.8C shows fragment B was expressed mainly in the 
insoluble fraction, as there is a larger band in this insoluble fraction lane.  
However, there was a small band in the soluble fraction.  This was not further 








Figure 3.8  β-lactamase expression analysed by SDS PAGE.    
The red boxed bands are the correct size bands for each of the β-
lactamase protein or protein fragments.  A) Full-length β-
lactamase is expressed in the soluble fraction.  B) Fragment A is 
expressed in the insoluble fraction. C) Fragment B of β-lactamase 



























































3.3 Protein purification of β-Lactamase and β-Lactamase 
fragments 
Purification of full-length β-lactamase was performed by affinity 
chromatography.  There was a His tag present and therefore, immobilised 
nickel on agarose beads was used to purify the protein by affinity 
chromatography as described in Chapter 2 Section 2.7.1.  The cell lysate was 
loaded on to the column, and a sample of the flow through was collected.  The 
column was then washed with 10 CV of wash buffer and a sample from the 
last CV was collected.  The protein was eluted with elution buffer and collected 
in two 1 ml samples. Figure 3.9 shows all the samples and a molecular weight 
ladder.  The protein was then dialysed into a PBS with 20 % glycerol, flash 
frozen in liquid nitrogen and stored at -80oC until it was used in downstream 
experiments.  
 
Figure 3.9 Purification of full-length β-lactamase.  
Nickel affinity chromatography was used to purify β-lactamase.  A 
sample of the flow through, final wash and two elutions were 
collected, and analysed.  The marker is shown in the very left lane 
and the numbers down the left side of the gel are molecular 
























































Fragment A was purified from inclusion bodies as it was in the insoluble 
fraction, as shown in Figure 3.10.  This involved a two-step purification, initially 
isolating the inclusion bodies in denaturing conditions, followed by nickel 
chromatography.   The denaturing conditions meant that fragment A unfolded, 
and therefore required refolding into a functional protein. See Chapter 2 
Section 2.7.1.1 for a detailed description. 
 
 
Figure 3.10 Purification analysis of fragment A.   
The gel on the left shows the various stages of the inclusion body 
preparation.  The first lane is the molecular weight marker, 
followed by the inclusion bodies in detergent. The next two lanes 
are subsequent wash steps to clear the detergent.  The large band 
is the correct size for fragment A.  The gel on the right shows the 
inclusion bodies being further purified using a nickel IMAC 
column.  The first lane is the same as the final lane on the left gel 
(solubilised inclusion bodies) but at 5X lower concentration.  This 
is followed by two wash samples, three elution samples and a 
repeat of the marker.  All of these purification steps were done 







































































































































The pellet from the expression of fragment A was thawed on ice and 
resuspended in 50 mM Tris buffer pH 8.0.  The cells were lysed by sonication, 
the insoluble fraction was pelleted and the supernatant was discarded.  The 
insoluble pellet was then re-suspended in a detergent wash buffer and 
incubated for 1 h at room temperature on a see-saw rocker.  The insoluble 
fraction was pelleted and the supernatant discarded.  The pellet was washed 
twice by resuspending in 50 mM Tris.HCl pH 8.0 and incubated for 1 h at room 
temperature on a see-saw rocker.  The purified inclusion bodies were pelleted 
and stored at -20 °C.  The inclusion bodies were then purified on a Ni2+ NTA 
column under denaturing conditions (8 M urea).  Once eluted, the protein 
needed to be refolded. 
Initially, serial dialysis with lower and lower concentrations of urea was carried 
out in an attempt to refold the protein.  In this initial trial, the reduction in urea 
was in 1 M concentration steps each equilibrating for a minimum of 8 h.  
However, the protein fragment precipitated between 4 M and 3 M urea.  A 
second attempt was made with the increments reduced to 0.25 M steps after 
4 M urea.  The protein precipitated again between 4 M and 3.75 M.  On column 
folding was tried next, as described in the methods section.  In short, 
purification and refolding of the N-terminal fragment was accomplished on a 
Ni2+NTA column.  The inclusion bodies were resuspended and poured on to 
the equilibrated column, followed by 10 CV re-suspension buffer.  50 CV of 
wash buffer were added and as the wash buffer does not contain denaturant, 
the protein should re-fold on the column.  The fragment was eluted in 3 CV of 
elution buffer. There was no visible precipitate either associated with the 
column or in the elution fraction.  The pooled and dialysed fractions were flash 
frozen in liquid nitrogen and kept at -80 oC until required. 
Initially, fragment B was also purified from inclusion bodies as there was a 
much larger amount of fragment B in the insoluble fraction.  Unfortunately, this 
did not result in any protein in the elution fractions.  Another attempt was made 
using the soluble fraction and a small amount (0.55 μg) of protein was purified.  
Further optimisation of expression of fragment B would be prudent, but as time 
was restricted and there was enough to proceed with, the expression was not 




was completed to have enough protein to determine kinetic parameters of the 
protein fragments both on their own and together.  
 
 
Figure 3.11 Purification of fragment B.  
A 500 ml culture was lysed and the soluble fraction was purified.  
The flow through or unbound protein are in the first lane followed 
by the first wash.  The final wash only contains a band equal to the 
size of the protein.  Elutions 1-5 were pooled and dialysed into PBS 


















































































3.4 Reconstruction of an active protein from two fragments 
To investigate if the purified fragments of β-lactamase could be brought 
together, they were incubated with nickel ions in the form of nickel sulphate.  
These ions should be able to coordinate the His tags from each fragment 
located precisely where the loop was before β-lactamase was split.  Figure 
3.12 shows how the nickel ion could coordinate two polypeptide chains with 
His tags on them.  As the two His tags are brought into close proximity the 
hypothesis is that the two protein fragments would come together and regain 
activity.  Nickel has a variety of coordination numbers and geometries (Eaton 
and Zaw 1972).  For example, when the coordination number is 4, both 
tetrahedral and square planar complexes can be found, and for a coordination 
number 5, both square pyramid and trigonal bipyramid complexes are formed 
(Eaton and Zaw 1972).  An equilibrium of each of these different forms exists 
(Eaton and Zaw 1972). 
 
Figure 3.12Nickel ion coordinating histidine residues.    
Nickel has a variety of coordination numbers and geometries.  For 
example, when the coordination number is 4, both tetrahedral and 
square planar complexes can be found, and for a coordination 
number 5, both square pyramid and trigonal bipyramid complexes 




Detection of active β-lactamase can be performed in a number of ways.  First, 
in a survival based assay using any β-lactam antibiotic, such as ampicillin.  
Second, with a coloured assay using nitrocefin as a substrate which, when 
turned over by β-lactamase, turns from a yellow substrate to a red product and 
can be quantified by measuring absorbance at 482 nm.  Finally, a fluorescent 
assay can also be performed using CCF2 as a substrate.  CCF2 is a derivative 
of cephalosporin which has two additional fluorescent groups attached 
(Qureshi 2007).  This split β-lactamase a very versatile protein.   
CCF2 AM is a fluorescent substrate that requires a cytoplasmic esterase and 
therefore can only be used in certain eukaryotic cell types.  After the 
cytoplasmic esterase has processed CCF2, β-lactamase hydrolyses the 
product and fluorescence is detected.  In addition to the restriction of cell type, 
CCF2 was prohibitively expensive for use in this study. Nitrocefin is a 
chromogenic substrate for β-lactamase that is yellow in colour, but when 



































Figure 3.13 Hydrolysis of nitrocefin by a β-lactamase  
The hydrolysis of nitrocefin involves hydrolysing the β-lactam ring 
with the associated colour change from yellow to red.  The β-
lactam ring is shown in black. 
Traditionally, nitrocefin has been utilised in several different ways: 
• Slide Surface Assay:  a single colony is added to a drop of 0.5 mg/ml 
nitrocefin on the surface of a clean glass slide.  If the solution changes 
to red, β-lactamase is present (Parr, Pai et al. 1984). 
• Direct Contact Assay:  one drop of 0.5 mg/ml nitrocefin is placed directly 
on the surface of a colony.  If the colony changes to red, β-lactamase is 
present. (Brook and Gober 1984). 
• Broth Suspension Assay:  3-5 drops of 0.5 mg/ml nitrocefin is added to 
1 ml of broth suspension, and if β-lactamase is present the suspension 
changes to a red colour (Brook and Gober 1984). 
• Lysed Cell Assay:  3-5 drops of 0.5 mg/ml nitrocefin is added to 1 ml of 
lysed cells and if the lysate turned red then β-lactamase is present 




• Filter Paper Assay: add 3-5 ml of 0.5 mg/ml nitrocefin to filter paper and 
smear isolated colonies over the paper, if β-lactamase is present the 
area where the smear is located will turn red (Parr, et al. 1984). 
In each of these cases, the appearance of red colour within 20-30 min 
indicates β-lactamase activity and gives a present/absent result.  A more 
quantitative assay was needed to measure the activity of β-lactamase, in order 
to compare different levels of activity. This involved measuring the absorbance 
of product formation at 500 nm.   Nitrocefin is a chromogenic substrate that 
turns from yellow to red upon hydrolysis.   Looking at the spectra, the λ max 
was checked for both intact and hydrolysed nitrocefin.  After a sample of 
nitrocefin was hydrolysed, both the hydrolysed and intact nitrocefin spectra 
were recorded.  
 
Figure 3.14 Spectra of Intact and hydrolysed nitrocefin.   
The yellow spectrum is for intact nitrocefin as it is yellow in colour.  
The red spectrum is for hydrolysed nitrocefin as it is red in colour. 
The λmax shifts from 380 nm to 500 nm. Reading the absorbance 
at 500 nm would indicate the amount of product produced from a 


























To investigate the association of the fragments into a functional protein, many 
experimental controls were required.  Recombinant full-length β-lactamase 
was used as a positive control, indicating the substrate is turning over 
correctly.  Recombinant full-length β-lactamase with nickel ions was also 
included as a second positive control to ensure the nickel ions did not interfere 
with the normal turnover of the enzyme.  Each of the fragments, both with and 
without nickel, were included in this experiment to indicate their individual 
levels of turnover.  Finally, as a negative control, the assay was set up without 
the enzyme, again both with and without nickel.  Purified β-lactamase and β-
lactamase fragments were produced as described in Section 3.2. 
 
 
Figure 3.15 Nitrocefin Assay for the recombination of the β-lactamase 
fragments.   
The photographs were taken after a 16-hour incubation.  The top 
row has full-length β-lactamase in the first two wells, both with and 
without nickel, indicated with a ‘+’ or ‘-‘.  The third and fourth wells 
on the top row contain both fragments of β-lactamase, with and 
without nickel.  Each of the fragments on their own are shown on 
the bottom row.  A red colour indicates turnover of the substrate 





Figure 3.15 shows the full-length β-lactamase in the first two wells on the top 
row. Both are red, indicating the nitrocefin substrate was turned over.  The only 
difference in the two samples was the presence and absence of nickel ions 
respectively, thus indicating that the nickel does not make a difference to the 
nitrocefin being turned over.  The next two wells on the top row contained both 
fragments of β-lactamase.  The sample with nickel has turned red, whereas 
the sample without nickel has a slightly orange colour.  This suggests that the 
fragments on their own do turn over the substrate but only at a very low level, 
and will add to the background.  The sample with the nickel is red rather than 
orange indicating that when the fragments are held together with nickel the 
turnover rate is higher. 
The bottom row contains samples of the fragments of β-lactamase individually, 
again with and without nickel.  All the samples remained yellow inferring that 
the fragments do not turn over the substrate without their partner fragment.  
Figure 3.15 shows recombinant β-lactamase, that was used as a positive 
control, started to decolourise, as shown by the faded colour in the first well on 
the top row.  Furthermore, it is more clear on Figure 3.16 where there is an 
obvious decrease in absorbance after about 15 h.  It was necessary to 
investigate this further, because a value for the positive control could be 
reducing when the two fragments with nickel were increasing, thereby giving 
skewed results. 
3.5 Nitrocefin time course 
Figure 3.16 shows a time course of the measurement of the hydrolysis of 
nitrocefin in each of the following conditions: Full-length recombinant β-
lactamase, Fragment A of β-lactamase, Fragment B of β-lactamase, Fragment 
A & B of β-lactamase.  All of these sets of proteins were assayed both with and 
without nickel.   
To process the data shown in Figure 3.16 the absorbance for nitrocefin alone 
was subtracted from each of the assay mixes without nickel.  The absorbance 
for nitrocefin with nickel was subtracted from each of the assay mixtures with 




a small amount of precipitate was observed.  A precipitate would cause light 
to scatter and give a false reading of a higher than actual absorbance.  The 
absolute values were small and did not reach an absorbance higher than 0.5 
at 492 nm.  The error bars are not displayed on the main graph for clarity.  The 
insert graph shows the error bars for full-length β-lactamase.  The largest error 




















Nitrocefin assay time course.  Absorbance at 492 nm over several hours for full-length β-lactamase, and for β-lactamase 































Full-length recombinant β-lactamase both with and without nickel shows a high 
rate of product formation in the first hour followed by a reduction in absorbance.  
This is not the product reducing, because hydrolysis of a cephalosporin is a 
one way reaction (Page and Proctor 1984). The most plausible explanation is 
a bleaching effect as the mixture is exposed to light.  However, the same effect 
did not happen for the fragment A and B in the presence of nickel, even after 
50 hours.  It is encouraging that in both cases, with and without nickel, the 
hydrolysis rate remains similar and has the same pattern, as shown by the red 
squares and blue diamonds in Figure 3.16. 
Fragment A and fragment B of β-lactamase, both with and without nickel, seem 
to show a very low level of product formation over time, which could be an 
effect of the instrument heating up over time.  Effectively, this looks like a 
baseline, but slightly higher than each of the fragments on their own.  
In absorbance measurements, the intensity was less than 0.1 at 492 nm after 
50 h.  When fragments A and B were mixed together there was an increase 
over each of the fragments on their own, and after 50 h an absorbance of 0.2 
was almost reached.  When nickel was present to hold the two fragments 
together, the absorbance reached 0.5 after 20 h.  Each of the assays exhibited 
different rates and this seemed to be the best way to show the differences 





Figure 3.17 Nitrocefin assay of β-lactamase and β-lactamase fragments 
displayed as a rate.   
The first 20 minutes of the nitrocefin assay were recorded and the 
initial rates were determined and shown in a bar chart.  
 
There is an obvious difference between the fragments of β-lactamase when 
nickel was introduced.  In the absence of nickel the rate for fragment A and B 
was only 0.0038 absorbance units/min, and after addition of nickel the rate 
went up to 0.028 absorbance units/min; representing a more than 7-fold 
increase.  
3.6 Kinetic parameters 
The substrate nitrocefin was used to calculate the kinetic parameters for 
recombinant TEM-1 β-lactamase and fragments of TEM-1 β-lactamase in the 
presence and absence of nickel ions.  The absorbance of hydrolysed nitrocefin 












































































it should be noted that nitrocefin is light sensitive and these assays were 
performed on the bench top.  Therefore, some variability was expected.   
Published data for TEM-1 β-lactamase quote the KM to be around 61 μM and 
the kcat to be about 122 s-1 (de las Heras, et al. 2008).     
Table 3-2 Kinetic parameters for β-lactamase and β-lactamase 
fragments. 
β-lactamase variant  KM (µM) kcat (s-1) 
Recombinant β-lactamase 89 ± 9 65 ± 10 
Fragment A and B with Ni2+ 36 ± 3 3.2 ± 0.3 
Fragment A and B only  68 ± 8 0.31 ± 0.06 
 
The kinetic results do show a small difference in the KM, between the β-
lactamase fragments in the presence and absence of nickel, but the interesting 
difference is in the kcat.   Recombinant β-lactamase has a turnover rate of 65 
s-1 which is reduced to only 0.31 s-1 for the β-lactamase fragments on their 
own.  When the fragments were brought together with nickel ions the turnover 
rate increased, some 10-fold, to 3.2 s-1.  This demonstrates that in theory an 
enzyme can be split and brought back together in a functional purified format, 
although there is an obvious question about the efficiency with which high 
levels of activity can be restored.   
3.7 Discussion 
TEM-1 β-lactamase was expressed and purified, and an N-terminal and C-
terminal fragment of β-lactamase was cloned, expressed and purified.  These 
fragments were brought back together in a functional format in an in-vitro 
experiment using nickel ions.  This indicates that a split enzyme could work in 
a completely purified system, for example in a biosensor type assay, although 
there are clearly challenges associated with this process. These include the 
ability to produce sufficient quantities of fragments ideally without refolding, 





Natively purified β-lactamase is reported in literature to have a kcat of 960 s-1 
(de las Heras, et al. 2008). In the de las Heras study there was a significant 
drop in turnover from 960 sec-1, for natively purified β-lactamase, to 122 s-1 for 
recombinant β-lactamase (de las Heras, et al. 2008).  Values in the current 
study are within an agreeable level of those for recombinant TEM-1 β-
lactamase.  The rate of turnover for recombinant full-length β-lactamase was 
65 s-1.  A further 20-fold drop in turnover down to just 3.2 s-1 was recorded 
when the fragments were brought back together in close proximity with nickel 
ions.  This compared well with what was reported in literature as 6.5 s-1 (de las 
Heras, et al. 2008).  A background was reported in the literature (de las Heras, 
et al. 2008) but quantitative data was not given.  The background in this study 
was due to a turnover rate of 0.31 sec-1. There was a difference between the 
signal and noise, and this could be further improved, by further optimisation of 
the fragments. 
Improvements could be made to this system to make it more effective.  The 
addition of the mutation M182T is known to disrupt an inactive molten 
intermediate of the full-enzyme and this should give fragment A more stability 
and higher activity (Galarneau, et al. 2002).   
The addition of a tri-peptide Asn-Gly-Arg at the C-terminal of fragment A could 
also improve the split β-lactamase assay. In a study by Wehrman et al 
(Wehrman, et al. 2002) it was noted that the antibiotic resistance was improved 
by the addition of this tripeptide. 
However, as the recombinant β-lactamase activity is already significantly 
reduced before the protein was even split, it was decided to investigate a 
different enzyme.  Furthermore, the stability of nitrocefin was questionable. 
Instability of nitrocefin in light, moisture and temperature make this system less 
than optimal.  The activity data show that one batch of nitrocefin was so 
sensitive to light that after several hours it lost the red colour.  Moreover, the 
batch to batch variance was substantial for this split β-lactamase to be used in 
a reliable colorimetric biosensor.  The reduced activity of the β-lactamase 





Ideally, a dimeric protein, which can be expressed as a functional recombinant 
protein, without affecting the activity, would be best suited to the proposed 
diagnostic application.  An enzyme with potential from this perspective is 
alkaline phosphatase, which is a routinely used enzyme within biochemistry 




Chapter 4  







For a protein complementation system, an enzyme should be split into two 
fragments which, by themselves, do not turn over the substrate, but when 
brought into close proximity can interact and gain the ability to turn over 
substrate to generate a measurable signal.  In a biosensor, it is envisaged that 
this signal amplification would arise from the binding of two Affimer proteins to 
separate epitopes on a single target protein. This binding would bring the 
enzyme fragments together to allow multiple substrate turnover events.  A 
major problem with some split enzyme systems is that the level of recovery of 
enzyme activity, relative to wild-type activity, can be quite low; meaning the 
signal generated from the split enzyme would be relatively weak.  Another 
option to consider is the use of a dimeric enzyme where the dimer interface is 
engineered to prevent spontaneous monomer association, but still retaining 
the ability of the two subunits to associate and form a functional enzyme. E. 
coli alkaline phosphatase is a good model enzyme for investigating subunit 
interactions in homodimeric enzymes as it exhibits cooperativity (Garen and 
Levinthal 1960).  In this study, it is also a good candidate for use as an 
amplification tool in a biosensor 
E. coli alkaline phosphatase does not turnover substrate when in a monomer 
form but only functions as a dimer indicating some form of cooperativity 
between the subunits, although this is poorly understood. So, in order to create 
a stable monomer, and to understand the mechanism of control and regulation 
of AP achieved by the subunits’ interactions, several mutants of the enzyme 
have been constructed in previous studies (Martin, et al. 1999, Boulanger and 
Kantrowitz 2003, Orhanovic, et al. 2006). 
Four positions on the dimeric interface have been previously investigated: 
R10, R24, T59 and T81 that when mutated to an alanine were found to have 
a small negative effect on substrate turnover.  These mutations did, however, 
show a notable effect on the stability of the protein (Martin, et al. 1999, 
Boulanger and Kantrowitz 2003, Orhanovic, et al. 2006).  However, the only 
mutation to successfully result in a stable monomer was at T59 when mutated 




Figure 1.19  shows why the T59R monomers are unlikely to form a dimer due 
to steric hindrance and charge repulsion. The T59R mutant was generated in 
this study to confirm lack of dimer formation and to provide a negative control 
in stability, activity, and structural assays. 
R10, R24, and T59 are all situated on the dimer interface (Martin, et al. 1999).  
The mutational variants R10A, R24A, and T59A were all described as having 
an effect upon protein stability and a small negative effect on substrate 
turnover.  The largest effect was due to R10A that showed a reduction in kcat 
from 69.5 ± 4.5 s -1 to 53.9 ± 3.4 s -1.  The stability of the dimer or monomer 
forms were also investigated, as was that of the double mutant R10A-R24A 
that showed instability similar to that of the single mutants.  At pH 5 all of the 
mutant proteins were a mixture of both dimeric and monomeric forms, whereas 
at pH 4 all were monomeric (Martin, et al. 1999).  The pH optimum for wild type 
alkaline phosphatase is approximately pH 8.0 although it displays reasonable 
activity at even higher pH values and thus, to be used in a biosensor, the 
enzyme must exist as a monomer at basic pH values.   
The T81A mutation is also at the subunit interface and has a small negative 
effect on substrate turnover, with kcat reduced from 61.8 s -1 to 36.9 s-1 at pH 
8. The thermostability of this variant was reduced compared to wild type, 
indicating an effect on the stability of the dimer in 1 M Tris pH 8.0 (Orhanovic, 
et al. 2006). Figure 1.18 in Chapter 1 shows the R10, R24, T59, and T81 
residues and their interactions with the nearest residues on the other chain of 





4.2 Producing wild-type alkaline phosphatase 
Figure 4.1 shows a map of an expression plasmid pECAP-T81A-Sort 
containing a mutant version of alkaline phosphatase that was available in the 
lab.  It contained the point mutation T81A and a sortase tag.  Mutagenesis was 
used to revert the mutant alkaline phosphatase back to a wild type Thr version, 
while the sortase tag was retained as it had no bearing on the function of the 
protein. Primers were designed to introduce the A81T change into pECAP-
T81A-Sort as detailed in Chapter 2, Section 2.5.1.2 creating the plasmid 
pECAP-Sort. 
 
Figure 4.1 Vector diagram of pECAP-T81A–Sort containing T81A (taken 
from DNA 2.0 gene synthesis report).  
Features include a P_rhaBAD promoter which is rhamnose 
inducible, a strong ribosome binding site (RBS) and a kanamycin 
resistance marker. The pUC ori is a mutated form of origin of 
replication derived from E. coli plasmid pBR322 which allows 





DNA sequencing confirmed successful mutagenesis and the new vector, 
pECAP, was used for wild type alkaline phosphatase protein production.  The 
protein was produced in SHuffle cells that are deficient in the phoA gene, so 
there is no endogenous alkaline phosphatase and they are designed to allow 
the formation of disulfide bonds in proteins within the cytoplasm. For more 
details see Chapter 2 Section 2.2.3. 
 
The rhamnose promoter makes this expression system tunable by varying the 
amount of rhamnose used to induce protein production. A range of rhamnose 
concentrations from 0.001 % to 0.2 % were tested and samples were taken 6 
h post-induction.   
Figure 4.2 shows that the amount of protein produced varies depending upon 
the amount of rhamnose added.  The proportion of protein in the insoluble 
fraction increases to appreciably more than that in the soluble fraction at 0.1 
% rhamnose.  This suggests that at 0.1 % rhamnose protein production is so 
rapid that protein folding is compromised.  In the soluble fraction, the quantity 
of protein produced is approximately the same between rhamnose 
concentrations of 0.005 % to 0.01 %.  Thus 0.01 % rhamnose was used for 






Figure 4.2 Expression of wild-type alkaline phosphatase at different 
concentrations of rhamnose inducer.   
The marker lane shows molecular mass markers and their sizes in 
kDa are indicated to the left.  Two lanes are shown per 
concentration. Sol; soluble protein, In; insoluble protein. The 
samples have been induced with 0%,  0.001%, 0.005%, 0.01%, 
0.1%, and 0.2 % rhamnose.  The lane marked CIP is calf intestinal 
phosphatase (70 kDa), CIP is larger than E. coli alkaline 



































































































Figure 4.3 shows an SDS PAGE gel of levels of protein production at different 
induction times. Samples were taken before induction (uninduced) and at 
various times post induction with 0.01 % rhamnose; 50 μl of each of the 
samples were normalised by reducing the OD600 to 0.5.   There was little 
obvious difference between 4, 6, and 16 h levels.  Following quantification, 
using a BCA assay as described in Chapter 2 Section 2.9.2, the amount of wild 
type protein produced at 4 and 6 h was determined to be between 9 and 10 
mg/L. Overnight incubation resulted in a decrease to between 5 and 7 mg/L.  
However, for different experiments conducted during this study, either 4 h, 6 h 
or overnight grow ups were used for convenience. 
 
 
Figure 4.3 Expression of wild type alkaline phosphatase: optimizing the 
length of time for induction.    
Marker lanes show molecular mass markers with the size noted in 
kDa.  Soluble and insoluble fractions are shown as uninduced and 
then 2, 4, 6, and 16-hour post-induction samples. The soluble AP 




















































































Wild-type alkaline phosphatase was purified using IMAC chromatography with 
nickel NTA beads, as described in Chapter 2, Section 2.7.2. Briefly, after the 
induction phase, the cells were harvested by centrifugation and frozen at -80 
oC for storage.  For protein purification, the cell pellet was thawed at room 
temperature and mixed with 10 ml of lysis buffer per gram of cells.   The lysate 
was clarified, and the soluble fraction was incubated with Ni2+ NTA beads for 
40 mins before being poured into a Thermo Scientific, Pierce, disposable 
plastic column, then washed with 20 ml of wash buffer, or until the OD280 was 
less than 0.1.  The protein was eluted in 0.5 ml fractions of elution buffer until 
the OD280 stabilised.  Samples from the soluble fraction, flow through, wash 
steps, and elution fractions were analysed by SDS PAGE.  Figure 4.4 shows 
a 15 % SDS PAGE gel of fractions of a purification.  Elution fractions 1 to 3 
were pooled and after dialysis, as described in Section 4.2.1, the concentration 
was determined using both a BCA assay and by absorbance at A280 using an 








Figure 4.4 Purification of wild-type alkaline phosphatase.  M, molecular 
mass markers with sizes shown in kDa.   
From left to right, the lanes contain the soluble fraction loaded 
onto the column, the flow-through showing unbound material, 
three wash steps, and then four elution fractions. The arrow 
indicates the position of alkaline phosphatase.  
 
Traditionally, alkaline phosphatase from E. coli is produced using phosphate 
deficient media (Garen and Levinthal 1960).  The protein produced is a natural 
product and is present in sufficient amounts to enable characterisation.  The 
aims of this project included investigating numerous mutants of alkaline 
phosphatase, many of which were thought to be inactive.  Thus, using 
phosphate deficient media as an approach to produce the mutants would not 













































































active alkaline phosphatase. Moreover, the conventional approach for 
purification is ammonium sulfate precipitation followed by ion exchange 
chromatography. Mutations would change the properties of the enzyme and 
potentially require tailoring of the purification protocol for each mutant.   
The approach used here involves IMAC, in this case, nickel NTA, and only 
requires a His tag to be associated with the recombinant protein, making 
protein isolation facile, fast and essentially independent of the physicochemical 
properties of the protein, including any mutational variants.  The potential 
drawback of producing and purifying alkaline phosphatase in this way is that 
the kinetic parameters could be affected when alkaline phosphatase is 
produced in the reducing environment of the cytosol.  Alkaline phosphatase 
has two disulfide bridges in each chain between Cys-168 and Cys-178, and 
between Cys-286 and Cys-336 (Sone, et al. 1997).   The SHuffle cells used 
for alkaline phosphatase production are deficient in endogenous alkaline 
phosphatase and facilitate cytoplasmic disulfide bond formation.  The kinetic 
parameters for wild-type AP were, therefore, determined and compared with 
those previously reported. 
4.2.1 Dialysis of alkaline phosphatase. 
Stringent dialysis of alkaline phosphatase is required. Reasons for this include 
the fact that alkaline phosphatase is inhibited by imidazole, which is present in 
all the buffers used to purify the protein, and also, because if zinc is not present 
in the active site, the protein is inactive.  To overcome both issues the protein 
was rigorously buffer exchanged; firstly into 50 mM Tris-HCl pH 8.0 for 2-4 hrs, 
then into the ion addition solution (50 mM Tris-HCl pH 8.0, 1 mM ZnSO4 0.1 






4.3 Determination of kinetic parameters for wild-type alkaline 
phosphatase. 
A general assay to investigate alkaline phosphatase enzyme activity is through 
turnover of the colourless substrate pNPP that upon catalytic hydrolysis of the 
phosphate results in p-nitophenol, a chromogenic product that can be 
monitored spectrophotometrically at 405 nm.  
 
Figure 4.5  Assay for alkaline phosphatase activity 
 p-nitrophenyl phosphate is dephosphorylated to produce p-
nitrophenol, a chromogenic (yellow) product that can be 
monitored spectrophotometrically at 405 nm. 
The kcat of recombinant wild type alkaline phosphatase is reported to be 
between 26 - 80 s-1 and the Km is between 7.3 - 160 μM.  Temperature and 
buffer composition affect the enzyme activity and contributes to the variability 
reported in the literature (Garen and Levinthal 1960, Garen and Garen 1963, 
Coleman 1992, Martin, et al. 1999, Boulanger and Kantrowitz 2003, 
Orhanovic, et al. 2006).  In this study, the kcat of recombinant alkaline 
phosphatase was determined to be 49 ± 4 s-1 with a Km of 34 ± 12 μM.  These 
experimental data fall within the published range of values, indicating that the 






4.3.1 Optimisation of specific activity assays  
To ascertain the appropriate quantities of enzyme and substrate for specific 
activity assays, a range of enzyme concentrations, and two concentrations of 
pNPP, were investigated.  The concentration range for the enzyme was varied 
from 1 mg/ml to 5 μg/ml with substrate at 2 mM and 0.5 mM. The results of this 
preliminary test are shown in Figure 1.8. The assay was allowed to continue 
for 2 mins and stopped with 50 μl of 5 M NaOH.  The conditions determined 
for subsequent assays were 2 mM substrate with enzyme concentrations of 
0.6 mg/ml and 0.25 mg/ml. 
 
 
Figure 4.6 Optimisation of specific activity assay.   
A range of concentrations of wild type alkaline phosphatase from 
0.005 to 1 mg/ml were tested for activity at two concentrations of 
pNPP: 2 mM and 0.5 mM.  The assay was allowed to continue for 2 






4.4 pH Optimum of wild-type alkaline phosphatase 
Previous studies have reported different pH optima (Garen and Levinthal 1960, 
Torriani 1960) using various buffers, but the buffer composition may also affect 
enzyme activity.  In the present study, a tri-buffer system was used to buffer 
the reaction from pH 6.5 to pH 11.5 without changing the buffer composition.  
Table 4-1 specifies the buffer components and their individual buffering range. 
Table 4-1 Buffer composition of a three-component buffer system used 
to determine the pH optimum of wild-type alkaline phosphatase. 
Buffer component pKa of 
buffer 
Useful pH range 
N-2-aminoethane sulfonic acid (ACES) 6.9 6.1 - 7.4 
Tris (hydroxymethyl) aminomethane (Tris) 8.0 7.0 - 9.0 
N-cyclohexyl-3-aminopropanesulfonic acid 
(CAPS) 
10.4 9.7 - 11.1 
1 M sodium chloride (NaCl)  
5 M hydrochloric acid (HCl) Used to change pH 
5 M sodium hydroxide (NaOH) Used to change pH 
 
ACES can buffer from 6.4 to 7.4 overlapping with Tris, which buffers well up to 
pH 9.0, and CAPS buffers to pH 11.1.  In fact, the assays were performed up 
to pH 11.5 which is beyond the buffering capability of this system.  To test the 
integrity of the tri-buffer system, experiments were also performed with each 
of the buffers individually.  The differences between these sets of data are 
shown in Figure 4.7, where both the single and tri-buffer system show a similar 
trend, although there is less variation in the tri-buffer system. 
Sodium chloride at 1 M was added to ensure a high ionic strength, minimising 
the influence of other components, that are present at lower concentration, on 
the ionic strength.  1 M NaCl is far from the typical ionic strength at which the 
reaction takes place, furthermore, the addition of excess neutral salt means 
the introduction of additional ions, that can interfere with the enzyme reaction.  
To examine if there was indeed an effect of the high concentration of NaCl on 




from 50 mM to 1 M in 50 mM steps, and no difference was observed on the 
activity of wild type alkaline phosphatase indicating that 1 M NaCl was 
appropriate for establishing a constant ionic strength. 
 
 
Figure 4.7 Measurement of pH optimum for wild type recombinant 
alkaline phosphatase.   
The solid line are data for the three-component buffer system and 
the dashed line is generated from each of the single buffers.   
These sets of data suggest that there are two optima in the pH series, at pH 8 
and pH 10.5, but that for highest enzyme activity, the optimum pH is 10.5.  
However, as previous studies on some of the mutational variants were 
investigated at pH 8 (Martin, et al. 1999, Boulanger and Kantrowitz 2003, 
Orhanovic, et al. 2006), assays in this study were also performed at pH 8.0 to 

































4.5 Saturation Mutagenesis at position Thr59  
T59R results in a stable monomer showing no enzyme activity (Boulanger and 
Kantrowitz 2003), but as shown in Figure 1.19 it is expected that steric 
hindrance prevents the production of a stable functional dimer.  In order to 
explore whether any other amino acid at position 59 would lead to a monomer 
that could nonetheless engage in intersubunit complementation, a saturation 
mutagenesis experiment was performed.  A series of primer pairs were 
designed to replace the threonine at position 59 with every other amino acid, 
except cysteine as this could potentially result in disulfide bonds. A disulfide 
bridge at the dimer interface would be expected to stabilise the dimeric form of 
the enzyme, which is not compatible with the requirements for a split alkaline 
phosphatase.  
The QuikchangeTM mutagenesis reactions (Section 2.5.1.2) were set up in 
parallel and Dpn I was added to destroy the parental template DNA which 
should leave predominantly mutated DNA products for transformation into E. 
coli (Section 2.4). Figure 4.8 shows products of the mutagenesis reactions and 
the size of the expected product is 3704 bp.  Initially T59Q and T59W reactions 










Figure 4.8 QuikchangeTM mutagenesis products after Dpn I digestion 
from saturation mutagenesis of T59.   
Gel A contains the products for T59A, T59D, T59E, T59F, T59G, 
T59H, T59I, T59K, T59L, T59M, T59N, and T59P, which display a 
band at the expected size.  Gel B contains products for T59Q, 
T59S, T59V, T59W, and T59Y, unfortunately, T59Q and T59W have 
bands at an incorrect size.  These were repeated and are shown 







The DNA was transformed into XL-1 blue cells and, after overnight growth, five 
colonies for each variant were cultured in 5 ml of LB medium and the plasmid 
DNA extracted using a QIAGEN mini prep kit (Section 2.5.4).  The mutations 
were confirmed by DNA sequencing and a single clone for each was selected 
for protein production.  
The variant proteins were produced using the same protocol as for wild type 
alkaline phosphatase (Section 4.2).  Briefly, the plasmid DNA was transformed 
into SHuffle expression cells.  A 5 ml starter culture in 2TY with 30 µg/ml 
kanamycin was inoculated with a single colony and grown overnight. 1 ml was 
used to inoculate 50 ml 2TY/ kan 30 µg/ml medium for 4-6 h at 25oC. Protein 
was purified from the cultures, dialyzed as described in section 4.2.1, and the 
concentration of protein determined by a BCA assay. This process was 
successful for all variants except T59P that was not produced in the culture 
and therefore could not be studied further. The purified proteins are collectively 
referred to as T59X variants.    
4.6 T59X variant protein activity  
The specific activities for each of the T59X variants was determined using 17 
nM of three independent preparations for each protein.  A sample of wild type 
was also produced for comparative assays.  The data are reported as 
percentage of the wild-type activity in Figure 4.9. 
The specific activities of most of the variants was greater than 75 % of wild 
type activity, the exceptions being T59K, T59W and T59Y and, as expected, 






Figure 4.9 Relative specific activity levels of the T59X variants shown as 
% of wild type activity.   
The values measured are shown above each bar. 
Thr 59 is situated in the centre of an alpha helix at the dimeric interface. As 
noted, T59P did not produce protein and as a proline would distort the alpha 
helix this likely affects normal protein folding.  T59K and T59R introduce large 
positively charged side chains. As previously discussed, mutation to arginine 
was reported to eradicate activity (Boulanger and Kantrowitz 2003).  Lysine in 
this position also reduces activity to 65 % of wild type but this is not as drastic 
as Arg, perhaps due to the greater flexibility of the lysine side chain, which 
presumably adopts a conformation that still allows enzyme dimerization, 
although apparently not as efficiently as wild-type.  T59Y and T59W both 
introduce aromatic side chains which are bulky and probably lead to some 
steric hindrance, albeit with 72 % and 55 % activity retained respectively, and 
are not as deleterious as Arg.  With the exception of T59R, none of these 
variants alone resulted in a sufficient level of monomerisation and associated 
loss of activity to be used for this project.  Thus, investigations into further 





































4.7 PDBSum analysis to identify important residues at the 
dimer interface 
PDBSum (Laskowski, et al. 1997, Laskowski 2001) is a program that describes 
the inter- and intra-molecular interactions of a protein from the coordinates in 
a PDB file.  This program was used to specifically investigate the interactions 
at the dimer interface. The PDBSum results for E. coli alkaline phosphatase, 
from PBD accession code 1ALK, were 504 non-contact bonds, such as van 
der Waals or hydrophobic interactions, 49 hydrogen bonds, and no other 
electrostatic interaction between 80 residues on chain A and 82 residues on 
chain B.  Non-contact bonds cannot be overcome by a mutation as they are 
not specific to a side chain. Hydrogen bonds form between a hydrogen atom 
and an electronegative atom, usually oxygen, in a protein. Such bonds can 
involve both backbone and side chains, and for the purposes of protein 
engineering, only bonds involving side chains are amenable to modification, 
unless unnatural compound incorporation is used, which was not the case in 
these studies. 
The 49 hydrogen bonds were investigated further and the 4 residues 
mentioned previously: R10, R24, T59, and T81 were included in this group.  
To reduce the number of interactions, for experimental investigation, first 
duplicate interactions in the form of mirroring interactions where the same 
residues on chain A interact with chain B and vice versa, were removed.  Next, 
those where the interactions did not involve the amino acid side group were 
also removed. Thus, remaining interactions could potentially be manipulated 
through mutagenesis as shown in Figure 4.10.  In addition to R10, R24, T59, 
and T81, the residues D28, R34, R62, and Y98 were investigated further.  
These all have at least one hydrogen bond interaction between their R-group 
and another residue (Figure 4.10).  Thus, initially, each residue was mutated 
to an alanine, which, with a methyl side chain, cannot form side chain hydrogen 
bonds. The stability of the dimer interface interaction should be reduced as the 
number of hydrogen bonds holding the two peptide chains together is reduced.  
Hopefully, decreasing some of these interface interactions would convert the 





Figure 4.10 Hydrogen bonds formed between Chain A and Chain B of E. 
coli alkaline phosphatase.   
The Figure is adapted from PDBsum output.  The residues 
highlighted in red have been mutated to an alanine in this study.  
Only one set of interactions has been shown for simplicity. Arg34 
and Arg10 interact with the backbone of the peptide and therefore 
their interacting partners are not shown. 
 
Asp 28 was chosen because it was proposed that when mutated to an alanine 
it would remove interactions to Asn 428 and His 425.  Arg 34 was proposed to 
interact with the backbone of chain B, but this would also be prevented by an 
alanine mutation.  As T59A has already been shown to reduce the stability of 
alkaline phosphatase (Martin, et al. 1999, Boulanger and Kantrowitz 2003), 
R62 was theorized to increase the instability as it is part of the same interacting 
group and forms two hydrogen bonds to Gln 416.  Finally, Tyr 98 was chosen 




T59A and T59R had been produced in the T59X saturation mutagenesis. The 
R10, R24, and T81 residues were reported in literature to destabilize the dimer 
interface (Martin, et al. 1999, Boulanger and Kantrowitz 2003, Orhanovic, et 
al. 2006), and so were also mutated to Ala. A further four residues indicated 
from the PDBSum data to potentially influence dimer interface stability, namely 
D28, R34, R62, and Y98, were also mutated to Ala.   
4.8 Creating point mutations on the dimer interface  
The mutagenesis reactions were not as straightforward as for the saturation 
mutagenesis at T59 and some reactions had to be optimized.  Figure 4.11 
shows a 1% agarose gel of the initial reaction for each of the single point 
mutations.  R10A, R34A, and Y98A reactions contained DNA of the correct 
size, and were transformed into XL-1 blue cell. Colonies were cultured in 5 ml 
of LB medium and the plasmid DNA isolated using a QIAGEN mini prep kit.  
 
Figure 4.11 Mutagenesis reaction after Dpn I digestion from point 
mutagenesis reactions for R10A, R24A, D28A, R34A, R62A, and Y98A.  
The expected products for R10A, R34A, and Y98A are indicated by 














































The mutagenesis reactions for R24A, D28A, and R62A had failed according to 
the results shown in Figure 1.15. The primers for R24A, D28A, and R62A were 
used to set up mutagenesis reactions at a range of annealing temperatures in 
order to ascertain the appropriate annealing temperature.  The resulting gel 
contained two bands; one at approximately 3704 bp, that was likely to be the 
expected product, and one at approximately 4000 bp that was not expected.  
The DNA from the 3704 band was isolated by gel extraction by using the 
dialysis tube/electrophoresis method due to the low levels of product and 
potential 50% losses seen for product recovery from gel extraction kits 
(Chapter 2 Section 2.5.2.1).   
The DNA was transformed into XL-1 blue cells, 5 colonies were cultured, 
plasmid DNA was isolated and, following DNA sequence analysis, the correct 
sequences were confirmed.  Protein production, protein purification, 
concentration, and activity assays were performed as previously described in 
Section 4.2 and 4.6. Figure 4.12 shows the specific activities of the mutant 
forms of alkaline phosphatase relative to wild type alkaline phosphatase. Most 
of the specific activities are above 68 % of wild type activity, with the exception 
of R62A.  The activity level of R62A was only 15 % of wild type, which is a 
notable reduction in activity.  However, further improvements were sought by 
combining this point mutation into a small double mutant library, and by 






Figure 4.12 Relative specific activities of mutant forms of alkaline 
phosphatase  
The values are showns as a percentage of wild type activity with 2 
mM pNPP.  The standard errors (n=3) are shown on the bar chart. 
4.9 Combining the alanine mutations into a small double 
mutant library 
Each of the single point mutants were used as a template, coupled with the 
primers for each of the other mutations, to create a small double mutant library 
as shown in Figure 4.13.   As T59A and R62A are close together in the 
sequence, new primers were designed to introduce both mutations 
simultaneously. Mutagenesis was straightforward as the conditions for each 
set of primers had been optimised (Section 4.8), with the exception of T59A-
R62A, but this proved successful using the same conditions as for the R62A 
primers.  Once the mutations had been confirmed by DNA sequencing, protein 
production, protein purification, concentration, and activity assays were 





Figure 4.13 A schematic of the double mutant forms of AP produced in 
this study.   
Each of the coding regions for single mutants were used as a 
template together with appropriate primers to introduce a second 
mutation, with the exception of T59A-R62A for which new primers 






































































4.9.1 Enzymatic activity of double mutant forms 
As alkaline phosphatase is not active as a monomer, in order to provide an 
indicator that the mutations affected dimerisation the specific activities of the 









Figure 4.14 Relative specific activity as a percentage of wild-type activity of double mutant forms of R10A, R24A, D28A, and 
R34A.  



























































































Figure 4.15 Relative specific activity as a percentage of wild-type activity of double mutant forms of T59A, R62A, T81A, and 
Y98A.  




























































Figure 4.14 and Figure 4.15 show the specific activity, relative to wild type, for 
of all the double mutants.  Mutants of interest have reduced activity because a 
reduction in activity is an indicator of the enzyme being, at least in part, in a 
monomeric form. Table 4-2 lists all of the mutants with activity of less than 10 
%.  The R62A group is of particular interest as all double mutants show less 
than 7 % wild-type activity.  In fact, the majority of mutant enzymes, seven out 
of eleven with reduced activity, contain the R62A mutation. The R34A-Y98A 
mutant did not express. 
Table 4-2 Specific activity of low-level mutant alkaline phosphatase 
relative to wild type. 
Mutant 
Activity  (% of 
wild type) 
Mutant 
Activity  (% of 
wild type) 
R10A-R62A 7.0 ± 0.7 T59A-R62A 1.7 ± 0.3 
R24A-R62A 1.4 ± 1.0 T59A-Y98A 4.5 ± 0.5 
D28A-R62A 3.1 ± 0.5 R62A-T81A 7.0 ± 2.0 
D28A-T81A 1.5 ± 0.2 R62A-Y98A 6.6 ± 1.1 
D28A-Y98A 3.4 ± 0.3 T81A-Y98A 10.0 ± 2.1 
R34A-R62A 2.9 ± 0.4   
 
All of the variants listed in Table 4-2, together with wild-type and T59R, were 
investigated further to ascertain whether they would be good candidates for 
use in a split enzyme biosensor, as described in Chapter 5.   
4.10 R62X saturation mutagenesis 
When Arg 62 is mutated to alanine it has a dramatic effect on the activity of 
the enzyme, as shown in Figure 4.12, resulting in 15 % of wild type activity.  A 
database search for similar sequences to E. coli alkaline phosphatase was 
performed using Basic Local Alignment Search Tool (BLAST) (Altschul, et al. 





Table 4-3 Search parameters for BLAST search. 
Search Parameter Name Search Parameter Value 
Program Blastp 
Word size 6 
Expected value 10 
Hitlist score 100 
Gapcost 11,1 
Matrix BLOSUM62 
Filter string F 
Genetic Code 1 
 
The algorithm returns a ranked order of scores with the highest indicating more 
similar sequences.  The sequences with high similarity were confirmed to be 
alkaline phosphatases originating from several different organisms.  These 
sequences were aligned using the Clustal W (Larkin, et al. 2007) software to 
perform a multiple sequence alignment that illustrates identity and similarity 
between the sequences.  This analysis shows the equivalent of Arg62 to be 
conserved across a wide range of organisms, as shown in Figure 4.16, 
indicating that it is a key residue for either structural stability or biological 





4.10.1 BLAST search & multiple sequence alignment 
Figure 4.16  A multiple sequence alignment for several different alkaline phosphatases.   
The species range from human (several isotypes) to E. coli.  The red box shows the arginine conserved throughout 







To investigate R62 further, saturation mutagenesis was performed with 
arginine being mutated to every amino acid, except cysteine, to avoid disulfide 
bridge formation at the dimer interface, as described in Chapter 2 Section 
2.5.1.2.  Each mutation was confirmed by DNA sequencing and the protein 
was produced as described in Section 4.2 and 4.6.  The concentration of each 
of the R62X proteins was determined using a BCA assay and then the enzyme 
activity was investigated. 
4.10.2 R62X specific activity 
Figure 4.17 shows the specific activity for each of the R62X mutants.  For 
clarity the values are shown above each data point.  The presence of any other 
amino acid in place of arginine has a detrimental effect on enzyme activity.  
Changing to lysine has the least effect, with the R62K mutant retaining 82.8 % 
of wild-type activity. R62A, R62H, and R62P also had greater than 12 % 
activity so these three variants were also disregarded.    
 
Figure 4.17 Specific activities of R62X mutants of alkaline phosphatase.   
The activity was determined as a percentage of wild-type at 2 mM 











































Further investigation of a subset of the variants with low activity R62D, R62E, 
R62G, R62I, R62L, R62M, R62N, R62Q, and R62Y was undertaken together 
with an analysis of the 11 variants identified from the double mutant pool. This 
analysis is described in Chapter 5. 
4.11 Discussion 
Monomeric alkaline phosphatase from E. coli does not turn over the substrate, 
but in the homodimeric form it turns over several different phosphate esters 
(Heppel, et al. 1962).  A monomeric form of alkaline phosphatase was required 
for use as a split enzyme. In order to explore the creation of a stable monomer, 
residues at the dimer interface of alkaline phosphatase were mutated.  A 
reduced specific activity was used as an indicator that the enzyme may be 
predominantly monomeric.  There are a number of mutations of residues along 
the dimer interface that are reported in the literature to reduce the stability of 
the dimer, and it has also been reported that monomeric formation is possible.  
These mutations are R10A, R24A, T59A, T59R, and T81A (Boulanger and 
Kantrowitz 2003, Orhanovic, et al. 2006).  T59R was a stable monomer 
(Boulanger and Kantrowitz 2003) but steric hinderance would prevent 
association of these monomers into a functional dimer. The various reported 
point mutations were included in this study, along with D28A, R34A R62A, and 
Y98A, based on bioinformatic data that indicated that mutations at these 
positions may affect the stability of the dimeric interface.   
Saturation mutagenesis of positions T59 and R62 was carried out to determine 
whether an alternative side chain could create a stable monomer.  The T59X 
group of mutants did not yield any further interesting variants other than the 
already established T59R.  However, the R62A mutant appeared of interest, 
because of its reduction in activity and, from double mutant libraries, 11 
variants with substantial reductions in activity were identified. These were; 
R10A-R62A, R24A-R62A, D28A-R62A, D28A-T81A, D28A-Y98A, R34A-
R62A, T59A-R62A, T59A-Y98A, R62A-T81A, R62A-Y98A, and T81A-Y98A. 
These variants all include R62A, T81A, or Y98A, and, with the exception of the 





by Tyler-Cross et al. (Tyler-Cross, Roberts et al. 1989) reveals that deleting 9 
amino acids from the N-terminal end of alkaline phosphatase does not affect 
the turnover of the enzyme. The point at which amino acid deletion began to 
impact upon the enzyme was upon removal of R10, whilst removing a further 
24 residues to position 36 did not result in any further change.  This study along 
with that of Tyler-Cross et al. (Tyler-Cross, et al. 1989) indicate that the R10A, 
R24A, D28, and R34A mutations do not contribute to the same extent as other 
residues to the stability at the dimer interface. 
The large reduction in activity of R62A to just 15% of wild type indicates that 
this residue is important.  Furthermore, the fact that the residue is highly 
conserved throughout many different species indicates it is important for the 
function of the enzyme.  Saturation mutagenesis of R62 showed that mutating 
this residue to any other amino acid, with the exception of lysine, has a marked 
effect on the activity of the enzyme.  R62K had the least effect, retaining over 
80 % of wild-type activity.  Both arginine and lysine have positively charged 
side chains, indicating that a positive amino acid in this position is required for 
optimal function. The pKa of the side chains of arginine and lysine are 12.48 
and 10.53 respectively.  The activity measurements were performed in a Tris 
buffer at pH 8.0, therefore, the dominant form of these amino acids would be 
positively charged. 
The pyrrole ring in histidine has a pKa of 6.0, and therefore at pH 8.0 the 
dominant form would be neutral.  R62H retained 22 % of wild type activity, 
which is a marked reduction and is indicative of the dominant neutral form at 
pH 8.0.  The level of activity could be due to an equilibrium between neutral 
and charged species. All other mutants gave rise to a marked reduction in 
activity.  
The saturation mutagenesis libraries omitted mutating to a cysteine because it 
would for a disulphide bridge and would not come apart.  Although it could be 
argued that because the enzyme is destabilised, when the subunits are 
brought back together would you get a S-S bond which might actually lead to 





A subset of these mutants: R62D, R62E, R62G, R62I, R62L, R62M, R62N, 
R62Q, and R62Y were further characterised along with the 11 double mutants 






Chapter 5  






The alkaline phosphatase variants from Chapter 4 that showed a low enzyme 
activity were: 
R10A-R62A R34A-R62A T81A-Y98A R62L 
R24A-R62A T59A-R62A R62D R62M 
D28A-R62A T59A-Y98A R62E R62N 
D28A-T81A R62A-T81A R62G R62Q 
D28A-Y98A R62A-Y98A R62I R62Y 
 
These include 11 double mutants and 9 R62X mutants chosen from the R62X 
saturation mutagenesis group.  It was necessary to characterise whether any 
of these would be suitable for use, initially in a split enzyme assay, and 
subsequently in a split enzyme biosensor. This analysis process required the 
re-reconfiguration of the variants. 
5.2 Re-activation of Split- Alkaline Phosphatase 
The underlying principle of a split enzyme assay is that the two parts of the 
split enzyme can undergo intramolecular complementation if they are brought 
together by suitable molecular interactions. It was therefore necessary at this 
stage to provide a suitable mechanism for the stabilisation of the variant 
subunits in order to restore enzyme activity.  A schematic of alkaline 
phosphatase is shown in Figure 5.1(a).  The two monomers in the dimer form 
are shown, with the N-terminus indicated by a green circle, and the C-terminus 
by a red circle. Figure 5.1(b) shows the presence of a mutation at the dimeric 
interface.  The experimental approach was designed to re-stabilise the 
mutationally destabilised parts by associating them via a coiled coil interaction.  
The DNA sequence encoding the K4 coiled coil (De Crescenzo, et al. 2003) 
was cloned into the vector pECAP-Sort to generate an N-terminal fusion with 
alkaline phosphatase pK4-ECAP-Sort.  The coiled coil used is shown in Figure 
5.1(c) and is called ‘K4’ as it is 4 repeats of a lysine-rich heptad sequence and 
it is shown as a schematic coiled coil structure.  To give the coil directionality, 
two asparagine residues were used since buried polar interactions on the 
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interface of the coiled coils can orient the coiled coils in a particular way 
(Oakley and Kim 1998). Figure 5.1(d) presents a schematic of each of the 
mutated alkaline phosphatase subunits, with the K4 coiled coil holding them 
together.  
 
Figure 5.1 Introduction of the K4 coiled coil at the N-terminus of alkaline 
phosphatase to test whether the monomer association can lead to 
restored enzyme activity. 
 a) A schematic of alkaline phosphatase, with the N-terminus 
shown as a green circle, and the C-terminus as a red circle. b) A 
schematic of alkaline phosphatase with the dimer interface 
disrupting mutations. c) The K4 coiled coil showing the residue 
interactions designed to facilitate association of the two coils d) A 
schematic of alkaline phosphatase with the K4 coiled coils 




5.2.1 K4 coiled coil – alkaline phosphatase fusion protein. 
A plasmid; pE4-K4 which contained the coding region for the K4 coiled coil, 
was kindly supplied by the Wälti laboratory (University of Leeds) and this was 
used as a template for PCR amplification of the coiled coil coding region.  The 




Figure 5.2 Mega primer amplification.   
Primers to amplify the K4 coding region from pE4-K4 were used in 
a PCR reaction to produce a K4 megaprimer.  The primer was 
designed to include the flanking region of alkaline phosphatase 
and the N-terminal of alkaline phosphatase on pECAP-Sort 
The megaprimer was then used to insert the K4 coding region into the pECAP-
Sort plasmid. The result was a plasmid encoding a fusion protein with the 



















Figure 5.3 Megaprimer mutagenesis of pECAP-Sort.   
A K4 megaprimer was used as the primers for a mutagenesis 
reaction to add the K4 coding region to the alkaline phosphatase 
gene. 
This was done by introducing overlapping ends, which are complementary to 
regions flanking the position where the K4 coiled coil was introduced, using 
the QuikchangeTM method described in Chapter 2 Section 2.5.1.3.  The 
introduction of the coiled coil was confirmed by DNA sequencing and the 
resulting plasmid was called pK4-ECAP-Sort.  There was a stutter introduced 
between the K4 coiled coil and alkaline phosphatase: 3’ 
ggtggtacccctgagatgccggtgctggctgctatcaaaggtggt 5’.  This extra DNA 
translated into 15 amino acids: G G T P E M P V L A A I K G G.  Several 
attempts were made to remove the extra DNA, but this was unsuccessful, and 
at the same time the K4 – alkaline phosphatase fusion protein was produced 
from pK4-ECAP-Sort.  It was decided that if the protein behaved the same as 
the wild type form then the experiment could continue with this construct and 
























5.2.2 Protein production 
The pK4_ECAP- Sort vector was transformed into competent Shuffle cells and 
then protein was produced in the same way as wild type alkaline phosphatase, 
as described in Chapter 2 Section 2.6.2.  Each mutation was introduced into 
this plasmid by using the previously successful QuikchangeTM approach but 
using K4_ECAP rather than pECAP as the template.  Purification of the K4-
wild type protein resulted in a yield of around 2-3 mg/L, which is markedly lower 
than achieved for wild type alkaline phosphatase (10-15 mg/L) The mutant 
versions of the alkaline phosphatase with the K4 coil proved even more difficult 
to produce with yields of 0.1 - 0.25 mg/L.  To generate sufficient protein for the 
planned experiments, 6 litre cultures were used to produce the proteins with 
purification performed in the same way as for wild type alkaline phosphatase, 
as described in Chapter 2 Section 2.7.2 
5.2.3 Assays of coiled coil containing variants  
Enzyme assays to measure the specific activity of each of the K4-AP variants 
and the corresponding variants lacking the K4 were undertaken. This was 
expected to ascertain whether any of the mutants displaying low activity would 
show an increase in enzyme activity in the coiled coil format.  
5.2.3.1 Wild type and T59R 
Wild type alkaline phosphatase and K4 wild type were compared to establish 
whether the addition of the coiled coil adversely affected enzyme activity.  
T59R and K4_T59R were also tested to ascertain whether this mutant could 





Figure 5.4 Activity of wild type alkaline phosphatase and a T59R mutant 
with and without K4 coiled coil attached.   
With the coiled coil is displayed in dark grey and without the coiled 
coil is displayed in light grey.   
 
Figure 5.4 shows that the addition of the K4 coiled coil does not affect the 
activity of either wild type or the T59R mutant.  T59R could thus be used as a 
negative control in future activity experiments. There were three different 
protein preparations and these were measured three times with each of the 
protein preps.  There was good agreement between the three repeats of wild 










Table 5-1 shows the results for wild type and T59R.  The average of these 
three repeats was taken as 100% wild type activity, and the activities of all 
mutants were compared to this activity.  As a control, wild type activity was 
measured every time a batch of proteins containing mutations was tested, to 
confirm the correct assay parameters for wild type activity. 
 
5.2.3.2 Specific activities of double mutants 
The relative specific activity of each double mutant, with and without the K4 
coiled, is shown in Figure 5.5.  These were each tested alongside wild type 
and T59R and two repeats of each were averaged. 
batch	1 batch	2 batch	3 batch	1 batch	2 batch	3
repeat	1 1.14 1.11 1.26 repeat	1 1.23 1.16 1.22
repeat2 1.20 1.19 1.22 repeat2 1.20 1.21 1.20
repeat3 1.26 1.14 1.30 repeat3 1.17 1.18 1.25
batch	1 batch	2 batch	3 batch	1 batch	2 batch	3
repeat	1 0.02 0.02 0.02 repeat	1 0.03 0.03 0.02
repeat2 0.02 0.02 0.02 repeat2 0.02 0.03 0.03







Figure 5.5 Specific activity of the double mutants.   
The dark grey shows the activity of the mutant with the addition of the K4 coiled coil.  The light grey shows the activity 
of the mutant without the coiled coil.  The data are presented as a percentage of wild type activity.  
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Figure 5.5 indicates that three of the double mutants showed a significant K4 
associated increase in activity; D28A-Y98A, R34A-R62A, and T59A-R62A. 
R34A-R62A increased by 8% of wild type activity; D28A-Y98A increased by 
12% of wild type activity.  Out of these three, T59A-R62A shows the largest 
increase, with an increase of 27% of wild type activity.  When the data are 
analysed as the magnitude of the increase in activity as a ratio of +K4/-K4, the 
order doesn’t change.  R34A-R62A activity increased 3.5 fold; D28A-Y98A 
activity increased 4.2 fold, and T59A-R62A shows the largest increase, with 
an activity increase of 5.5 fold. 
 
5.2.3.3 R62X mutants 
The eight R62X mutants that displayed low specific activity were also 
investigated alongside the versions incorporating the K4 coiled coil. There 
were two different protein preparations and these were measured three times 
with each of the protein preps.  R62G, R62I, and R62N all have increased 
activity as presented in  Figure 5.6.   
 
 Figure 5.6 Activity of the R62X mutants.   
The dark grey shows the activity of the mutant with the addition of 
the K4 coiled coil.  The light grey shows the activity of the mutant 
without the coiled coil.  The data are presented as a percentage of 
wild type activity 
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Figure 5.6 shows that R62I and R62G increased in activity to 18% and 25% of 
wild type activity respectively, although the greatest increase was for R62N, 
which increased from 5 to 27% of wild type activity.  
5.3 Secondary structure analysis of alkaline phosphatase 
mutants. 
The secondary structure of the alkaline phosphatase double mutants and 
R62X mutants was investigated by far UV CD to determine whether the 
proteins were likely to be folded correctly. As the activity of alkaline 
phosphatase mutants was measured in 1 M Tris-HCl pH 8.0, it was important 
to check whether the secondary structures were affected in this buffer.  Buffers 
that contain chloride ions absorb light strongly below 200 nm (Kelly, et al. 
2005), and therefore the data were analysed between 200 nm to 260 nm.  Wild 
type alkaline phosphatase was investigated as a positive control and as it 
showed the expected level of enzyme activity it should be folded correctly, 
allowing comparison with the spectra of variants.  
5.3.1 CD analysis of wild type and T59R proteins 
CD experiments were performed on a Jasco J715 spectropolarimeter and the 
spectra were recorded in a 0.02-cm path length using a scan speed of 50 
nm/min, a time constant of 0.5 s and a bandwidth of 2 nm. Three scans of each 
sample were performed. The Jasco J715 spectropolarimeter reports its raw 
output in ellipticity (θ) measured in millidegrees (mdeg). To compare the data 
across samples, θ was converted to Molar Ellipticity ([θ]) in units of 
degrees/cm2/decimole.  Hence, [θ] = θ / (10 x c x l) where c is the molar 





Figure 5.7 Far UV CD spectra of wild type (dark grey line) & T59R (light 
grey line) alkaline phosphatase.   
The spectra show that there is little change in secondary structure 
between wild type and the T59R mutant  
The CD spectra of wild type alkaline phosphatase and T59R overlay directly 
between 205 and 260 nm, as shown in Figure 5.7.  The shape of the curves 
gives an indication of secondary structure and therefore suggests the proteins 
are folded correctly.  The shape is indicative of α-helix secondary structure 
(Kelly, et al. 2005) and also indicates that there is a high degree of similarity 
between wild type and T59R secondary structures.  
5.3.2 CD analysis of double mutant proteins 
Figure 5.8 shows the CD spectra of the double mutant proteins: R10A-R24A, 
D28A-R62A, D28A-Y98A, R34A-Y98A, T59A-R62A, R62A-T81A, R62A-
Y98A, and D28A-T81A.  These spectra are very similar to the wild type shown 
in Figure 5.7, which indicates that these proteins have essentially identical 
secondary structure profiles to the wild type and can therefore be considered 
to be correctly folded.  By contrast the CD spectra shown in Figure 5.9 indicate 
that the low enzyme activity measured for R24A-R62A, T59A-Y98A, and 









































Figure 5.8 Far UV CD spectra of alkaline phosphatase double mutants.  
R10A-R24A - dark blue, D28A-R62A - red, D28A-Y98A – green, R34A-Y98A – purple, T59A-R62A – light blue, 
R62A-T81A – orange, R62A-Y98A - lilac, D28A-T81A - salmon.  The spectra shows that there is little change in 






Figure 5.9 Far UV CD spectra of the double mutants not showing 
secondary structure.  
R24A-R62A – top, T59A-Y98A – middle and T81A-Y98A bottom.  All 




5.3.3 R62X mutants 
The R62X mutants all have similar spectra to wild type as shown in Figure 
5.10, indicating that the proteins are correctly folded.  
 
Figure 5.10 Far UV CD spectra of alkaline phosphatase point mutants.  
R62D - dark blue, R62E - red, R62G – green, R62I – purple, R62L – 
light blue, R62M – orange, R62N - lilac, R62Q – salmon R62Y – light 
green.  The spectra show secondary structures essentially 
identical to wild type.  The spectra are stacked for clarity. 
 
5.4 Colloidal and thermal stability of alkaline phosphatase 
mutants 
In a thermal ramp experiment with CD, the signal from a particular secondary 
structure element, such as the alpha helices, reduces as the protein melts. To 
look at the stability of a wide range of mutants, Optim can give a large amount 




5.4.1 Optim data 
Optim (AVACTA analytical) experiments detect the shift in intrinsic 
fluorescence from tryptophan residues and, to a lesser extent, tyrosine 
residues present in the protein.  When tryptophan and tyrosine move from an 
internal folded non-polar environment to an exposed polar environment, their 
fluorescence changes and is taken as indicative of protein unfolding.  Colloidal 
stability can also be investigated in the same experiment.  Light scatter gives 
information on the protein’s propensity to aggregate. 
5.4.1.1 Optim analysis of wild type and T59R 
The thermal stabilities of wild type alkaline phosphatase and T59R were 
investigated by measuring the barycentric mean (BCM).  These data allow for 




Figure 5.11 BCM analysis of wild type alkaline phosphatase and the T59R mutant.   
Blue lines show the three repeats of wild type alkaline phosphatase, Green lines show the repeats of T59R.  The Tm 
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Figure 5.11 shows the BCM vs temperature for wild type alkaline phosphatase 
and T59R.  T59R shows a sigmoidal curve that begins relatively flat, then 
increases through the transition to a plateau.  The arrow points to the midpoint 
of the transition on this curve that represents the melting temperature.  The 
melting temperature for T59R is approximately 47oC.  Wild type alkaline 
phosphatase does not reach a plateau by the maximum temperature 
measured and thus an accurate Tm cannot be determined.  Wild type alkaline 
phosphatase begins to unfold at about 85 oC, and therefore the melting 
temperature is greater than 85 oC. 
5.4.1.2 Analysis of double mutants 
Each of the double mutants was investigated for their thermal and colloidal 
stability.  There are three repeats of each protein, the average of the melting 
temperature (Tm) and the temperature at the onset of aggregation (Tagg) are 
displayed in Figure 5.12. 
 
Figure 5.12 Tm and Tagg of all of the double mutants that demonstrated 
low enzyme activity.   
 
For all the double mutants, the melting temperature was followed closely by 
the onset of aggregation. The highest thermal stabilities were shown by D28A-
Y98A, R34A-R62A, and T59A-R62A.  R24A-R62A, T59A-Y98A, and T81A-
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Y98A have a Tm of 25 oC, 21 oC, and 22 oC respectively which is near room 
temperature. 
5.4.1.3 Analysis of R62X mutants 
The melting temperature and the onset of aggregation were investigated using 
Optim. 
 
Figure 5.13 Tm and Tagg of a subset of the R62X mutants that 
demonstrated low activity.   
The melting temperature of R62D, R62E, R62G, R62M, R62Q, and R62Y are 
all just over 42 oC with aggregation following shortly afterward. R62I and R62N 
appear to have higher Tm values.  However, on further analysis of the primary 
data as shown in Figure 5.14, it is clear that this is not the case.  The beginning 
of the change in BCM is the same for R62I, R62N and R62M.  The difference 
between R62I, R62N and R62M is that the transition is longer, suggesting that 





Figure 5.14 BCM primary data for R62I, R62N, and R62M.  Each 



































































The best performing variant was T59A-R62A and so this was characterised 
further to ascertain the stability of this mutant when held together with the K4 
coiled coil. Further analysis was completed to investigate whether the mutant 
exists in a monomeric form.  Additionally, inhibition studies of the K4-T59A-
R62A activity by addition of excess K4 peptide were performed to establish 
whether it was the K4 coiled coil that was responsible for mediating the dimer 
association.  Finally, pH and temperature shift assays were completed to 
further investigate the K4-T59A-R62A interaction.  
5.5 Characterisation of T59A-R62A 
The double mutant T59A-R62A showed the largest increase in enzyme 
activity, from 6 to 33% of wild type, between the original protein and the K4 
coiled coil version.  The initial analysis measured the secondary structure of 
the mutant with the addition of the K4 coiled coil for comparison with the earlier 
CD data of this mutant without a coiled coil. Next, information on the thermal 





5.5.1 Secondary structure 
Figure 5.15 shows the CD spectra of the T59A-R62A mutant with and without 
the K4 coiled coil.  These CD experiments were performed in the same way 
as described in section 5.3.1.  There are some differences between the two 
spectra, but both show secondary structure similar to wild type.  All the spectra 
show an overall α-helical structure.  Some differences were to be expected as 
the addition of a coiled coil itself gives an α-helical signal which would change 
the overall spectra of the fusion protein.  
 
Figure 5.15  Far UV CD spectra of T59A-R62A (dark grey line) & K4-T59A-
R62A (light grey line) alkaline phosphatase.   
The spectra show that there are some differences in secondary 




































5.5.2 Thermal stability  
To investigate the thermal stability of the T59A-R62A mutant, both with and 
without the K4 coiled coil, thermal melt experiments using CD were performed.  
CD experiments were performed on a Jasco J715 spectropolarimeter and the 
intensity of the CD signal at 220 nm was recorded. A 0.02-cm path length 
cuvette was used with a scan speed of 50 nm/min, a time constant of 0.5 s, 
and a bandwidth of 2 nm. Three repeat measurements were performed for 
each sample.  
 
Figure 5.16 Thermal melt experiment at 220 nm, indicating the melting 
temperatures of the proteins.   
Wild type is in dark blue, T59R is in green, T59R-R62A is in light 
blue, K4 wild type is in red, K4 T59R is in purple and K4-T59A-R62A 
is in orange.  The Tm of T59R and T59A-R62A is approximately 43 
oC.  The Tm  of wild type is higher than 90 oC.  The addition of a K4 
coiled coil increases the Tm in line with wild type.  
 
Figure 5.16 indicates that the Tm of the two mutants; T59R and T59A-R62A, is 
approximately 43 oC.  The Tm  of wild type is higher than 90 oC, although the 
exact experimental value cannot be established with this technique.  The 
addition of the coiled coil seems to reduce the stability of wild type, but this 



























increases the Tm of T59A-R62A, in fact K4-T59A-R62A seems much more 
stable than even the wild type enzyme as it remains as almost a flat line at 90 
oC. 
5.6 Inhibition assays of K4-R62A-T59A 
To validate that the K4 coiled coil mediates the dimerization of the monomer 
form of alkaline phosphatase, leading to the increase in enzyme activity, the 
interaction was inhibited by the addition of free K4 peptides as outlined 
schematically in Figure 5.17 
 
Figure 5.17 A schematic of the K4-T59A-R62A mutant before and after 
addition of free K4 peptide.   
The protein is held in a dimeric state (top) by the K4 coiled coil, 
and this association is disrupted by competition with free K4 
coiled coil peptide (bottom). 
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A final concentration of 0.4 nM K4-T59A-R62A protein was incubated with K4 
peptide over a concentration range from 0 pM to 20 nM for 2 h in 1 M Tris pH 
8.0.  Enzyme activity was measured by addition of 100 μl (2 mM final 
concentration) of pNPP, and the assay was stopped after 5 min with 50 μl 5 M 
NaOH.  The A405 values were converted to amount of product produced per 
unit time by using the Beer Lambert law as described in Chapter 2 Section 
2.9.3.2.  The concentration of pNP was plotted against the Log10 of the 
concentration of K4 peptide.  The resulting IC50 value was 0.4 ± 0.1 nM, which 
indicates a 1:1 interaction of the coiled coil and the protein, as shown in Figure 
5.18.  This reduction in enzyme activity with increasing competitor 
concentration indicates that the inactive monomers are indeed being held 
together by the K4, and the addition of the free K4 peptide disrupts this 
interaction. 
K4-T59R was incubated with 25 pM to 20 nM K4 peptide but, as expected, no 
change in absorbance was observed when pNPP was introduced.  K4 wild 
type was also investigated in the same manner and, again as expected, the 
absorbance remained at the initial level and did not reduce with increased 
concentration of K4 peptide. This indicates that the K4 plays no part in the 




Figure 5.18 IC50 of K4-T59A-R62A mutant enzyme with the free K4 coiled 
coil.   
K4-T59A-R62A protein was incubated with 25 pM to 20 nM K4 
peptide for 2 h in 1 M Tris pH 8.0.  The activity was detected at 405 
nm using 2 mM final concentration of pNPP. 
5.7 pH/temp shift assay of T59A-R62A 
The thermal stability of the K4 coiled coil increased with pH, and as the K4 
peptide was attached to alkaline phosphatase it would be interesting to 
investigate whether the attachment of the coiled coil affected the enzyme 
activity in the same manner.  The T59A-R62A protein and wild type both with 
and without the K4 peptide were examined. Further controls included assay 
mix only and T59R, both with and without the K4 peptide.  Each of these 
purified proteins was split into two batches and buffer exchanged into Tris 
/ACES/ CAPS tri-buffer as described in Chapter 4 Section 4.4.  One batch of 
each sample was exchanged into buffer at pH 8 and the other into buffer at pH 
11. Aliquots of both batches were then incubated at either 20 oC or 50 oC for 1 
h.  Then 100 μl (10 μg) samples of enzyme and 100 μl (2 mM final 
concentration) of pNPP was added to a 96 well plate and after 5 mins the 





Figure 5.19 Temperature and pH shift assay for alkaline phosphatase 
with a K4 coiled coil.   
A) shows the different pH and temperature in each of the four wells 
and a schematic of what was expected from the K4 coiled coil 
interactions under the different temperature and pH conditions. B) 
Control reactions including buffer only, wild type, T59R, with and 
without a K4 coiled coil.   C) K4-T59A-R62A mutant under the same 













































The assay mix did not show any activity in any of the 4 conditions.  The wild 
type alkaline phosphatase could turn over substrate in all of the conditions; 
both with and without the K4 coiled coil attached.  T59R did not turn over 
substrate in any condition.  Interestingly, when T59A-R62A had the K4 peptide 
attached, it turned over substrate at pH 8 and pH 11 when incubated at 20 oC. 
It also turned over substrate at pH 11 when incubated at 50 oC but did not turn 
over substrate at pH 8 when incubated at 50 oC.  This is consistent with the 
melting temperature of the K4 coiled coil; the expected coiled coil formations 
are shown at the top of Figure 5.19.  
5.8 Oligomerisation of alkaline phosphatase R62A-T59A 
The assumption that low activity in a mutant is due to destabilisation of the 
dimeric interface required further examination.  Size exclusion 
chromatography (SEC) and analytical ultracentrifugation (AUC) were used to 
investigate whether the various proteins existed in predominantly the 
monomeric or dimeric state.  The retention time on a SEC column gives an 
indication of the hydrodynamic radius, and, when used with protein standards, 
can indicate the size of the protein. 
5.8.1 Size Exclusion Chromatography  
Size exclusion chromatography was performed on a 120 ml, HiPrep 16/60 
Sephacryl S100HR preparative column so that the protein could be recovered 
for subsequent assays. The flow rate was set to 0.5 ml/min on an ÄKTA FPLC 
and the eluate was collected in 2 ml fraction for 1.25 column volumes. To begin 
with, five protein standards: β-amylase, alcohol dehydrogenase, albumin, 
carbonic anhydrase and cytochrome c, were separated on the SEC column.  





Table 5-2 Approximate molecular weight of protein standards used in 
size exclusion chromatography. 




β-amylase 200 42.1 
alcohol dehydrogenase 150 45.1 
albumin 66 47.5 
carbonic anhydrase 29 62.5 
cytochrome c 12.4 82.6 
 
The size of alkaline phosphatase in its native dimer state is 98 kDa and so 
would be expected to elute after albumin at 47.4 ml but before alcohol 
dehydrogenase at 45.1 ml.  The monomer form of alkaline phosphatase should 
elute between carbonic anhydrase at 62.5 ml and albumin at 47.5 ml.  Figure 
5.20 shows wild type eluted at approximately 44.9 ml and T59R, the monomer 
version of alkaline phosphatase, eluted at 49.0 ml.  This was in reasonable 
agreement with the expected result supporting the occurrence of wild type AP 
as a dimer and T59R as a monomer.  The blue trace on Figure 5.20 
representing T59A-R62A has several peaks.  The two peaks at approximately 
36 and 38 ml are probably some form of larger associations or aggregates as 
they elute considerably before the 200 kDa marker at 42.1 ml.  The other two 
peaks are at 45.3 ml and 49.5 ml, which indicates a mixed population of 




Figure 5.20 Absorbance data for the elution of alkaline phosphatase from 
a size exclusion column.   
Wild type (black) alkaline phosphatase eluted at 44.9 ml. T59R (red) 
a known monomer eluted, at 49 ml.  The blue trace indicates T59A-
R62A, which has a double peak corresponding with both dimer 
and monomer sizes.   
 
5.8.2 Analytical Ultracentrifugation (AUC) 
In AUC the sedimentation coefficient (S) is a good indicator of the size and 
multimeric state of proteins.  All of the AP proteins had an A280 value of 
between 0.3 to 0.5, and were exhaustively dialysed against 50 mM Tris pH 8.0, 
using four buffer changes; the first two after 2 h each, followed by overnight 
incubation, followed by a further 2 h the next day.  A XL-I AUC instrument 
(Beckman Coulter) was used. After the AUC cells were filled, a quick 
centrifugation step from 3,000 to 30,000 rpm was performed to ensure the cells 
were not leaking.  A continuous scan from 5.8 to 7.3 cm at 30000 rpm was set 
up and data were recorded every third scan.  200 scans were recorded at a 
constant temperature of 19.8 oC. The data were fitted using the SEDFIT and 
SEDPHAT programmes (Schuck 2000). For full details on how the AUC data 




Figure 5.21  Sedimentation coefficient distributions derived from 
sedimentation velocity profiles  
Wild type (black), T59R (blue) and T59A-R62A (red).  The raw 
sedimentation signals acquired at different time points with 
absorbance at 280 nm, a rotor speed of 30000 rpm and a 
temperature of 19.8 °C 
 
Figure 5.21 shows a clear difference between the sedimentation coefficient of 
wild type shown in black and T59R shown in blue.  T59A-R62A shown in red 
shows a mixture of species, probably monomer and dimer, which agrees 
reasonably with the SEC data. The SEC and AUC data suggest that the 
predominant form of T59A-R62A is monomer, with potentially with some dimer, 




5.9  Zinc incorporation 
Alkaline phosphatase requires two zinc ions to function; both coordinate one 
of the phosphate oxygens. Two points of the tetra-coordinated Zn1 and one 
point of the penta-coordinated Zn2 are coordinated by the imidazole nitrogens 
of histidines as shown in Figure 5.22 (Kim and Wyckoff 1991).  The 
coordination of zinc in the active site is described in detail in Chapter 1 Section 
1.5.2.1.  To investigate the amount of zinc in the active site of the mutant 
enzymes a zinc binding assay was used.   
 
Figure 5.22 Zinc coordination in the active site of alkaline phosphatase.   
Zn1 is tetra-coordinated by His 412, His 331, Asp 327 and 
phosphate.  Zn2 is penta-coordinated by His 370, Asp 360, Asp 51, 
Ser 103 and phosphate.  Figure adapted from (Bobyr, et al. 2012). 
 
5.9.1 Zinc binding assay with 4-(2-Pyridylazo) resorcinol 
4-(2-Pyridylazo) resorcinol (PAR) is a chemical that displays an altered 
absorbance spectrum upon binding to zinc, as shown in Figure 5.23. When 
zinc is present there is an increase in absorbance at 500 nm that is proportional 







Figure 5.23 PAR spectrum with (red line) and without (blue line) zinc.  
Note the increase at 500 nm when zinc is present 
To investigate the amount of zinc present in wild type alkaline phosphatase, 
T59R, and T59A-R62A, 100 μl aliquots of 100 μM PAR were dispensed into a 
96 well plate. ZnSO4 (100 μl) solutions were added at concentrations from 20 
mM to 1 μM to create a calibration curve.   
Diethyl pyrocarbonate (DEPC) was used to dissociate zinc from its histidine 
ligands. DEPC binds with high affinity to histidine, preventing interaction with 
zinc which is released into solution. 100 μl aliquots of 0.5 mg/ml wild type, 
T59R, or T59A-R62A in 1 M Tris, was added to 100 μl of 100 μM PAR in 1 M 
Tris containing 1% DEPC, and the absorbance at 500 nm was measured after 
a 2 h incubation at room temperature.  The quantity of zinc was then calculated 
from the calibration curve.  Wild type had 2 (± 0.3) zinc molecules per 
monomer, whilst T59R showed a negligible amount of zinc present.  T59A-
R62A has 2 (± 0.4) molecules of zinc per monomer.  In addition to these three 
proteins, T59A-Y98A was also investigated and had 0.4 (± 0.4) molecules of 




5.10 Distance dependence of dimerization interactions 
When the K4 coiled coil interacts to associate the alkaline phosphatase 
subunits, there is, in effect, no distance between the two coils.  Although the 
distance between the subunits of variants of alkaline phosphatase, would be 
determined by the linker length between the N-terminal residue of alkaline 
phosphatase and the start of the coiled coil. A starting point needed to be 
established to begin investigating the distance permissible between two 
epitopes on a target molecule. In order to investigate the distance dependence 
of the T59A-R62A interaction, an experiment was devised whereby DNA would 
be used as a molecular ruler.   
Zinc finger motifs that bind to DNA were used to ascertain the permissible 
distance between two alkaline phosphatase monomers.  Fusion proteins were 
designed to fuse a zinc finger motif to alkaline phosphatase. DNA oligos with 
the binding site for the zinc fingers were also designed.  Several pairs of oligo 
were designed as described in Chapter 2 Section 2.9.7.2 with the binding site 





Figure 5.24 DNA template for zinc finger binding assay.   
Three oligos were mixed together in an annealing reaction to create a duplex DNA construct capable of binding a zinc 
finger motif.  The binding site for the zinc finger was moved further apart by 5 and 10 base pairs thereby introducing 
distance between the binding sites. 
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It was hypothesised that an oligo construct without any base pairs in between 
the zinc finger binding sites would hold the monomers of alkaline phosphatase 
together and eventually at a critical juncture would hold them apart as exhibited 
in Figure 5.25. 
 
 
Figure 5.25 Schematic showing zinc finger motif moving the subunits of 
alkaline phosphatase along double-stranded DNA.   
The green bars represent DNA, the purple zig-zag on the DNA 
represents the zinc fingers.  Note as the zinc finger moves along 
the DNA from left to right this holds the subunits of alkaline 
phosphatase apart. 
 
The vector pzifAP was designed, as shown by the schematic in Figure 5.26 to 
include GST to enhance solubility, followed by a TEV site to enable removal 
of the GST. The zinc finger protein, 268, was designed to be fused to the N-
terminal of alkaline phosphatase via a colicin linker in between.  A strep tag is 
present after the C-terminal of alkaline phosphatase so that StrepTactin resin 





Figure 5.26 Schematic of the protein construct designed for the zinc 
finger distance dependence experiments.   
GST was used to enhance solublity, the TEV site was used to 
cleave off the GST, and the zinc finger motif bound DNA in a 
specific manner.  This was followed by a linker and the alkaline 
phosphatase (ALP), and finally a strep tag which was used for 
purification. 
 
5.10.1 Mutagenesis and protein production 
T59A-R62A and T59R were introduced into the pzif vector using a site-directed 
mutagenesis approach as previously described in Chapter 2 Section 2.5.1.2.  
The vectors: pzifAP, pzifAPT59A-R62A and pzifAPT59R were introduced into 
competent ArcticExpress cells, as these cells can be gown between 4 and 12 
oC, giving the recombinant protein time to fold correctly.  A single colony was 
used to inoculate 1 ml aliquots of LB broth containing carbenicillin These 
cultures were incubated at 37°C with shaking at 220 rpm overnight.  A 50 μl 
aliquot of this culture was added to 50 ml of LB broth containing no selection 
antibiotics, as described by the manufacturer and incubated at 30°C with 
shaking at 220 rpm for 3 h.  The culture was transferred to 10 °C and incubated 
with shaking at 220 rpm for approximately 10 minutes to equilibrate the culture, 
IPTG was then added to 1 mM to each flask and the culture incubated at 10 
°C, with shaking at 220 rpm for 24 h. For full details see Chapter 2, Section 
2.6.3 
The protein was purified using Streptavidin agarose resin from Pierce.  Full 
details are in Chapter 2 Section 2.7.3.  Briefly, this comprised equilibrating the 
streptavidin column with three column volumes of binding buffer, adding the 
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sample to the column, then washing with 10 CV of binding buffer. The bound 
sample was eluted with 3 CV of elution buffer and collected in 0.5 – 1 ml 
fractions. 
 
Figure 5.27 Purification and cleavage of zifAP.   
Gel A shows the molecular weight markers, noted in kDa on the 
left of the gel, followed by the final wash and elution fractions 1 to 
3.  Fractions 2 and 3 were pooled.  Gel B shows the cleavage of 
GST from zifAP.  The molecular weight markers are shown in kDa, 
followed by the zifAP protein before and after cleavage with TEV.  
 
5.10.2 DNA oligonucleotides 
The DNA oligos were supplied by Integrated DNA Technology as single-
stranded DNA and were annealed to produce duplex DNA for zifAP and zifAP 
mutants to bind.  For full details see Chapter 2 Section 2.9.7.2.  Briefly, 20 nM 
single strand DNA samples were mixed together in a PCR tube, which was 
heated to 95 oC for 10 mins and brought back down to room temperature in 1 
oC per minute steps.  Figure 5.28 shows each of the DNA duplex reactions on 


























































Figure 5.28 Agarose gels showing duplex DNA.   
The marker for gel A and B is a 10 bp marker from fermentas, and the marker for gel C & D is a 10 bp marker from 
NEB.  Gel A shows the DNA in various combinations for duplex DNA without a space in between the zinc finger binding 
sites.  Gel B shows the DNA in various combinations for duplex DNA with a 5 bp gap in between the zinc finger binding 
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Duplex DNA without a spacer, and with a 10 bp spacer, presents on the gels 
as expected.  The 5 bp duplex DNA without a nick also looks as expected, but 
when a nick is introduced into the construct then there appears to be a problem 
with how the DNA was annealed, as shown in Figure 5.28, gel B.  This 
construct was omitted from the assay 
5.10.3 Zinc finger activity assay 
To determine the permissible gap for T59A-R62A, 15 nmol enzyme and 15 
nmoles oligo were added to a 96 well plate.  Wild type was used as a positive 
control and T59R as a negative control. 100 μl pNPP (2 mM final 
concentration) was added and reactions containing wild type alkaline 
phosphatase turned yellow immediately.  All of the other reactions initially 
remained clear.  After 24 h, absorbance at 405 nm was measured and a 
difference was observed for T59A-R62A.  Wild type remained high at an 
absorbance of over 3.4 absorbance units, and the absorbance for T59R 
remained negligible.  The absorbance for T59A-R62A changed depending 
upon the oligo present.   
 
Figure 5.29 Zinc finger activity assay.  
The activity of 15 nM of the enzyme with 15 nM of oligo and 2 mM 
pNPP was investigated after a 24-hour incubation period.  The 
absorbance at 405 nm was recorded.   The same batch of protein 
was assayed with a N=2 sample size.  
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As presented in Figure 5.29, when the DNA oligo was absent, the absorbance 
from the product remained negligible.  When DNA without a spacer was 
present there was an increase in absorbance to over 0.8 absorbance units.  
The same DNA, but with a nick present remained at a similar level; 0.7 
absorbance units.  A 5 bp spacer appeared to increase the absorbance to 1.5 
absorbance units. However, when the spacer increased to 10 bp the 
absorbance reduced again to a negligible level.  These initial data suggest that 
the distance dependence is between 5 and 10 base pairs; as DNA has a 
distance between base pairs of 3.4 Å (Voet, et al. 2008) this is between 17 to 
34 Å. 
5.11 Discussion 
Eleven double mutants and nine R62X mutants were investigated initially by 
looking at the re-activation of the mutants by inserting a coiled coil. In this 
scenario several of the mutants showed an increase in activity upon re-
activation.  Three double mutants: D28A-Y98A, R34A-R62A, and T59A-R62A, 
and three R62X mutants: R62G, R62I, and R62N. 
The secondary structure was investigated for all 20 of the mutants and three 
of the mutants lacked secondary structure: R24A-R62A, T59A-Y98A, and 
T81A-Y98A.  This is a satisfactory explanation as to why these three mutants 
did not re-gain activity when held in place with the coiled coil.  It does not 
explain why other mutants have secondary structure but do not have activity 
when held in place with a coiled coil.  The investigation into the colloidal and 
thermal stability of all 20 mutants revealed small variations in stability for the 
double mutants. The 3 mutants with highest colloidal and thermal stability: 
D28A-Y98A, R34A-R62A, and T59A-R62A were the three mutants that gained 
activity.  The thermal stability for the R62X mutants was essentially the same 
at 42 oC  and analysis of the primary data explained the shift in Tm for R62I 
and R62N.  The largest increase in activity when coupled with a coiled coil was 
seen for the double mutant T59A-R62A.   
The distance between the linker and the coiled-coil was an arbitrary length, 
and optimisation of the length, and type, of the linker would warrant further 
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investigation.  It is well documented that a linker contributes to the overall 
stability and function of proteins (Chen, et al. 2013). It could be that a rigid 
linker would hold the alkaline phosphatase chains in place better than the 
flexible linker used in the construct in this study.  Also, in this investigation, 
only homodimers were investigated; it would be interesting to explore the many 
combinations of heterodimer and see if there is a winning combination, which 
would provide a higher signal when stabilised into the dimer form of the 
enzyme. 
T59A-R62A was characterised further by looking at the thermal stability of the 
mutant both with and without the coiled coil present.  The coiled coil gave the 
mutant a near wild-type level of thermal stability. This was established by 
inhibiting the coiled coil interaction by addition of further coiled coils that were 
free in solution; it was found that the coiled coil mediating the increase in 
stability and increase in activity.  Furthermore, the coiled coil also helped 
stabilise the mutant alkaline phosphatase at pH 11. T59A-R62A was shown to 
be a mixture of monomer and dimer at pH 8.0 by SEC and AUC, with the 
majority being in the monomer form.  A zinc-binding assay indicated T59A-
R62A has a full complement of zinc, which is required for functionality (Ma, et 
al. 1995).  It would be interesting to investigate the amount of bound zinc in all 
of the 20 mutants taken forward for characterisation.  This could give an 
explanation for the other nonfunctional, folded mutants. 
Initial data show the distance dependence of T59A-R62A is between 17 and 
34 Å.  Optimising the zif interaction, including the linker length and 
experimental parameters, such as concentrations and incubation time, would 
be advantageous.  These initial data are promising.  However, further 
information on the distance dependence of different constructs would be 




Chapter 6  





6.1 Introduction  
In this study, the Affimer was chosen as a molecular recognition element.  An 
Affimer is a scaffold protein that behaves like an antibody molecule but it is 
only 12-14 KDa, and can be produced in E. coli in 3 days as opposed to raising 
antibodies in an animal.  Some antibody fragments can be produced in E. coli, 
but all Affimers can be produced in this way.  The target to demonstrate the 
split enzyme concept needed to be over 20 KDa; large enough to have two 
epitopes for two different Affimers to bind. A model protein, modified GFP 
(mGFP), was selected, as it is a 27 KDa protein and would be expected to 
have several epitopes for Affimer binding.  Several Affimers had been raised 
against mGFP for a previous study and were supplied in a pDHis phagemid 
vector.  
 
6.1.1 Sub-cloning into an expression vector 
The Affimer coding regions were sub-cloned into pET11 by PCR amplification 
from the pDHIS vector. The primers were designed to introduce a 5’ Nhe I site 
and a C-terminal cysteine and 3’ restriction site for Not I.  The amplified DNA 
was digested for 3 h with Not I and Nhe I (New England Biolabs - NEB) before 
separation on a 10 % agarose gel.  The DNA was gel purified as described in 
Chapter 2 Section 2.5.1.4.  The Affimer insert was then ligated into a modified 
pET11a vector digested with Not I and Nhe I and then treated with Antarctic 
Phosphatase.  The ligation reaction contained 40 ng of linearised, 
phosphatase-treated pET11a, a 3-fold to 7-fold molar excess of the Affimer 
insert, which is 6-15 ng of DNA, 1 µl 10x T4 DNA ligase buffer (Roche), 200 U 
T4 DNA ligase (Roche), and ddH2O to 10 µl.  The reaction was incubated at 
16 °C for 16 h, followed by introduction into XL-1 Blue competent cells.  
Aliquots of 50 µl and 250 µl of this transformation mix were spread onto each 
of two 2TY/carbenicillin (50 μg/ml) agar plates and incubated inverted at 37°C 
for 16 h.  Plasmid DNA was prepared using a QIAGEN miniprep kit from 5 
colonies, and analysed for successful ligation by colony PCR followed by 
agarose gel electrophoresis, for full details see Chapter 2 Section 2.5.2.  The 
clones containing an insert were confirmed by DNA sequencing.  
 
 190 
6.1.2 Affimer protein production and purification 
The pET11a plasmids containing the coding regions for the Affimers were 
introduced into BL21 Star (DE3) cells.  A single colony was then used to 
inoculate 5 ml of 2TY medium supplemented with 50 ng/ml carbenicillin and 
incubated overnight at 37 oC with shaking (220 rpm).  A 1 ml aliquot of this 
culture was used to inoculate 400 ml TB auto-induction medium (Formedium) 
supplemented with 50 ng/ml carbenicillin, 0.2% w/v lactose and 25 mM 
succinate.  This culture was incubated for ca. 48 h at 25 oC with shaking (220 
rpm).  The cells were pelleted at 3600 x g for 10 min at 4 oC for full details see 
Chapter 2 Section 2.7.4. 
Cell pellets from 400 ml of culture were added to 40 ml of lysis buffer, 
supplemented with 2 mg/ml lysozyme, a cOmplete protease inhibitor tablet 
(Roche), and 200 U OmniCleave (Epicenter), then incubated at room 
temperature with agitation for 2 h.  Affimers are stabile to over 50 oC , therefore, 
the cell lysate was then incubated at 50 oC for 20 min to denature proteins 
which are not stable upto 50 oC, followed by centrifugation at 25,000 x g for 35 
min.  The supernatant was then filtered (0.22 μm) to remove any large 
impurities.  The soluble fraction of the cell lysate was then incubated for 1.5 h 
with 160 μl HisPur Ni-NTA resin (Pierce) with agitation at room temperate.  The 
cell lysate and resin mix were then loaded into an empty disposable 2 ml 
column (Pierce) to collect the resin and let the liquid flow through.  This 
ensured all of the resin was captured.  The resin was removed from the column 
and incubated with 10 ml of wash buffer for 10 min while rolling at room 
temperature.  The wash buffer resin mix was then loaded into a disposable 2 
ml column and the resin was further washed with 20 column volumes of wash 
buffer followed by elution with 2.5 ml of elution buffer, in five 0.5 ml fractions.  
Samples were taken from the flow through, the final wash, and fractions 1, 3 




Figure 6.1 Purification of GFP Affimers.   
The PA gel shows the molecular weight markers, noted in kDa on 
the left of the gel, followed by the flow through, final wash and 
elution fractions 1, 3 and 5 loaded in equal amounts of protein.  
Fractions 1-5 were pooled.   
 
The C-terminal cysteine on each of the Affimers was biotinylated to allow 
oriented binding to streptavidin chips in a BLItz experiment.  Any 
intermolecular disulfide bonds were reduced using a TCEP reducing gel 
(Thermo Scientific) and biotinylated with EZ-link BMCC biotin (Thermo 
Scientific).  Full details are in Chapter 2 Section 2.8.2. 
6.1.3 Characterisation of Affimers 
One Affimer; mGFP21, was chosen at random to determine the KD of the 
Affimer for mGFP, using Bilayer interferometry (BLItz).  The experimental 
parameters for the BLItz experiment can be found in detail in Chapter 2 Section 
2.9.8.1.  Briefly, the streptavidin chip was incubated in PBS buffer for the first 
30 seconds to obtain a baseline.  The biotinylated Affimer was loaded onto the 
streptavidin chip for 2 min, which can be seen in real time, followed by another 

































































The loaded chip was then exposed to the target, in this case mGFP, and an 
association curve was produced, followed by a dissociation curve when 
incubated with buffer.  The BLItz software then creates a fit to obtain an 
association (kon) and a dissociation (koff) rate as well as calculating a KD. Figure 
6.2 demonstrates an example of the fit, which is not very accurate even after 
many optimisation experiments. 
 
Figure 6.2 An example of a fit for the association and dissociation curves 
produce by BLItz software.   
Here the Affimer, mGFP21, was challenged with mGFP to create 
the association curve, and then incubated with PBS buffer to 
create the dissociation curve.  Two different concentrations of 
mGFP were used: 1 μM, and 500 nM.  
 
Initial BLItz data indicated a KD value of approx. 8.8 nM for mGFP21.  The pool 
of mGFP Affimers were then used in an experiment to investigate dual binding 
to mGFP.  The binding of two separate epitopes was key to future work, and 
therefore a sandwich phage ELISA assay was performed to ascertain if the 
mGFP Affimers could indeed bind mGFP at two separate epitopes.  There was 
over 1 g of mGFP21 Affimer available from the first expression.  It showed a 
high signal in the initial phage ELISA and was consequently chosen as the 









In a 96-well Nunc Maxisorp plate, 50 μg of Affimer mGFP 21 was placed in the 
first 4 columns, while the second four columns were left blank.  The plate was 
incubated for 16 h at 4oC followed by two washes with 250 μl PBS.  200 μl of 
1 X blocking buffer (Sigma) was added to each of the wells and incubated for 
16 h at 25oC.  10 μg of mGFP was added to all 8 columns and was incubated 
for 2 h at room temperature.  The plate was washed twice again with PBS, 
followed by 10 μl of 1 X blocking buffer, and 40 μl of the supernatant from the 
phage growth containing each of the mGFP Affimers were added to each well.  
The same set in each of the 4 columns, so the sample columns and the blank 
columns had the same phage in each of the wells.  This was incubated at room 
temperature for 1 hour followed by a single wash with PBS.  The enzyme-
linked anti-pIII antibody was added followed by 10 washes with PBS and 50 μl 
TMB was added to give the colour change.  For full details see Chapter 2 
Section 2.9.8.1.  Figure 6.3 shows the results from the phage ELISA.  The 
sample plate is labelled ‘A’ and the control plate is labelled ’C’.  The annotated 
plate, labelled ‘B’ is the exact same plate as A with annotated numbers on it.  
Each of the wells contains an Affimer from the original pool of mGFP Affimers.  
These were all sequenced, and the number on the annotated plate represents 
the Affimer in the well.  Affimer mGFP21 was in the pool as a control.  Where 
mGFP 21 was present this should not produce a signal as it should not be able 
to bind, because the binding site(s) for mGFP21 should all be taken.  Wells 
labelled 21 in Figure 6.3 are those containing mGFP21 phage and as expected 
showed no binding signal. The control plate ‘C’ does not contain mGFP.   
Therefore, the Affimers in the three wells that show colour development on the 
control plate presumably bind to the well, and these Affimers were discarded. 
 
Within the pool some other Affimers were expected to bind to the same or 
similar areas as mGFP21, and some were expected to bind elsewhere on 
mGFP.  If the Affimer bound in the same or similar position then there would 
not be a signal produced, but where there was binding at a separate site then 
a signal would be given.  Three repeats of mGFP20 were negative suggesting 
that Affimer 20 binds the same or an overlapping epitope as mGFP21.  Three 
replicate wells tested with mGFP18 phage all show a strong positive result, as 
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do two repeat wells for both mGFP32 and 33.  Thus Affimers 18, 32 and 33 
seem likely to bind a distinct epitope to mGFP21.   
 
 
Figure 6.3 mGFP sandwich phage ELISA.  
The sample plate is labelled ‘A’ and the control plate is labelled ’C’.  
The annotated plate, labelled ‘B’ is the exact same plate as A with 
annotated numbers on it.  Each of the wells contains an Affimer 
from the original pool of mGFP Affimers.  These were all 
sequenced, and the number represents the Affimer in the well.  The 
two ‘21’ circled wells on the plate show two samples of MGFP21, 
which cannot bind due to the binding site for MGFP21 already 
being bound, and they are clear.  Affimer 18, 32 and 33 circles all 
show a strong positive result.  Affimer 20 demonstrates a negative 
result. Plate C shows the blank control, with three positive results.  
These three samples indicated on the annotated plate with red 
circles were discarded as the Affimer probably binds to the plate.   
 
In the phage pool of mGFP Affimers, there were 20 unique Affimers that bound 
mGFP.  In this phage ELISA experiment 13 of these failed to bind mGFP21 
immobilised mGFP indicating that they likely bind the same or overlapping 
  
















epitope as mGFP21.  By contrast mGFP Affimers 18, 32 and 33 gave a good 
positive signal and Affimer mGFP32 was arbitrarily chosen as the binding 
partner for Affimer mGFP21. 
6.1.4 Colloidal Stability 
mGFP21 and mGFP32 were buffer exchanged from the elution buffer into PBS 
but a white precipitate was observed in the dialysis tubing.  The protein 
concentration in the solution was quantified using the BCA assay and was 
confirmed using a Bradford assay (see Chapter 2 Section 2.9.2). The 
concentration of protein was between 1 and 2 mg/ml.  A second batch of 
mGFP21 was buffer exchanged into PBS with the addition of 10% glycerol 
resulting in a concentration of 10 mg/ml of protein in solution, and a lower level 
of white precipitate was observed.  
This result was corroborated by light scattering data using an Optim 1000 
(Avacta Analytical).  A stepped thermal ramp program was used with the 
temperature setting being staged between 20 oC and 95 oC in 1 °C increments.  
An 8.8 μl aliquot of each protein (1 mg/ml) was measured in triplicate, and 
Optim 1000 software was used to process the data.  Colloidal stability was 
measured by monitoring SLS at 266 nm against temperature. A transition 





Figure 6.4 Static light scattering (SLS) data at 266 nm over a range of 
temperatures for Affimers mGFP21 and mGFP32.  
The SLS data are also shown for the Affimer scaffold as a 
comparison.  The Affimer scaffold does not aggregate at 
temperatures up to 95 oC, the highest temperature measurable in 
the Optim 1000.  The mGFP Affimers started aggregating at lower 





For mGFP21 the absorbance reading started to increase at around 72 oC in 
PBS and reached approximately 600,000 counts.  By contrast, the absorbance 
did not rise until around 80oC and only reached 250,000 counts.  This indicates 
that mGFP21 is less prone to aggregation in the presence of 10% glycerol.  A 
similar pattern was observed with mGFP32.  The Affimer scaffold did not 
exhibit a high-level of light scattering in either PBS or PBS with 10% glycerol, 
indicating that it does not precipitate, in agreement with the lack of observable 
precipitate during dialysis. 
6.1.5 Monomeric or Dimeric Affimer 
A Superdex 200 10/300 GL column was used to analyse the multimeric state 
of mGFP21 and mGFP18.  The column was equilibrated with PBS containing 
10 % glycerol before a 1.2 ml aliquot of 2 mg/ml Affimer was added to the 
column. This was eluted in an isocratic fashion using PBS with 10 % glycerol.  
The flow rate was set to 0.5 ml/min on a ÄKTA FPLC and the eluate was 





Figure 6.5 Affimer SEC spectra.   
The elution profile for the Affimer scaffold (blue), mGFP32 (orange) 
and mGFP21 (grey) were monitored at 280 nm.  Affimer scaffold 
and mGFP32 show a single peak characteristic of monomer. By 
contrast mGFP21 has two broad peaks suggesting a mixed 
population of monomer and dimer.  
 
The Affimer scaffold and mGFP32 behave similarly on the SEC column, 
suggesting these proteins are principally monomeric.  By contrast mGFP21 
shows two broad peaks suggesting a mixed population of molecular species. 
To investigate the nature of the protein in these peaks, a HiPrep 16/60 
Sephacryl S-100 HR preparative size exclusion column was used with 





Figure 6.6 SEC profile showing separation of mGFP 21 species. 
 
As expected Figure 6.6 shows two peaks for mGFP21, suggesting the 
presence of monomer and dimer. The peak eluting at 58.7 ml has an integrated 
area of 776 au, whilst the peak at 81.6 ml has an integrated area of 3227 au.  
The ratio is approximately 1:4, suggesting 4 times more of the smaller species.  
Two samples from each peak were analysed on a native gel along with the 
Affimer scaffold, a mixture of mGFP21 and Affimer scaffold, and mGFP21 that 
















Figure 6.7 Native 10% polyacrylamide gel of mGFP21.   
The samples are shown above the lanes.  The right hand 4 lanes 
are fractions from the SEC (Figure 1.7) taken at 56 and 58 ml from 
the first peak and 80 and 82 ml from the second peak. 
 
The native gel in Figure 6.7 shows one band for the Affimer scaffold, two bands 
for mGFP21, and three bands for the mixture.  The overall charge on the 
Affimer scaffold is -1 while for mGFP21 it is +1. This partly explains for the 
faster migration of the Affimer scaffold towards the anode. The two samples 
from the second peak have two bands in the same migration pattern as the 
mGFP21 sample that was not on a SEC, although the second band is smaller.  
This suggests the monomer – dimer formation is in equilibrium, the SEC trace 
in Figure 6.6 suggests 20% putative dimer and 80% putative monomer, 
although the samples from the dimer peak do not have a monomer band.  This 
could suggest that once an Affmer is in a dimer form, it remains in the dimer 
form.  However, another explanation based on the data from SEC and the 
native gel showing mGFP21 is that the upper band is the monomer not the 
dimer because of the relative intensities of the bands. As native gels separate 
on the basis of hydrodynamic radius and charge.  Whilst it was expected that 
the dimer would migrate more slowly, the dimer could be compact and the 
positive charge might be masked by dimer formation, leading to the dimer 











































































samples for the 56 and 58 ml which were originally dimeric have reached a 
new monomer dimer equilibrium that favours the monomer, as the sample is 
more dilute coming off the column than when it went on.   
6.2 Crosslinking alkaline phosphatase with Affimers 
To facilitate simple cross-linking between an Affimer and other molecules, 
Affimers with a C-terminal cysteine were used. To ensure the thiol group on 
the cysteine residue of each Affimer was reduced, the sample was treated with 
TCEP reducing gel (Thermo Scientific) according to Chapter 2 Section 2.8.1.  
Alkaline phosphatase was buffer exchanged by dialysis into PBS containing 1 
mM EDTA to avoid the presence of Tris that interferes with the chemical 
crosslinking reaction.   Alkaline phosphatase was mixed with 1 SM(PEG)2 
(Pierce) a PEGylated SMCC cross-linker.  SM(PEG)2 has two reactive groups, 
a NHS ester and a maleimide, therefore it is reactive towards amino and 
sulfhydryl groups respectively.  The PEG spacer arm gives a flexible linker of 
about 17.7 Å. 
0.1 mM Alkaline phosphatase was mixed with 1 mM cross-linker and the 
reaction was incubated at room temperature for 1 hour before desalting using 
dialysis. The derivatised enzyme was then mixed with 0.1 mM reduced Affimer 
and incubated at room temperature for a further hour.  To examine whether 
the crosslinking reaction was successful, samples were separately run on a 
15% SDS PAGE gel. Figure 6.8 shows samples of mGFP21 and alkaline 
phosphatase flanking samples taken from two independent cross-linking 
reactions. Although the cross-linking samples do not show a distinct single 
species, the presence of higher molecular mass species than alkaline 
phosphatase together with the reduced level of monomeric Affimer, confirm 
that crosslinking has occurred.  There is a high concentration of non-
crosslinked alkaline phosphatase and the conditions for cross linking could be 





Figure 6.8 Crosslink reaction SDS PAGE gel.   
Molecular weight markers are noted in kDa on the left of the gel. 
The cross-linked reaction samples show high molecular mass 
species, indicating that cross-linking has occurred. 
 
The cross-linked Affimer-AP samples were not purified further, but were 
desalted and buffer exchanged as described previously (Chapter 4 Section 
4.2.1). 
6.3 Enzyme-linked Affimer assay 
Dilutions of biotinylated mGFP were immobilized onto streptavidin-activated 
plates (Pierce) in triplicate at concentrations between 10 - 0 μg/ml in 200 μl 
PBS and incubated at 4 °C overnight.  Plates were washed three times with 
PBS before blocking non-specific sites with 5% skimmed milk in PBS overnight 
at 4 oC.  Plates were then washed three times with PBS/0.05% Tween-20 
(PBST). The alkaline phosphatase linked mGFP21 was added and incubated 
for 2 h at room temperature and then washed six times with PBS. Enzyme 


































































concentration) for 30 min at room temperature.  The reaction was stopped by 
the addition of 50 μl 3 M NaOH and the absorbance reading measured at 405 
nm (Figure 6.9).  
 
Figure 6.9 Enzyme-linked Affimer assay for mGFP with alkaline 
phosphatase linked mGFP21.   
Three repeats of 0-10 g of GFP were incubated on plates and 
detected with enzyme-linked mGFP21 Affimer.  Concentrations 
above 0.02 g/ ml of GFP were reliably detected 
 
The background reading of 0.3 absorbance units is shown on the graph where 
the amount of mGFP added is zero.  0.01 g/ml shows a slight increase in 
signal above the background to 0.8 absorbance units.  The data reading from 
0.02 to 10 g/ml of GFP incubated on the plates shows an increase in 
absorbance to over 2 absorbance units. There is not a correlation between 
increase in concentration from 0.02 g/ml to 10 g/ml and an increase in 
absorbance.  This could be because at 20 ng/ml the plate surface has reached 
saturation.   This experiment shows that 20 ng/ml or more mGFP can be 



































6.4 Enzyme-linked sandwich Affimer assay 
Biotinylated mGFP32 was immobilized onto strepavidin-activated plates 
(Pierce) at a concentration of 10 μg/ml in PBS and incubated at 4 °C overnight. 
Plates were washed three times with PBS before blocking non-specific sites 
with 5% skimmed milk in PBS overnight at 4 oC.  Plates were then washed 
three times with PBST. 200 μl dilutions of mGFP from 0 to 10 g/ml were 
prepared in 1% skimmed milk/PBST, added to duplicate wells and incubated 
for an additional hour at room temperature, followed by six further washes with 
PBST. The alkaline phosphatase linked mGFP21 was added and incubated 
for 2 h at room temperature, and washed 6 times with PBST. Enzyme activity 
was measured as described in chapter 2 Section 2.9.3.2 and the data are 
shown in Figure 6.10.  
 
Figure 6.10 Sandwich enzyme-linked Affimer assay.  
 mGFP32 was used as a capture Affimer, and alkaline phosphatase 
linked mGFP21 was used for detection.  10 g of mGFP32 were 
immobilised on streptavidin plates and three repeats of 0-10 g of 
GFP were incubated with mGFP32, and detected with enzyme-
linked mGFP21 Affimer.  Concentrations above 2 g/ ml of GFP 



















































The background reading of 0.25 absorbance units is shown on the graph 
where the amount of mGFP added is zero.  0.01-0.05 g shows a slight 
increase in signal above the background to 0.7-0.8 absorbance units.  The 
data reading for 0.1 and 1 g of GFP incubated on the plates shows an 
increase in absorbance to over 1.5 absorbance units on average, but there is 
a large error between the three repeats. 2, 5 and 10 g of mGFP give a good 
signal of over 2 absorbance units.  This experiment shows that 2 g or more 
mGFP can be reliably detected by a sandwich enzyme-linked assay. 
6.5 Split enzyme-linked Affimer assay 
A split enzyme-linked Affimer assay was developed to establish a working 
example of the split alkaline phosphatase system.  The split alkaline 
phosphatase (T59A-R62A) characterised in Chapter 5 was linked to mGFP32 
and mGFP21 Affimers, as shown in the schematic in Figure 6.11 
 
Figure 6.11 Schematic of split enzyme-linked Affimers.  






Two experiments were set up; one where the target was immobilised and one 
where the target was free in solution.   For the immobilised target, dilutions of 
the mGFP between 10 and 0.1 μg/ml were prepared and added in duplicate to 
Maxisorp microtiter plates (Nunc), and were incubated overnight at 4 oC. After 
six washes with PBS, two split alkaline phosphatase linked Affimers were 
added and incubated for 2 h at room temperature, and then washed six times 
with PBS.    
In parallel, dilutions of the target mGFP between 10 and 0.1 μg were added to 
96 well plates (Nunc). Two split alkaline phosphatase linked Affimers were 
added and incubated for 2 h at room temperature.  These plates were not 
washed because nothing has been immobilised, and the reaction should 
happen in solution. 
Activity on both plates was measured by reading the absorbance at 405 nm 
after incubation with 100 l of pNPP (2 mM final concentration) for 30 min, 60 
min, 8 h, and 16 h at room temperature. Unfortunately, the readings were not 
above the background level, suggesting that functional dimers were not 
formed. 
6.6 Discussion 
Affimers for mGFP were explored to see if they could bind more than one 
epitope.  mGFP21 was used to block its binding site on mGFP and, after being 
screened against a modest pool of other Affimers, mGFP32 was chosen as a 
binding partner.  The Affimers were prone to precipitation, but after addition of 
10 % glycerol, the amount of precipitate reduced. An analytical SEC was used 
to investigate if the Affimers were monomers or dimers.  mGFP32 was a 
monomer, while mGFP21 was a mixture of monomer and dimer.  The dimer 
and monomer were separated on a preparative SEC, but native gel data 
suggest the monomer – dimer formation was in equilibrium.  As 80 % of the 
sample was in the monomer form, the two Affimer were chemically linked to 
wild-type alkaline phosphatase and T59A-R62A.  These fusion proteins with 
wild-type alkaline phosphatase were used in enzyme-linked Affimer assays 
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and sandwich enzyme-linked Affimer assays.  The fusion proteins with T59A-





Figure 6.12 Split enzyme-linked Affimer assay.  
A) Two different Affimers fused to T59A-R62A alkaline 
phosphatase.  When GFP was introduced the experiment could 
progress one of two ways: B) successful signal produced upon 
the Affimer binding GFP, or C) Affimer binding at epitopes where 





The enzyme-linked Affimer assay establishes that AP linked mGFP21 can bind 
GFP and give a signal.  The sandwich enzyme-linked assay determines that 
mGFP32 can hold GFP in place and AP linked mGFP21 can still give a signal.  
From these experiments, we know that mGFP21 and 32 bind and that the 
alkaline phosphatase remains active.  We do not know, however, where the 
Affimers bind or the distance between the epitopes.  The epitopes could be too 
far apart as demonstrated in Figure 6.12.  Box A shows two Affimers fused to 
T59A-R62A alkaline phosphatase and the target, in this case GFP.  Box B and 
C show how the experiment could proceed once the fusion proteins and GFP 
were mixed together: B) a successful signal produced upon the Affimer binding 
GFP, and C) the Affimers bind at epitopes where the enzyme cannot establish 
the correct dimer form and turn over substrate. 
The data in Chapter 5 indicate that the distance dependence of the zif split 
alkaline phosphatase system is between 17 Å and 34 Å. A direct comparison 
cannot be made because the linker is different, as is the binding molecule.  
However, these measurements can be used as an approximation and can help 
determine what may have happened with the split enzyme-linked Affimer 
assay.  The cylinder of GFP has a length of 42 Å, and a diameter of 24 Å (Hink, 
et al. 2000), therefore it is easy to imagine that the epitopes, where mGFP21 
and 32 bind, are distant enough that they are not at a permissible distance.  
mGFP21 was shown to be mixed species between a dimer and a monomer.  
It may improve the split AP assay if a pure monomer could be used.  The 
sandwich phage ELISA revealed 13 Affimers that were negative and did not 
bind at the same time as MGFP21, but which probably bound at the same 
epitope.  There were also 7 possible Affimers, including mGFP32, which could 
be further investigated.   
The method of linking to Alkaline phosphatase was non-specific, and therefore 
the AP was not orientated in a particular way.  This was fine for wild-type AP 
but split AP could need orientating.  The linker between split AP was a 
chemical linker, SM(PEG)2, which has a spacer arm of 17.6 Å.  Optimisation of 
the linker type and length could help improve the split AP assay.  SM(PEG)n 
can be bought with 2, 4, 6, 8, 12, and 24 PEG chain lengths, which would be 
an easy way to investigate linker length. 
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The ideal way forward would be to co-crystallise the different Affimers with 
mGFP and then rationally design linkers once the distance between the 
epitopes is known. 
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7.1 General discussion 
The purpose of this study was to split an enzyme for use in biosensor 
technology.  Initially as it was readily available and had been widely studied 
previously, β-lactamase was selected as a test system. In Chapter 3 N-
terminal and C-terminal fragments of β-lactamase were cloned expressed and 
purified.  Full-length and the C-terminal fragment were produced in the soluble 
fraction and were purified using a nickel column.  The N-terminal fragment of 
β-lactamase was more difficult to produce, and was eventually purified from 
the insoluble fraction.  It was solubilised in 8 M urea and purified using a nickel 
column.  The chaotropic agent was removed once the protein fragment was 
bound to the nickel column.  Purified N-terminal and C-terminal fragments of 
TEM-1 β-lactamase could be associated in vitro in a functional format by nickel 
ions that interacted with His tag regions on each monomer.   
For use in a biosensor split enzyme system it is necessary to be able to 
produce the enzyme fragments in a simple and reproducible manner, to 
generate sufficient quantities of enzyme fragments that are capable of 
generating near-native levels of enzyme activity. Unfortunately, purified β-
lactamase fragments proved difficult to produce and required refolding.  The 
restored level of enzyme activity was only 5 % of that of the recombinant β-
lactamase and only 0.3 % of native β-lactamase.  There is such a vast 
difference here because the protein fragments are unstable, as they do not 
have their full structure to be able to fold correctly.  Even when the fragments 
come together and the full sequence is available, the native chaperones in the 
cell are not available for efficient correct folding.  There are disulphide bonds 
in β-lactamase, which required a non-reducing environment for correct folding, 
which is not available when folded in vitro or in the cytosol of E. coli.  As the 
recombinant β-lactamase activity is already significantly reduced before the 
protein was even split, and was even lower afterwards, it was decided to 
investigate a different enzyme.  
Alkaline phosphatase was a good candidate to begin using in a split enzyme 
system.  Alkaline phosphatase, a homodimeric enzyme from E. coli, is simple 




refolding.  E. coli alkaline phosphatase is also a good model enzyme as it 
exhibits cooperativity, but only turns over substrate in a dimer form and not as 
a monomer (Garen and Levinthal 1960).   
An inactive monomeric form of alkaline phosphatase was required for use in a 
split enzyme system such that when two monomers were associated they 
would give rise to enzyme activity. In order to disrupt the dimer interface to 
generate a monomeric form, amino acid residues at the dimer interface have 
been mutated. Previous reported studies provided a basis for this aspect of 
the work.  The mutations R10A, R24A, T59A, T59R, and T81A (Boulanger and 
Kantrowitz 2003, Orhanovic, et al. 2006) were reported to reduce the stability 
of the dimer. Bioinformatics analysis of the dimer interface to identify residues 
that may affect interface stability was conducted during the present study, 
discussed in Chapter 4, and led to the identification of further residues that 
were subsequently mutated. These were D28A, R34A R62A and Y98A.  A 
reduction in specific activity relative to wild type enzyme was used as an 
indicator of predominantly monomeric or dimeric state.  
Eleven double mutants and nine R62X mutants were investigated in Chapter 
5, initially by looking at the intramolecular re-complementation of the ability of 
the mutants to associate by inserting a coiled coil region.  Several of the 
mutants showed an increase in activity by inserting a coiled coil region; three 
double mutants: D28A-Y98A, R34A-R62A, and T59A-R62A, and three R62X 
mutants: R62G, R62I, and R62N.  Of these, T59A-R62A displayed the greatest 
gain in relative activity and was characterised further. T59A-R62A was shown 
by SEC and AUC to comprise a mixed population of monomer and dimer at 
pH 8.0, with the majority being in the monomer form.  A zinc-binding assay 
indicated that T59A-R62A has a full complement of 2 zinc ions per monomer, 
as is required for full activity (Ma, et al. 1995).  
In Chapter 5 Section 5.10, zinc finger motifs that bind to DNA were used to 
determine the permissible distance between two alkaline phosphatase 
monomers.  Fusion proteins were designed to fuse a zinc finger motif to 
alkaline phosphatase. DNA oligos with the binding site for the zinc fingers were 




moved along the DNA.  Initial data showed that the permissible distance 
between two T59A-R62A monomers in a split system is between 17 and 34 Å. 
The Affimer was chosen as a molecular recognition element in this study as it 
is a scaffold protein that behaves like an antibody molecule but it is only 12-14 
KDa and can be produced in E. coli.  Affimers that bind mGFP were used in a 
series of model experiments to see if a split enzyme system between Affimers 
and split alkaline phosphatase could be designed.  Affimer mGFP21 and 
mGFP32 were selected as they bind at different epitopes on mGFP.  Initially, 
wild-type alkaline phosphatase was cross-linked to Affimer mGFP21   and was 
used successfully in an enzyme-linked Affimer assay, much like an ELISA.  
The enzyme-linked Affimer assay indicated that levels of protein as low as 20 
ng/ml of mGFP could be detected.  Next, two Affimers were used in a sandwich 
enzyme-linked Affimer assay.  mGFP32, a second mGFP binding protein, was 
used as a capture molecule, and enzyme-linked mGFP21 was used as a 
reporter molecule. The limits of detection for the sandwich assay were 
approximately 2 μg/ml of mGFP. The same Affimers were cross-linked to 
T59A-R62A, and used in a split enzyme-linked Affimer assay.  Unfortunately, 
this assay was not successful, but further optimisation strategies are discussed 
in Section 7.3.1. 
7.2 Comparison with other studies. 
TEM-1 β-lactamase and fragments of TEM-1 β-lactamase were purified by de 
las Heras (2008) and the fragments were brought into a functional format with 
nickel ions in the same format as in this study.  In the de las Heras (2008) 
study, full length β-lactamase was purified from the insoluble fraction, whereas 
in this study soluble expression was accomplished.  In both studies the N-
terminal fragment was purified from the insoluble fraction and had to be re-
folded, while the C-terminal fragment was purified from the soluble fraction. 
Fry et al.  (2008) took the purified split β-lactamase and used it in a cell free 
assay to investigate the interactions of the human cytomegalovirus (HCMV) as 




A split linked β-lactamase has been used by Saunders et al. (2016) for 
screening a protein’s inclination to aggregation and for the inhibition of 
aggregation.   The systems involves placing a test protein the middle of the N 
and C-terminal domain of β-lactamase via two linkers, a schematic of the 
construct is shown in Figure 7.1. 
 
 
Figure 7.1 Structure of test protein for protein aggregation.  
The test protein is flanked by two G/S linkers, and the N and C-
terminal of β-lactamase, adapted from Saunders (2016). 
 
Each of the β-lactamase fragments are linked via a test protein, and if that test 
protein is correctly folded, the fragments would be accessible to each other 
and a functional β-lactamase could be formed.  If the test protein was 
aggregated then the fragments would be held far apart from each other and 
would not be functional.  This experimental investigation was done in the 
periplasm of E. coli and the system was able to measure the extent of protein 
aggregation via a simple readout of antibiotic resistance. Eight different 
proteins were investigated four that were prone to aggregation and four that 
were not inhibitors of aggregation were also tested (Saunders, et al. 2016).  
The advantage to this approach is that it was done in cells, where β-lactamase 
is in its natural environment, along with the cells natural machinery to assist in 
folding.  Each of the fragments are linked, via a test protein, so they will not 
diffuse away from each other, thus increasing the probability that the fragments 
will be able to form into a functional enzyme.  In contrast, in this study the β-
lactamase fragments were purified and experimental investigation was 
performed in an in vitro environment, and each fragment was free in solution. 
As discussed in Chapter 1 Section 1.5.2.2 and Section 1.5.3, the kinetic 




R10K, R24A, R24A, R24K, R10A-R24A, and T59A were assessed in a study 
by Martin et al. (1999). T81A was compared with wild-type in a study by 
Orhanovic et al. (2006).  The T59R mutation also successfully produced a 
stable protein (Boulanger and Kantrowitz 2003).  This mutant monomer was 
unlikely to be ever brought back into association as a homodimer as there is 
an obvious steric hindrance and positive charge repulsion (Boulanger and 
Kantrowitz 2003).  No further work on the dimeric interface of E. coli alkaline 
phosphatase has been published to date.  This is probably due to the difficult 
nature of producing stable variants, and difficulty in selecting mutations that 
would give the desired effect. The present study included the mutations from 
these previous studies and went further to include mutations at four additional 
amino acid residues D28, R34, R62, and Y98.  The R62 mutation displayed 
properties of particular interest and the most effective mutant for monomer 
association as a dimer was T59A-R62A.   
7.3 Future work 
There are a number of areas that require more intensive investigation, such as 
the distance dependence of T59A-R62A dimerization interactions. This 
includes analysing different linker lengths and base pair gaps between the 
binding sites of the zinc finger.  Furthermore, rational design of other mutants 
at the dimeric interface would be advantageous.  However, pragmatically the 
most appropriate strategy would be the creation of a larger variant library to 
enable the screening of a much more substantial area of sequence space.  
Whilst the concept underlying this research project was to develop a split 
enzyme system for use in a biosensor, such a system could be used in a 
system such as an assay or device that can simultaneously measure multiple 
analytes.  A split enzyme system is designed to amplify the signal generated 
by a binding event between a binding protein and its analyte through catalytic 
turnover. However, despite the attraction of an intramolecular 
complementation system for the development of a high specificity biosensor 
that relies upon two binding events with the target molecule, the fundamental 
limitation is that full enzyme activity is highly unlikely to be achieved. The 




generate what ends up being a less efficient detection catalyst in the 
biosensor. Ultimately the point of a biosensor is to provide the most sensitive 
detection system for low concentrations of target analyte and thus one would 
want to achieve signal amplification at least equivalent to the parent enzyme. 
This leads to the suggestion that an alternative direction for consideration 
would be reversing an enzyme/inhibitor interaction upon binding or switchable 
enzymes. These various options will be discussed in the following section. 
7.3.1 Distance dependence of T59A-R62A dimerization 
interactions 
Initial data in Chapter 5 shows the permissible distance between two alkaline 
phosphatase monomer of the T59A-R62A variant is between 17 and 34 Å, 
which is promising. However, the experimental parameters, such as 
concentrations of the alkaline phosphatase variant and of the substrate, as 
well as the incubation time, need to be optimised with a duplex DNA oligo that 
is known to hold the T59A-R62A mutant alkaline phosphatase together.  Next, 
the exact point where activity is lost needs to be investigated.  The alkaline 
phosphatase variant was active when using oligos with a 5 bp (17 Å) gap and 
then inactive when using an oligo with a 10 bp (34 Å) gap.   Using DNA 
oligonucleotides with 6, 7, 8, and 9 base pair gaps will give a more precise 
measurement of the permissible distance between two alkaline phosphatase 
monomers.  
The protein linker length between the zinc finger and the T59A-R62A variant 
of alkaline phosphatase is 30 amino acids long.  The linker length can be 
changed with a simple mutagenesis reaction providing a deletion of one or 
more amino acids, and the whole experiment could be repeated to investigate 
if this changes the permissible distance between the monomers.  This 
information could then be translated into what length peptide linker could be 





7.3.2 Rationally designed mutations  
Given the position of R62, and the interaction it makes, as demonstrated in the 
simple graphic in Figure 7.2,  it would be interesting to investigate the mutant 
Q416A as this would remove a fourth hydrogen bond, one more than T59A-
R62A.  The question to be investigated would then be whether Q416A would 
produce a fully monomeric alkaline phosphatase that can still be reactivated. 
 
Figure 7.2 Graphic of the network of hydrogen bonds involving Gln 416 
and Tyr 98.   
There are two hydrogen bonds from Gln416 to Arg62, one from 
Gln416 to Thr59, and one from Gln416 to Asp55.  Tyr98 has three 
hydrogen bonds, one to Thr392 and one to Asp394. 
 
The data presented in Chapter 4 Section 4.9.1 suggest that Tyr98 is involved 
in creating a stable protein.  When the Y98A mutation was introduced it did not 
have a notable detrimental effect on the activity of the enzyme.  Y98A in 
combination with R10A and R24A again did not have much of an effect.  When 
Y98A was in combination with D28A, R34A, T59A, R62A or T81A, the variant 
produced had very low activity.  It would be interesting to look into a saturation 
mutagenesis experiment at the Y98 position. Further work in Chapter 5 Section 
5.3.2 investigated the secondary structure using CD of some of the double 
mutants with low activity: D28A-Y98A, T59A-Y98A, R62A-Y98A and T81A-
Y98A.  This data indicated that two of these variants: T59A-Y98A and T81A-
Y98A did not have secondary structure and were probably unfolded.  
Introducing T392A and D394A would reduce the amount of hydrogen bonds 
that were disrupted from 3 (Y98A) to 2 (T392A) or 1(D394A), using these 
addition mutations along with D28A, R34A, T59A, R62A or T81A could provide 






7.3.3 Library generation  
To investigate potential new mutations in alkaline phosphatase that may 
influence monomeric state and intramolecular complementation potential a 
library, or libraries, could be generated by directed evolution. In any 
mutagenesis reactions, the randomisation is at the DNA level (Nov 2012).  In 
directed evolution experiments, random mutagenesis is a powerful tool for 
altering the properties of enzymes (Williams 2004).  Mutations are often 
created by error-prone PCR, (Pritchard, et al. 2005) (Abou-Nader and Benedik 
2010) or using mutator strains of E. coli (Miller 1998).    
Error-prone PCR or mutator strains cannot change any single codon to every 
other codon. This is obvious from the codon table and the low rate of mutations 
which mean you would usually only generate 3-5 point mutations per coding 
region to ensure reasonable retention of enzyme activity and therefore you 
would never get 2 mutations in a single codon let alone three.  However, error-
prone PCR coupled with recombination, such as DNA shuffling will give rise to 
a diverse library.  DNA shuffling is a method where copies of the same gene, 
each with different mutations, are randomly shuffled. This is done by digesting 
the library with DNAse I, then arbitrarily re-joining the fragments using self-
priming PCR. DNA shuffling can be applied to any libraries including those 
using error prone PCR and/or mutator strains (Voet, et al. 2008).  An 
advanatage to this approach is it allows the effects of different combinations of 
mutations to be tested, a disadvantage is that this technique is limited in 
searching sequence space.  Stemmer (1994) used three cycles of DNA 
shuffling, in the directed evolution of β-lactamase.  The variants were selected 
by increasing concentrations of the antibiotic.  The variant reported had a 
32,000-fold increase in its minimum inhibitory concentration from wild type 
(Stemmer 1994). 
An alternative, more focussed approach would be to conduct more structure 
based combinatorial saturation mutagenesis experiments.  As depicted in 
Figure 7.3, a saturation mutagenesis library uses a degenerate primer, or set 
of primers, in a mutagenesis reaction along with a parental plasmid containing 




resulting mutant products can be directly transformed into E. coli (Parikh and 
Matsumura 2005).   
 
Figure 7.3 Methods for producing site directed mutagenesis libraries.  
A parental plasmid can be used with a pair or more of 
complementary degenerate primers (small black arrows). The 
resulting PCR product can be directly transformed into E. coli.  A) 
is an example of one set of degenerate primers and one mutation 
site.  B) is an example of once set of degenerate primers but with 
two mutation sites.  C) is an example of three sets of primers with 








7.3.3.1 Bias when introducing the mutation. 
Bias when making mutation libraries is introduced in three different ways. 
Initially, the genetic code exhibits bias as some amino acids have six codons, 
and some only have one.  The chances of a mutation resulting in an arginine, 
leucine or a serine, which have six codons, are much higher than a tryptophan 
or methionine which only have one codon.  Adding to the complexity, there are 
three stop codons, that if mutated in the middle of a gene, would result in a 
large change as the protein would be truncated.  A second source of bias is 
due to the exponential nature of PCR which means that early mutations in the 
amplification process will be over-represented in the final library.  Some 
polymerases used in mutagenesis reactions can display a preference for AT 
to GC substitutions or vice versa and the position of the mutation can also be 
affected by surrounding sequences, meaning randomisation to every amino 
acid is not equally likely at each position. 
Primers can be fully degenerate using NNN, where N is any of the 4 bases: 
adenine (A), thymine (T), cytosine (C), or guanine (G), this uses 64 codons.  
The number of codons can be reduced using NNS, where S is either G or C 
reducing the number of codons to 32.  NNK, where K is G or T, again reducing 
the number of codons to 32, or NNB where B is either C or G reducing the 
number of codon to 48 (Mena and Daugherty 2005).  Moreover, using a more 
sophisticated randomisation scheme, such as that developed by Hughes et al 
(2003) called MAX; for maximally diverse libraries. A Max set of primers have 
just one codon per amino acid (Hughes, et al. 2003), removes the redundancy 
and gives each amino acid equal weighing.   
7.3.3.2 Library size 
An alkaline phosphatase monomer comprises 449 amino acids.  If each of 
these residues was randomised to any of the 20 amino acids, this would give 
rise to 20449 number of mutants, which is too large to screen in any meaningful 
way.  This number can be reduced by using saturation mutagenesis libraries.  
The number of mutants where all 8 positions; R10, R24, D28, R34, T59, R62, 




A library size of 2.6 x1010 is still very large to be able to generate and screen 
effectively.  Sub-libraries could be made; for example, as the alanine mutants 
at R10, R24, D28, and R34 appear to contribute less than T59, R62, T81 and 
Y98.  Therefore a 4 positions library could be made which would have 204 = 
1.6 x105 number of mutants. This would require a huge screening effort of over 
3×106 clones for 95 % coverage (Hogrefe 2010), which is still a considerable 
challenge to screen.    
7.3.3.3 Library screening 
The method of screening in this study was low throughput, assaying each 
individual purified protein for activity.  In this way, for a library of 4 mutations, 
sampling each just once would generate more than 1500, 96 well plates, which 
is not realistic.  A higher throughput method, such as screening the colonies 
directly on an agar plate, would mean more mutants could be tested faster.   
The first obstacle would be to make sure that the variants were translocated to 
the periplasm.  A range of signal sequences used to direct the protein to the 
periplasmic space can be used. The native signal sequence on the PhoA gene 
is a starting point as it is the native signal sequence.  The variants in this study 
had the PhoA leader sequence, but the protein was found to be produced in 
the cytoplasm.  If, as in this study, PhoA does not produce alkaline 
phosphatase variants in the periplasm, then there are many other signal 
sequences that can be tried. There are other signal sequences that use the 
Sec pathway (Manting and Driessen 2000) similar to PhoA, and others that 
use the SRP (Luirink and Sinning 2004) pathway and the Tat pathway (Berks, 
et al. 2003, Berks, et al. 2005).  Examples of signal sequencing that use the 
Sec pathway include: maltose-binding protein subunit, (MalE) (Lee and 
Bernstein 2001, Schierle, et al. 2003, Singh, et al. 2013); pectate lyase subunit, 
(PelB) (Singh, et al. 2013); alkaline phosphatase subunit, (PhoA) (Schierle, et 
al. 2003, Steiner, et al. 2006, Singh, et al. 2013); and outer membrane proteins, 
(OmpA) (Lee and Bernstein 2001, Steiner, et al. 2006).  Examples of signal 
sequences that used the SRP pathway include: periplasmic sensory protein, 
(TorT) (Steiner, et al. 2006); subunit of the Tol-Pal cell envelope complex, 




al. 2003, Steiner, et al. 2006).  Finally, the Tat pathway can be used for 
translocation and signal sequences from penicillin acylase, (Pac) (Lee, et al. 
2006); and subunit of trimethylamine N-oxide reductase I (TorA) (Blaudeck, 
Sprenger et al. 2001, Lee, et al. 2006) can be utilised to translocate a protein 
to the periplasmic space.  A subset of these signal sequences should be tested 
with variants of alkaline phosphatase including at least one signal sequence 
from each pathway.   
Once the secretion to the periplasm is confirmed, the colonies could be grown 
on a large, 24.5 cm square plate (Pierce) thereby increasing the area and 
number of colonies screened at once.   A standard petri dish (Pierce) has an 
area of approximately 58 cm2, the large 24.5 cm square plates have an area 
of 600 cm2.  Breed and Dotterer (1916) estimate the highest number of 
colonies allowable on a standard plate to be no more than 400.  Therefore, 
4000 colonies can be screened on the large plates, once plating the colonies 
was optimised.  To screen a 4 position library, to 95% coverage as discussed 
earlier, would still require 750 plates.  
For a direct colony assay, pNPP would not necessarily be the most appropriate 
substrate for a direct colony assay as it is yellow and would not stand out very 
well, but the colonies could be grown on a nictrocellulose or other filter on top 
of the pate and then this can be lifted off for assaying. The alkaline 
phosphatase substrate 5-bromo-4-chloro-3-indolyl phosphate (BCIP) (Sigma) 
is currently used in western blotting and immunohistological staining 
procedures, and produces a blue insoluble substance.  The 4-Chloro-2-
methylbenzenediazonium with 3-hydroxy-2-naphthoic acid 2,4-dimethylanilide 
phosphate (Sigma) substrate has been devised for use in western blotting and 
produces an insoluble intense red end product.  These two substrates could 
be tested in a direct colony based assay.  The colonies that change colour 
could then be picked and cultured, and then the plasmid DNA isolated and 
sequenced.  Initially colonies expressing wild type alkaline phosphatase 
should be tested with increasing concentrations of BCIP, and/or 4-chloro-2-
methylbenzenediazonium with 3-hydroxy-2-naphthoic acid 2,4-dimethylanilide 




Another simple approach might be using the FKBP and FRB system discussed 
in Chapter 1 Section 1.4.1.  Figure 1.11 shows that FKBP and FRB interact 
only in the presence of rapamycin.  The alkaline phosphatase variant library 
could be designed with FKBP or FRB as fusion proteins.  Cells that had low 
activity in the absence of rapamycin, but high activity in the presence of 
rapamycin would be considered a hit. 
Luker et al (2004) packaged N- and C-terminal incremental truncation libraries 
of luciferase which were fused to FKBP and FRB in phage and E. coli was co-
infected with the phage libraries. Selection was performed on agar plates, and 
colonies were blotted onto nitrocellulose filters which were soaked in the 
substrate luciferin.  Positive clones were isolated and then tested with 
rapamycin.  Plasmids were recovered from these clones to be further 
investigated (Luker, et al. 2004). 
A high throughput system, investigating a library of variants of alkaline 
phosphatase fused to FKBP and FRB, could be performed in a similar fashion.  
Colonies with a colour change in the presence and no or less colour change 
in the absence of rapamycin could be isolated and then further characterised. 
 
7.3.4 Using Affimers with split alkaline phosphatase in a system 
to measure multiple analytes.   
Typical biosensors tend to use instruments capable of monitoring one 
interaction at a time (Chambers, et al. 2008, Bohunicky and Mousa 2010, 
Ataei, T et al. 2013, Sonuc and Sezginturk 2014, Azzouzi, et al. 2015).  The 
first step towards measuring more than one different analyte at the same time 
is by using several different Affimer pairs in one system.  The library of Affimers 
can be screened to bind many different targets (Paschke, et al. 2007, Tiede, 
et al. 2014, Raina, et al. 2015, Bedford, et al. 2017, Xie, et al. 2017), and can 
be linked to split alkaline phosphatase. These fusion proteins can be used as 
universal binding partners.  One sample could be analysed for several binding 
partners in one test, which could be used to indicate contaminants in a food 




healthcare.  One blood sample to test several biomarkers would be a distinct 
advantage to streamline the diagnostic process, saving time and money. 
The difficulty with a system where several analytes need to be measured is 
that the same sample preparation is required for all analytes, and the 
concentration or detection sensitivity for different analytes can vary over orders 
of magnitude. For example, B-type natriuretic peptide (BNP) is a biomarker for 
heart failure and the level in a healthy adult is 10 pg/ml, which rises to over 
100 pg/ml when a patient is suffering from heart failure (Gaggin and Januzzi 
2013).  A second key biomarker for heart failure is Troponin T whose 
concentration is around 1 μg/ml, some 7 orders of magnitude greater than for 
BNP.  Affimers could, in theory, be chosen to bind with different affinities to 
access a wide range of analyte concentrations.   
Cross-reactivity could lead to false positive results and, therefore the Affimers 
would have to be very well characterised.  However, having a system that uses 
two Affimers inherently increase selectivity for the specific analyte.  Affimers 
have been raised against different Src Homology 2 (SH2) domains.  Specificity 
was tested through binding to other SH2 family members, and the Affimers 
were shown to be selective to the specific SH2 domain that they were panned 
against in some cases (Tiede, et al. 2017). 
A few instruments are now being developed as systems for measuring several 
analytes at the same time. They are powerful analytical tools and the 
commonly used ones include multiplex real-time PCR (Elnifro, et al. 2000), 
ELISA (Tighe, et al. 2015), microarrays (Moore, et al. 2016) and next-
generation sequencing (Xuan, et al. 2013).  These methods are good at 
accurate and precise diagnostic application, but they can require expensive 
equipment, can take several hours, and skilled users are needed to complete 
the test and analyse the results.  With investment of time and money, and 
using Affimers as recognition elements and split alkaline phosphatase as an 
amplification tool, a biosensor that can measure several analytes 
simulatiously, that is inexpensive, specific, facile, fast and equipment-free 




Alkaline phosphatase as the amplification tool, in its current form would have 
limited use for many medical samples because human serum, for example, 
contains alkaline phosphatase at approximately 0.5 mg/ml (Bowers and 
McComb 1975).  If a wash or separation step could be incorporated into the 
device then a split alkaline phosphatase could be used.  A split alkaline 
phosphatase would however, be an excellent tool for environmental samples 
such as those mentioned in Chapter 1 Section 1.1.2. 
 
7.3.5 Reversing an enzyme/inhibitor interaction upon binding 
A different approach based upon a published patent (Balint and Her 2003), 
uses β-lactamase with β-lactamase inhibitor protein (BLIP).  This system works 
by using an inhibitor to switch off the enzyme with inhibition being reversed 
upon binding of the analyte. This system could be used as a sensor for 
identifying the presence of a target molecule in a sample, much like the aims 
of this study. The sensor comprises β-lactamase and BLIP linked together by 
linkers that also include two epitope sequences for an antibody. Binding of the 
antibody displaces the BLIP from and prevents BLIP from rebinding to β-
lactamase, thereby activating β-lactamase (Balint and Her 2003). It is 
proposed that this system could be adapted to identify a target analyte, as 





  Figure 7.4 Schematic of dis-inhibition of β-lactamase.   
β-lactamase is linked to an antibody, and BLIP is linked to a weak 
antigen for the antibody.  Therefore, BLIP is held in place by the 
weak interaction and is inhibiting β-lactamase.  When a target 
molecule is introduced, which binds strongly to the antibody, this 
displaces the weak antigen and β-lactamase can give a signal. 
 
The biggest advantage of this approach is that β-lactamase is in its native 
format, meaning the turnover of the enzyme is optimal.  A drawback is that this 
work is in the process of being patented, which, would restrict its use without 
permission. However, the principle could be applied to other enzyme inhibitor 
systems. 
To use alkaline phosphatase instead of β-lactamase would overcome some IP 
issues, and the challenge is to find an appropriate inhibitor.  There are many 
known inhibitors of E. coli alkaline phosphatase, but they are small molecules 
and not a protein like in the β-lactamase example shown in   Figure 7.4 .  Future 
work could therefore involve the cross-linking of a small inhibitor molecule to a 























phosphatase.  If this proved successful and the presence of the small molecule 
linked antigen inhibited alkaline phosphatase, the next step would be to 
investigate if the antigen could be displaced, taking with it the linked small 
molecule and allowing alkaline phosphatase turnover.   
The affinity of Affimer mGFP21 for eGFP and mGFP would need to be 
investigated, and if mGFP21 has low affinity for eGFP, and a high affinity for 
mGFP, this experiment could prove successful.  An alkaline phosphatase 
linked Affimer has already been created with a mGFP21 Affimer in this study.  
Therefore the only other requirement for initial experiments is eGFP cross-
linked to a small molecule inhibitor of alkaline phosphatase.  Next, mGFP could 
displace the eGFP-linked inhibitor molecule, and the activity of alkaline 
phosphatase should be restored.   
7.3.6 Using alkaline phosphatase as a switchable enzyme, in 
enzyme based logic gates. 
A completely new direction for using split alkaline phosphatase is as a 
switchable enzyme in enzyme based logic gates.  A wide array of applications 
in sensing and therapeutics could be enhanced by the ability to engineer 
synthetic enzymes that can be controlled by a signal such as pH (Ostermeier 
2009). In particular there has been a lot of progress in biomolecular computing, 
which is a new field at the interface of biological science, engineering and 
computer science (Fu 2007).  This has resulted in the emergence of various 
biological systems performing Boolean logic operations, simulating their 
electronic counterparts (Unger and Moult 2006).   
Boolean algebra, first described by George Boole in 1848 can be used to 
describe logical expressions. The most common Boolean operators are gates 
called AND, OR and NOT.  Each input and output of the gates must be one of 
two states: true / 1 or false / 0. An AND gate has two inputs and both have to 
be 1 in order for the output to be 1.  The OR gate also has two inputs, either 
one or both inputs must be 1 for the output to be 1.  A NOT gate has just one 
input, the output of the circuit will be the opposite of the input, so if 0 is input, 





Figure 7.5 Boolean Logic Gates.  The standard symbol for AND, OR and 
NOT operators are shown. 
 
One method to engineer switchable enzymes is to create fusion proteins 
between an enzyme and a domain that responds to an input signal (Ostermeier 
2009).  In this study the K4 coiled coil fused to T59A-R62A alkaline 
phosphatase could be used as a biological system performing a Boolean logic 
operation.  A change in enzyme activity is sought through the change from an 
input (Ostermeier 2009).  In the case of a coiled coil fusion, the enzyme turns 
over at pH 11, but not at pH 8; thus, the input could be a pH change.   
Electronic circuits look at two or more inputs and have to make decisions or 
an electrical output or process. This process uses electronic logic and is based 
on digital switches.  Switchable enzymes can be used in Boolean operations 
where there usually needs to be two or more pairs of interacting domains. In 
this study a Boolean logic gate operation could be achieved by introducing 2 
separate interacting coiled coils fused to the T59A-R62A variant of alkaline 
phosphatase.  These two coils would replace the K4 homodimeric coiled-coil.  









7.3.6.1 Composition of an AND gate 
The final output signal is generated by turnover of alkaline phosphatase 
substrate, which could be electrochemical, see Chapter 1 Section 1.5.4.2.  
Figure 7.6 shows the modular design of an enzyme-based AND gate using the 
T59A-R62A variant of alkaline phosphatase with coiled-coils.  In an AND gate, 
coiled coil fusion proteins use two different coiled coils which interact, and 
when coil 1 AND coil 2 are present then an output signal is generated.  




Figure 7.6 Modular design of an enzyme-based AND gate.  
Two different coiled coils fused to the T69A-R62A variant of 
alkaline phosphatase are the inputs, and upon binding to each 
other the output from enzyme turnover would be observed. 
 
7.3.6.2 Composition of an OR gate 
Figure 7.7 shows the modular design of an enzyme-based OR gate using two 
coiled coils.  In an OR gate, a coiled coil fusion protein with the T59A-R62A 
variant would be used, but the coiled coils need to be engineered, such that 















hetrodimers.  Therefore, when either 2 homodimeric coiled coils OR a 
hetrodimeric coiled coil are present an output signal is generated. 
 
Figure 7.7 Modular design of an enzyme-based OR gate.   
Two different coiled coils fused to T69A-R62A variants of alkaline 
phosphatase are the inputs, and upon binding each other, or 
themselves, the output from enzyme turnover would be observed. 
 
7.3.6.3 NOT gate 
The NOT gate is an inverter, thereby changing AND or OR to NAND and NOR 
respectively. The inverter for the coiled coil  design could be simply the addition 
of free coiled coils in solution.  However, a more sophisticated approach is to 
have another coiled coil peptide which binds with a higher affinity than the 
original coiled coils in the current system.  The third coil would outcompete the 
bound coiled coil. 
Different biological tools have been developed to assemble biochemical 
information processing systems for enzymes (Niazov, et al. 2006), DNA (Pei, 
et al. 2012), and RNA (Simpson, et al. 2001, Win and Smolke 2008).  Here, 
coiled-coils can be used along with split alkaline phosphatase.  Initially, each 












could involve integrated logic circuits, using a more complex design of several 
coiled coils. 
7.4 Conclusions 
The area of research into split proteins has been further extended with the 
development of a split alkaline phosphatase.  Rationally designed mutations 
of alkaline phosphatase were identified by bioinformatics based on structures 
of E. coli alkaline phosphatase.  The resulting variants were investigated to 
identify any that could regain activity after reactivation with a coiled-coil. The 
identification of the alkaline phosphatase variant T59A-R62A, that was 
reactivated to approximately 30% of wild-type activity, is a significant 
achievement and has potentially important applications in biosensor 
technology.  The experiments described have provided a solid foundation for 
further studies.  There are clear indications that a universal biosensor utilising 
a split alkaline phosphatase is a real possibility.  Furthermore, the work 
presented here could be taken in new directions such as switchable enzymes 
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